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ABSTRACT 
This thesis examined the effect and biochemical me<c~anism by which combined vitamin E and C 
supplementation may influence tumour cell growth. The study initially addressed the effect of 
combined vitamin E succinate and Asc supplementation over a nutritional concentration range (5-
20JLg/ml) and (25-50JLg/ml) respectively, on the in vitro growth of non-malignant LLCMK and 
~- -
malignant BL6 cells. Supplementation of BL6 and LLCMK cells with combined vitamin E succinate 
and ascorbic acid, resulted in no significant increasing or decreasing trend in LLCMK cell growth, 
while in BL6 cells a significant decrease in cell growth was observed at all combined vitamin 
concentrations. It has been suggested that these vitamins may act synergistically to inhibit tumour cell 
growth through their antioxidant properties in quenching free radicals and lipid peroxidation and 
furthermore through their modulation of the activities of various enzymes and metabolites in the 
eicosanoid pathway. This study consequently investigated the effects of combined vitamin E succinate 
and ascorbic acid supplementation on these parameters. 
Throughout this study, emphasis was placed on the BL6 melanoma cells, as combined vitamin E 
succinate and ascorbic acid supplementation did not significantly affect growth or levels of seeondary 
metabolites in the non-malignant LLCMK cells. 
Combined vitamin E succinate and ascorbic acid supplementation of BL6 cells resulted in a marked 
but non significant increase in free radical and a significant increase in lipid peroxidation levels. This 
prooxidant effect was accompanied by a significant decrease in BL6 cell growth, suggesting that the 
growth inhibitory effects of combined vitainin E succinate and ascorbic acid on BL6 cells in vitro was 
not mediated through their synergistic antioxidant properties. Vitamin E succinate is a non-
physiological antioxidant in its esterified form, hence cleavage of the succinate group must occur in 
order for ascorbic acid to interact with the free alcohol, vitamin E. The inability of combined vitamin 
E succinate and ascorbic acid to reduce free radicals and lipid peroxidation levels within BL6 cells 
may not be due to their ineffectiveness as antioxidants but rather the presence of other contributing 
factors which influence the oxidation state within the BL6 cells. 
Vitamin E is believed to modulate membrane-bound enzymes through membrane stabilization. 
Furthermore, the stabilizing effect of vitamin E may be enhanced by the ascorbic acid-sparing effect 
of vitamin E. Hence, this study investigated the effect of combined vitamin E succinate and ascorbic 
acid in modulating the activity of various enzymes and secondary messengers in the eicosanoid 
II 
pathway. Supplementation with combined vitamin E succinate (5-20J..tg/ml) and ascorbic acid (25-
50J..tg/ml) resulted in significant increases in phospholipase A2, 5-lipoxygenase, cyclooxygenase and 
adenyl ate cyclase activity, with a significant decrease in BL6 cell growth. The possible synergistic 
actiOli of these vitamins in terms of modulating ~ membr.ane-bound enzymes was further substantiated 
by uptake and cellular distribution studies. Vitamin E succinate and vitamin E in the membrane 
fraction increased significantly compared to control cultures, while ascorbic acid levels were 
significantly higher in the stroma fraction when compared to membrane fracti<?-ns .. Consequently, 
another factor accounting for increased activities of phospholipase A2, 5-lipoxygenase and adenylate 
cyclase activities as a result of vitamin supplementation in BL6 cells may be an increased availability 
of Ca2+. 
Supplementation of BL6 cells with combined vitamin E succinate and ascorbic acid resulted in 
significant increases in intracellular Ca2+ levels at all combined vitamin groups. Furthermore, this 
increase in intracellular Ca2+ was positively correlated with cl1anges of the above-mentioned enzyme 
activities. 
Within the eicosanoid pathway, the rate of prostaglandin synthesis is regulated by phospholipase A2 
activity and arachidonic acid release, and the net prostaglandin production is dependent on 
cyclooxygenase activity, hence the effects of combined vitamin E succinate and ascorbic acid on 
arachidonic acid composition and prostaglandin production within BL6 cells was determined. The 
percentage arachidonic acid composition of the BL6 cells was elevated and inversely related to cell 
growth following combined vitamin E succinate and ascorbic acid supplementation. Prostagl~d!n E2 
and prostaglandin ~ levels increased significantly, while those of prostaglandin D2 and prostaglandin 
F2a increased markedly following supplementation of combined vitamin E succinate and ascorbic acid. 
These increases in prostaglandin levels were inversely related to BL6 cell growth, suggesting that the 
prostaglandins were involved in negative regulation of BL6 cell growth. When comparing the levels 
of prostaglandins, prostaglandin E2 levels were significantly higher when compared to prostaglandin 
D2, prostaglandin F2a and prostaglandin 12 suggesting that vitamin E succinate and ascorbic acid 
effects were mediated primarily through an increase in prostaglandin E2. Hence, prostaglandin E2 
levels in combined vitamin E succinate and ascorbic acid appeared to be dependent on the amount of 
precursor present and the activity of its synthetic enzymes. This was confirmed when BL6 cells were 
supplemented with arachidonic acid. Arachidonic acid had an inhibitory effect on BL6 cell growth 
and also stimulated prostaglandin E2 production. Prostaglandin E2 levels are in turn believed to 
modulate adenylate cyclase activity in BL6 cells, hence it is reasonable to conclude that adenyl ate 
III 
cyclase activity is dependent on prostaglandin E2 levels. Combined vitamin E succinate and Asc 
supplementation to BL6 cells resulted in significant increases in adenyl ate cyclase and cyclic adenosine 
monophosphate, which again correlated with a significan~ decrease in cell growth. As cyclic adenosine 
- -
monophosphate has a regUlatory role in the cell cycleAhis study suggested that the effect of combined 
vitamin E succinate and ascorbic acid supplementation was mediated through the final effect provided 
by the second messenger, cyclic adenosine monophosphate. This was confirmed when BL6 cells were 
supplemented with dexamethasone, a phospholipase A2 inhibitor. This treatment r~ult.ed in combined 
vitamin E succinate and ascorbic acid having no inhibitory effect on BL6 cell growth. Cyclooxygenase 
activity, prostaglandin E2 levels, adenylate cyclase activity and cyclic adenosine monophosphate levels 
were significantly lower in dexamethasone-treated cells compared to non-treated dexamethasone 
cultures. 
The reason for the increased free radical and lipid peroxidation levels in BL6 cells was further 
investigated. Cyclooxygenase enzymes are believed to generate free radical species during catalytic 
activity. Analysis of free radical and lipid peroxidation levels following supplementation with 
dexamethasone revealed markedly lower free radical and significantly lower lipid peroxidation levels 
in comparison with control cultures and non dexamethasone-treated cultures. These results s~ggest 
that the observed increases in free radical and lipid peroxidation levels in BL6 cells supplemented with 
combined vitamin E succinate and ascorbic acid were indirectly due to the increase in cyclooxygenase 
activity in these cells. 
IV 
TABLE OF CONTENTS 
CONTENTS PAGE 
Title -Page ..••.• ~ . • • . • • . . . . • • . . • _. • • • • '. • • . . . • • • • . • • . • • . • • • • • . . . . . 
Abstract ...................................••..•.............. ii 
Table of Contents ...•.......................•••...••.....•......• v 
~ - . 
List of Figures ................................................. xvii 
List of Tables ...................•.....••.•••.................... xv 
Acknowledgements ............................................. xviii 
Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. xix 
1. Literature Review .••.•.....................•.....•....•.....•.. 1 
1.1 
1.1.1 
1.1.2 
1.1.3 
1.1.4 
1.2 
1.2.1 
1.2.2 
1.2.2.1 
1.2.3 
1.2.3.1 
1.2.3.2. 
1.2.3.3 
1.2.3.4 
1.2.4 
1.3 
1.3.1 
1.3.2 
1.3.3 
1.3.3.1 
1.3.3.2 
1.3.3.3 
1.3.3.4 
1.3.4 
1.4 
1.4.1 
Cancer ...................... . --..... -................. 1 
Initiation ............................................ 2 
Promotion ........................................... 3 
Progression . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 4 
Chemoprevention . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 5 
Ascorbic Acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..-'.. 6 
History ..................................... -.... --. . .. 6 
Structure and metabolism of ascorbic acid . . . . . . . . . . . . . . . . . . . . . . .. 6 
Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 7 
Functions of ascorbic acid ................................. 9 
Ascorbic acid in enzyme reactions ............................ 9 
Ascorbic acid in the extracellular and intracellular matrix and collagen 
biosynthesis ....................................... -. -. -. 10 
Ascorbic acid and nitrosamines .............................. 12 
H20 2 formation by and antioxidant role of ascorbic acid . . . . . . . . . . . . . . . 13 
Ascorbic acid and cancer .................................. 13 
Vitamin E .•.............•......................••.•• 15 
History ............................................. 15 
Structure and metabolism of vitamin E .......................... 16 
Functions of vitamin E . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 
Vitamin E and nitrosamines ................................ 19 
Vitamin E and p53 ...................................... 20 
Vitamin E and membranes ................................. 20 
Antioxidant role of vitamin E ............................... 21 
Vitamin E and cancer .................................... 23 
Synergistic Action of Vitamin E and Vitamin C ...........••..••. 24 
Vitamin E and C and cancer ................................ 25 
v 
CONTENTS 
1.5 
1.5.1 
1.5.2 
1.5.2-.-1 
1.5.3 
1.5.4 
1.6 
1.7 
1.7.L 
1.7.2 
1.7.3 
1.7.3.1 
1.7.3.2 
1.7.3.3 
1.7.3.4 
1.7.4 
1.7.4.1 
1.7.4.2· 
1.7.4.3 
1.7.4.4 
1.7.5 
1.8 
1.8.1 
1.8.2 
1.8.3 
1.8.3.1 
1.8.3.2 
1.8.4 
1.8.4.1 
1.8.5 
1.8.5.1 
1.9 
1.9.1 
1.9.2 
1.9.2.1 
1.9.2.2. 
1.9.2.3 
1.9.3 
1.9.4 
1.9.4.1 
1.9.4.2 
1.9.4.3 
1.9.5 
PAGE 
Cell Membranes and Fatty Acids ....•.....••••...••••...•••• 27 
Fluid Mosaic Model of biological membranes ................ ..... 27 
Biosynthesis of fatty acids . . . . . . . '.' . . . . . . . . . . . . . . . . . . . . . .... 28 
Unsaturated fatty acids ......... , ........................... 28 
Fatty acids in the biomembranes . '. : . . . . . . . . . . . . . . . . . . . . . . . . .. 28 
Membranes and cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 
Free Radical Formation and Lipid Peroxidation •.....•••..••..... 29 
Prostaglandins ..............•.....•.....••....••.....• 32 
Structure and properties of prostaglandin endoperoxide synthase . . . . . . . . . . 34 
Mechanism of action of prostaglandin endoperoxide synthase . . . . . . . . . . . . 36 
Biosynthesis of prostaglandins D2, E2, F2a, and 12 ................... 37 
PGD synthase ......................................... 38 
PGE synthase ......................................... 39 
PGF synthase ......................................... 39 
PGI synthase . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 
Functions of prostaglandiQs ................................ 39 
Functions of prostaglandin D2 ............................... 40 
Functions of prostaglandin E2 ......... -. . . . . . . . . . . . . . . . . . . . . . 40 
Functions of prostaglandin F2a • • • • • • • • • • • • • • • • • • • • • • • • • •••••• 40 
Functions of prostaglandin Iz . . . . . . . . . ; . . . . . . . . . . . . . . . . . . . . . . 40 
Prostaglandins and cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41 
Calcium ....................•........•...... -. . ..'~.. . . 42 
Characteristic properties of calcium . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42 
Intracellular transport of calcium ........................ ..... 43 
Functions of calcium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43 
Calcium and cell proliferation .......................... ..... 43 
Calcium and enzymes .................................... 44 
Phospholipase A2 .................................. ..... 44 
Classification and properties of phospholipase A2 ... . . . . . . . . . . ..... ~ -. 44 
Functions of phospholipase Az .. . . . . . . . . . . . . . . . . . . . . . . . . ..... 45 
G Proteins and PLA2 mechanisms ............................ 46 
Adenylate Cyclase and Cyclic Adenosine Monophosphate ...•...•.... 46 
Structure and properties of adenyl ate cyclase . . . . . . . . . . . . . . . . ...... 46 
Properties of the adenylate cyclase components ............ ' ........ 47 
The receptor component . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47 
The regulatory component ................................ 47 
The catalytic component . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 48 
Mechanism of adenylate cyclase activity ......................... 48 
Factors influencing adenylate cyclase activity . . . . . . . . . . . . . . . . . ..... 49 
Membrane lipid composition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 
Prostaglandins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50 
Calcium-dependent regulatory protein .......................... 50 
Cyclic adenosine monophosphate ........................ ..... 50 
vi 
CONTENTS 
1.9.5.1 
1.9.5.2 
1.9.6 
1.10 
2. 
2.1 
2.2 
2.2.r 
2.2.1.1 
2.2.1.2 
2.2.1.3 
2.2.1.4 
2.2.1.5 
2.2.1.6 
2.2.2 
2.2.2.1. 
2.2.2.2 
2.2.3 
2.2.3.1 
2.2.3.2 
2.2.4 
2.2.4.1 
2.2.5 
2.2.5.1 
2.2.6 
2.2.6.1 
2.2.7 
2.3 
2.3.1 
2.3.2 
2.3.3 
2.3.4 
2.4 
3. 
3.1. 
PAGE 
Biological functions of cyclic adenosine monophosphate ............... 51 
Cyclic adenosine monophosphate and prostaglandins ................. 52 
Adenylate cyclase activity, cycljc adenosine monophosphate and cancer ..... 53 
Objectives ..........•................................ 54 
Combined Nutrient Supplementation and Cell Growth .............. 56 
Introduction ................................: -. .~. . . . . . . 56 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... 58 
Preparaton of culture reagents ............................... 59 
Preparation of the medium ................................. 59 
Filtration of the medium . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ..... 59 
Preparation of growth and freezing media . . . . . . . . . . . . . . . . . . . . . . . . 59 
Preparation of trypsin solution .............................. 60 
Preparation of medium containing vitamin E succinate and ascorbic acid .... 60 
Preparation of phosphate buffered saline solution ................... 61 
Cell culture ........ '. . . . . . . . . . . . . . . . . . .'. . . . . . . . . . . . . . . 61 
Routine cell culture procedures ........ -...................... 61 
Freezing of cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 
The effect of combined vitamin E succinate and ascorbic acid 
supplementation on cell growth .............................. 62 
Experimental cell culture procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62 
Harvesting of the experimental cell cultures .................. ... -: . 62 
The effect of combined vitamin E succinate, ascorbic acid and 
3H vitamin E succinate supplementation on cell growth ............... 63 
Experimental cell culture procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63 
The effects of combined vitamin E succinate , ascorbic acid and 
L-[carboxyl-14C] ascorbic acid supplementation on cell growth .......... 63 
Experimental cell culture procedure ........................... 63 
The effect of combined vitamin E succinate, ascorbic acid and 
3H arachidonic acid supplementation on cell growth .............. ... 64 
Experimental cell culture procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 
Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64 
Results .............................................. 65 
The effect of combined vitamin E succinate and ascorbic acid 
supplementation on LLCMK and BL6 cell growth .................. 65 
The effect of combined vitamin E succinate, ascorbic acid and 
3H vitamin E succinate supplementation on cell growth ............... 70 
The effect of combined vitamin E succinate, ascorbic acid and 
14C_ ascorbic acid supplementation on cell growth . . . . . . . . . . . . . . . . . . . 71 
The effect of combined vitamin E succinate, ascorbic acid and 
3H-arachidonic acid supplementation on cell growth ................. 72 
Discussion ........................................... 74 
The Effect of Combined Nutrient Supplementation on the Uptake and 
Metabolism of the Nutrients and on the Oxidation States in Cells • . . . . . . 77 
Introduction .......................................... 77 
vii 
CONTENTS PAGE 
3.2 The Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on Free Radical and Lipid Peroxidation Formation .... 78 
3.2.L Materials ............. _ ..... -.......................... 78 
3.2.2 
3.2.2.1 
3.2.2.2 
3.2.3 
3.2.3.1 
3.2.3.2 
3.2.4 
3.2.5 
3.3 
3.3.1 - -
3.3.1.1 
3.3.1.2 
3.3.1.3 
3.3.2 
3.4 
3.4.1 
3.4.1.1 
3.4.1.2 
3.4.1.3 
3.4.2 
3.5 
3.5.1 
3.5.1.1 
3.5.1.2 
3.5.1.3 
3.5.1.4 
3.5.1.5 
3.5.2 
3.6 
4. 
4.1 
4.1.1 
-~ . 
The Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on Free Radical Formation .................... 79 
Cell culture procedures .............................. ... _ . 79 
Free radical formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79 
r- -
The Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on Lipid Peroxidation Formation ••.••••.•••.... 80 
Cell culture procedures for lipid peroxidation experiment . . . . . . . . . . . . . . 80 
Lipid peroxidation determination ............................. 80 
Statistical analysis ....................................... 80 
Results .............................................. 80 
Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on [U 3H] Vitamin E Succinate Uptake .••..•...... 82 
Materials and Methods . . . . . . . . . . .... -, . . . . . . . . . . . . . . . . . . . . . 82 
Cell culture procedures ................................... 82 
Homogenization of cells and separation of cellular components .......... 82 
Determination of radioactivity in membrane and stroma fractions ......... 83 
Results .............................................. 83 
Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on [Carboxyl _14C] Ascorbic Acid Uptake .•••••.... 86 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 
Cell culture procedures ................................... 86 
Homogenization of the cells and separation in to cellular components ...... 86 
Determination of radioactivity in membrane and stroma fractions ......... 86 
Results ............................................ -. -. -86 
Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on Vitamin E Succinate Metabolism .......••••... 88 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88 
Glassware Preparation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 
Preparation of Ca2+ and Mg2+ free phosphate-buffered saline solution ...... 89 
Cell culture procedure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89 
Extraction of vitamin E and vitamin E succinate . . . . . . . . . . . . . . . . . . . . 89 
Vitamin E and vitamin E succinate determination . . . . . . . . . . . . . . . . . . . 90 
Results .......................................... -.... 90 
Discussion ........................................... 91 
Combined Nutrient Supplementation and Second Messengers ••••..... 94 
Combined Vitamin E Succinate and Ascorbic Acid Supplementation 
and Calcium Levels .................................... 94 
Introduction .......................................... 94 
viii 
CONTENTS 
4.1.2 
4.1.2.1 
4.1.2.2 
4.1.2.3 
4.1.2.4 
4.1.3 
4.1.4 
4.2 
4.2.C 
4.2.2 
4.2.2.1 
4.2.2.2 
4.2.2.3 
4.2.2.4 
4.2.3 
4.2.4 
4.3 
4.3.1 
4.3.2 
4.3.2.1 
4.3.2.2 
4.3.2.3 
4.3.2.4 
4.3.2.5 
4.3.2.6 
4.3.3 
4.3.4 
4.4 
4.4.1 
4.4.2 
4.4.2.1 
4.4.2.2 
4.4.2.3 
4.4.3 
4.4.4 
4.5 
4.5.1 
4.5.2 
4.5.2.1 
4.5.2.2 
4.5.2.3 
PAGE 
Materials and Methods . . . . . . . . . . . . ... . . . . . . . . . . . . . . . . . . . . . . 95 
Glassware preparation ... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95 
Cell culture procedures .... _. . . . . .. . . . . . . . . . . . . . . . . . . . . . . . . . 96 
Acid digestion of the cells and calcium detection ..............: .... 96 
Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 96 
Results .............................................. 96 
Discussion ........................................... 97 
Combined Vitamin E Succinate and Ascorbic Acid Supplementation and 
Phospholipase Az Activity ......•••......•.•........••.... 98 
Introduction .......................................... 98 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... 99 
Cell culture procedures .................................. 100 
Homogenization of cells and enzyme preparation .................. 100 
Protein Determination ................................... 100 
Determination of phospholipase A2 activity ...................... 100 
Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 101 
Discussion ........................................... 102 
Arachidonic Acid Levels with Combined Vitamin E Succinate and 
Ascorbic Acid and Arachidonic Acid Supplementation ••.....•....• 103 
Introduction ...................:..................... 103 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104 
Preparation of methanolic KOH (10%) ........................... 104 
Cell culture procedures ........................... -. . . .'. .. 104 
Homogenization of cells and separation of cellular components ......... 104 
Determination of 15-3H arachidonic acid uptake ................... 104 
Saponification, esterification and extraction of fatty acids . . . . . . . . . . . .. 105 
Free fatty acid analysis by gas-liquid chromatography ............... 105 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 105 
Discussion ....................................... .., -108 
Combined vitamin E Succinate and Ascorbic Acid Supplementation and 
5-Lipoxygenase Activity ........•...••...••....••...••.. 110 
Introduction ......................................... 110 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 111 
Cell culture procedures .................................. 111 
Homogenization of cells and enzyme preparation .................. 111 
5-Lipoxygenase assay ................................... 111 
Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 112 
Discussion .......................................... 113 
Combined Vitamin E Succinate and Ascorbic Acid Supplementation and 
Cyclooxygenase Activity ........••....•....•••.......... 114 
Introduction ......................................... 114 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 115 
Cell culture procedures .................................. 115 
Homogenization of cells and separation of cellular components ......... 115 
Determination of cyc100xygenase activity . . . . . . . . . . . . . . . . . . . . . .. 115 
ix 
CONTENTS 
4.5.3 
4.5.4 
4.6 --
4.6.1 
4.6.2 
4.6.2.1 
4.6.2.2 
4.6.2.3 
4.6.2~ 
4.6.3 
4.6.4 
PAGE 
Results ...................... ',' . . . . . . . . . . . . . . . . . . . . . 116 
Discussion .......................................... 117 
Prostaglandin Ez Levels and -Combined Vitamin E Succinate and ' 
Ascorbic Acid Supplementation ....•..••.•..••.••.........• 
Introduction ........................................ . 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
Cell culture procedures ................................. . 
Homogenization of cells and separation of cellular components -: -. ~ . . . . . . 
Extraction and isolation of prostaglandins . . . . . . . . . . . . . . . . . . . . . . . 
Prostaglandin E2 [1251] assay .............................. . 
Results ............................................ . 
Discussion 
119 
119 
120 
120 
120 
120 
121 
121 
122 
4.7 Combined Vitamin E Succinate and Ascorbic Acid and PGDz, PGFza and 
PGlz Levels ..........................•..........•.. 124 
4.7.1 Introduction ......................................... 124 
4.7.2 
4.7.2.1 
4.7.2.2 
4.7.2.3 
4.7.2.4 
4.7.2.5 
4.7.2.6 
4.7.3 
4.7.3.1 
4.7.3.2 
4.7.3.3 
4.7.3.4 
4.7.3.5 
4.7.4 
4.7.5 
4.8 
4.8.1 
4.8.2 
4.8.2.1 
4.8.2.2 
4.8.2.3 
4.8.2.4 
4.8.2.5 
4.8.2.6 
4.8.3 
The Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on PGDz and PGFza Levels in BI6 Cells •....•..•.. 124 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .... , 124 
Cell culture procedures .......... .. :..................... 124 
Homogenization of cells and separation of cellular components ......... 125 
Extraction and isolation of prostaglandins . . . . . . . . . . . . . . . . . . .... -: 125 
Prostaglandin D [3H] assay system .................... : ... ': .. 125 
Prostaglandin F2c< [3H] assay system .......................... 125 
The Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation on PGlz Levels in BI6 Cells .........•......... 126 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ... , 126 
Cell culture procedures .................................... .126 
Homogenization of cells and separation of cellular components ......... 126 
Extraction and isolation of PGI2 . . . . . . . . . . . . . . . . . . . . . . . . . ... , 126 
6-Keto-prostaglandin Flc< enzyme immunoassay (EIA) system. . . . . . . . . . . 126 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127 
Discussion .......................................... 128 
Combined Vitamin E Succinate and Ascorbic Acid Supplementation 
Adenylate Cyclase Activity and Cyclic Adenosine Monophosphate 
Formation ......................................... 130 
Introduction ......................................... 130 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 131 
Cell culture procedures .................................. 131 
Homogenization of cells and separation of cellular components ......... 131 
Protein Determination ................................... 131 
Adenylate cyclase activity assay ............................ , 131 
Cyclic adenosine monophosphate extraction . . . . . . . . . . . . . . . . . . . . . . 132 
Cyclic adenosine monophosphate [3H] assay ..................... 132 
Results ............................................ 133 
x 
CONTENTS 
4.8.3.1 
4.8.3.2 
4.8.4 
5. 
6. 
6.1 
6.2 -
6.2.1 
6.2.2 
6.2.2.1 
6.2.2.2 
6.2.2.3 
6.2.3 
6.2.4 
6.3 
6.3.1 
6.3.2 
6.3.2.1 
6.3.2.2 
6.3.2.3 
6.3.3 
6.3.4 
6.4 
6.4.1 
6.4.2 
6.4.2.1 
6.4.2.2 
6.4.2.3 
6.4.3 
6.4.4 
6.5 
6.5.1 
6.5.2 
6.5.2.1 
6.5.2.2 
6.5.2.3 
PAGE 
Adenylate cyclase activity ....... .... ' . . . . . . . . . . . . . . . . . . . .. 133 
Cyclic adenosine monophosphate levels ........................ 134 
Discussion ........................................... 135 
-~ . 
Combined Vitamin E Succinate and Ascorbic Acid Supplementation 
in Relation to Oxidation State, Second Messengers and Cell Growth . • . . 137 
Combined Nutrient and Dexamethasone Supplementation of BL6 cells .. 153 
Introduction ............................. ... ": -. ~ . . . . . . 153 
The Effect of Combined Vitamin E Succinate, Ascorbic Acid and 
Dexamethasone Supplementation on Cell Growth •...•..•......•. 154 
Introduction ......................................... 154 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 154 
Preparation of vitamin E succinate, ascorbic acid and dexamethasone 
stock solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 154 
Cell culture procedures .................................. 155 
Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 155 
Results ................. ...... _. . . . .. . . . . . . . . . . . . . .. 155 
Discussion .......................................... 156 
The Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation together with Dexamethasone on Free Radical and 
Lipid Peroxidation formation ...................•.....•. ..~ 157 
Introduction .................................. : ... ': . . 157 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158 
Cell culture procedures .................................. 158 
Free radical formation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158 
Lipid peroxidation determination ............................ 158 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 158 
Discussion ......................................... ~ .159 
Effect of Dexamethasone and Combined Nutrient Supplementation on 
Cyclooxygenase Activity ....•........•.•..•..•..•..•..•.. 160 
Introduction ......................................... 160 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 160 
Cell culture procedures .................................. 161 
Homogenization of cells and separation of cellular components ......... 161 
Determination of cyclooxygenase activity ....................... 161 
Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 161 
Discussion .......................................... 162 
Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation together with Dexamethasone on PGEz Levels ••.•••. 162 
Introduction ......................................... 162 
Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 163 
Cell culture procedures .................................. 163 
Homogenization of cells and separation of cellular components ......... 163 
Extraction and isolation of prostaglandins . . . . . . . . . . . . . . . . . . . . . .. 163 
Xl 
CONTENTS PAGE 
6.5.2.4 
6.5.3 
6.5.4 
6.6 
6.6.1 
6.6.2 
6.6.2.1 
6.6.2:2 
6.6.2.3 
6.6.2.4 
6.6.2.5 
6.6.2.6 
6.6.3 
6.6.4 
6.7 
7. 
Prostaglandin Ez assay system .............................. 163 
Results. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 163 
Discussion ........................................... 164 
-;;: . 
The Effect of Combined Vitamin E Succinate and Ascorbic Acid 
Supplementation together with Dexamethasone on Adenylate Cyclase 
Activity and Cyclic Adenosine Monophosphate Levels ••........••• 165 
Introduction ......................................... 165 
Materials and Methods .......................... r.·. ~ ...... 165 
Cell culture procedures .................................. 165 
Homogenization of cells and separation of cellular components ......... 165 
Protein determination ................................... 166 
Adenylate cyclase activity assay . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 166 
Cyclic adenosine monophosphate extraction . . . . . . . . . . . . . . . . . . . . . . 166 
Cyclic adenosine monophosphate [3H] assay ..................... 166 
Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 166 
Discussion .......................................... 167 
General Discussion on the Relationship between Arachidonic Acid 
Metabolites and Cell Growth . . . . . . . • . . . . . • • . • . . . • . . . . . • • . . 167 
General Discussion .............• ~ • . . • . . • . . . • . • . . . . . . . . 171 
Appendices 179 
Appendix 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 179 
Appendix 2 ............................................... 180 
Appendix 3 ............................................... 181 
Appendix 4 ............................................... 182 
Appendix 5 ............................................... 183 
Appendix 6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . '.~ -184 
Appendix 7 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185 
Appendix 8 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 186 
Appendix 9 ............................................... 187 
Appendix 10 .............................................. 188 
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. 189 
xii 
Figure 1: 
Figure 2: 
Figure 3: 
Figure 4: 
Figure 5: 
Figure 6: 
Figure 7: 
Figure 8: 
Figure 9: 
Figure 10: 
Figure 11: 
Figure 12: 
Figure 13: 
Figure 14: 
Figure 15: 
Figure 16: 
Figure 17: 
Figure 18: 
Figure 19: 
Figure 20: 
Figure 21: 
Figure 22: 
Figure 23: 
LIST OF FIGURES 
PAGE 
A multistep carcinogenesis model .; : . . . • • • • • • . • • . • • . • . • • • • • • •• 1 
The metabolic pathway of L-ascorbic acid biosynthesis in animals. •••••... 7 
Vitamin C metabolism in humans ••••••..••••••••••••••.•••••• 9 
The suggested role of ascorbic acid as a cosubstrate in an enzyme reaction ••• 10 
r- -
Chemical structures of naturally occuring tocopherols and tocotrienols • . . • • • 16 
(¥-Tocopherol acid succinate ..•••••...••••••.••••••••.•••••• 17 
(¥-Tocopherol inhibition of phospholipids •••..••••.•••••••••••••• 22 
Regeneration of vitamin E from vitamin E radical by vitamin C •• • • • . • • • • 24 
Schematic representation of the AA cascade pathway investigated in this 
study •••••.•••..•••••..••••••...••••.••••••••.• 26,54,139 
Three different ways of free radical formation •...••••••.•••••••••• 30 
Lipid peroxidation and sites of action of antioxidants in lipid peroxidation .•• 31 
Biosynthetic pathway for prostanoid formation . . .•••.•••••••..••••• 33 
A predicted model for the cyclooxygenase enzyme ••••.••••••••.•••• 35 
Reactions catalyzed by prostaglandin endoperoxide synthetase •.• -•••• '" ••• 36 
Modified biosynthetic pathway for prostanoid formation • • ••.•••••..••• 38 
Mechanisms involved in the regulation of the adenylate cyclase activity ••••• 49 
cAMP regulation of the cell cycle • . . • • • • • • • • • • • . • • • • • . • • • . . . • • 51 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on the uptake of 3H vitamin E succinate by both LLCMK and BL6 cells • • . • • 83 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on the uptake of 14C ascorbic acid by both LLCMK and BL6 cells •••.•••. 87 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on total 3H arachidonic acid uptake by LLCMK and BL6 cells •••••••••• 106 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and free radical formation • • . • • • • • • . • • • • • • • • • • 140 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and lipid peroxidation levels •••••••.••.••••••• 141 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and cyclooxygenase activity ..••••.•.••••••.••• 142 
Xlll 
Figure 24: 
Figure 25: 
Figure 26: 
Figure 27: 
Figure 28: 
Figure 29: 
Figure 30: 
Figure 31: 
Figure 32: 
Figure 33: 
Figure 34: 
Figure 35: 
Figure 36: 
Figure 37: 
Figure 38: 
PAGE 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and 5-lipoxygen~s~ activity ••••••.•••••••.•••• 143 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and Ca2+ levels •••••••••.•••••••••.••••.• 144 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
r- -
on BL6 cell growth and PLA2 activity ••••.•.•••..••.•••••••••• 145 
BL6 cell growth and uptake of 3H arachidonic acid with combined 
vitamin E succinate and ascorbic acid supplementation ••••••.•••••••. 146 
BL6 cell growth and total percentage arachidonic acid composition 
with combined vitamin E succinate and ascorbic acid supplementation 146 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and prostaglandin E2 levels .••••••.••••••••••• 147 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and prostaglandin D2 levels ••.••••••.•..•••••. 148 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and prostaglandin F2a levels ••••.•••••• -••.• ' ••• 149 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and prostaglandin 12 levels . • • • • • • • • • . • • • • • • . • . 149 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth and adenylate cyclase activity •••••.••••••••••• _. 150 
The relationship between cyclic adenosine monophosphate and BL6 cell growth 
with combined vitamin E succinate and ascorbic acid supplementation ••••• 151 
Structure of Dexamethasone ••••.••••••••••.••••••••••••••• 153 
The effect of combined vitamin E succinate and ascorbic acid 
supplementation together with dexamethasone on BL6 cell growth and 
cyclooxygenase activity .••.••...••••.•.••••.••.••.••••••• 168 
The effect of combined vitamin E succinate and ascorbic acid 
supplementation together with dexamethasone on BL6 cell growth and 
prostaglandin E2 levels . . . • • . . . . . . • . . • • . • . . • • • • . . • . . • • • . . . 169 
The effect of combined vitamin E succinate and ascorbic acid 
supplementation together with dexamethasone on adenyl ate activity and 
BL6 cell growth . . . • • • • . . • • • • • • . • • • • . . • • • • • • • • • • • • • • • • • 169 
xiv 
- FiguI"e 39: 
Table 1: 
Table 2a: 
Table 2b: 
-
Table 3a: 
Table 3b: 
Table 4: 
Table 5: 
Table 6: 
Table 7: 
Table 8: 
Table 9: 
Table 10: 
Table 11: 
Table 12: 
Table 13: 
PAGE 
The effect of combined vitamin E succinate and ascorbic acid 
-;, . 
supplementation together with dexamethasone on BL6 cell growth 
and cyclic adenosine monophosphate levels 170 
LIST OF TABLES 
Representative examples of carcinogenic agents •••.•.•••••.•••.•.•• 2 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on LLCMK cell growth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on BL6 cell growth . • • • • • • • • • • • • . • . • • • • • • • • • . • • • • • . • • . • . . 67 
The effect of vehicle treatments on LLCMK cell growth • • • • • • • • • • • • . . • 68 
The effect of vehicle treatments on BL6 cell growth .••.•••••.••.•..• 68 
The effect of succinic acid and vehicle treatments on LLCMK and BL6 cells •• 69 
The effect of vehicle treatment on LLCMK and BL6 cell growth • -. • •• '.. • • 70 
The effect of combined vitamin E succinate, ascorbic acid and 3H vitamin E 
succinate supplementation on cell growth ...••••..••.•..•.•••...• 70 
The effect of vehicle treatment on LLCMK and BL6 cell growth ..•...... 71 
The effect of combined vitamin E succinate, ascorbic acid and 
14C ascorbic acid supplementation on cell growth .•••••••••••••..••• 72 
The effect of combined vitamin E succinate, ascorbic acid and 
3H arachidonic acid supplementation on cell growth ••.••.•••••.••••• 73 
The effect of combined vitamin E succinate, ascorbic acid and 
arachidonic acid supplementation on cell growth •••••.•••••••..••••• 73 
The effect of 3H arachidonic acid and vehicle treatment on LLCMK and 
BL6 cell growth . • • • • • . . • • • • . . • . . • • • • • • • • • • . • • . • • • • • • . . • 74 
The effect of arachidonic acid and vehicle treatment on LLCMK and 
BL6 cell growth • • • . . . . • • . . . • . • • • • • • • . • • • • . • • • • . • • • • • • • • 74 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on free radical and lipid peroxidation levels in LLCMK and BL6 cells • . • • . . 81 
xv 
Table 14: 
Table 15: 
Table 16: 
Table 17: 
Table 18: 
Table 19: 
Table 20: 
Table 21: 
Table 22: 
Table 23: 
Table 24: 
Table 25: 
Table 26: 
Table 27: 
PAGE 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on the up-take of 3H vitamin E succi~a~e by the membrane and stroma 
fractions of LLCMK and BL6 cells •••••••..•••••••••.••..••••• 85 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on the uptake of 14C ascorbic acid by the membrane and stroma fractions 
r - ~ 
of LLCMK and BL6 cells ••••.••..••••••••••••••••••••••.• 88 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on vitamin E succinate and vitamin E levels in LLCMK and BL6 cells •••.• 91 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on calcium levels in LLCMK and BL6 cells ..•••••••.••.••.•••••. 97 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on phospholipase A2 activity detected in the respective LLCMK and 
BL6 cells •••.•••...••••.•..••.••••••••.•••••.••.•••• 101 
The effect of combined vitamin E succinate and Asc supplementation on the 
uptake of 15-3H arachidonic acid by membrane and stroma fractions of 
.' 
LLCMK and BL6 cells ••.••••••••••.••.•••••.•••• -••• -.,-.- •• 107 
The effect of combined vitamin E succinate and ascorbic acid and arachidonic 
acid supplementation on the percentage arachidonic acid composition in the 
respective membrane and stroma fractions of the LLCMK and BL6 cells 108 
The effect of combined vitamin E succinate and ascorbic acid on 
5-lipoxygenase activity in both LLCMK and BL6 cells • • • • • • . • • • • • • •• 112 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on cyclooxygenase activity in the LLCMK and BL6 cells •••••••.•••.• 117 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on prostaglandin E2 concentration in LLCMK and BL6 cells ••.••••••.• 122 
Comparison of prostaglandin levels in control cultures of BL6 cells •••••• 127 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on PGD2, PGF2a and PGI2 levels in BL6 cells •••••••••••••••••••• 128 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on adenyl ate cyclase activity in LLCMK and BL6 cells .••••••••••••• 134 
The effect of combined vitamin E succinate and ascorbic acid supplementation 
on cyclic adenosine monophosphate levels in LLCMK and BL6 cells • • • • • • 135 
xvi 
Table 28: 
- Table- 29: 
Table 30: 
Table 31: 
Table 32: 
PAGE 
The effect of combined vitamin E succinate and ascorbic acid supplementation, 
together with dexamethasone on BL6 cell growth ••..•.•••••••••... 156 
The effect of dexamethasone treatmept. on free radical and lipid peroxidation 
levels in BL6 cells supplemented with varying levels of combined vitamin E 
succinate and ascorbic acid .....•••••••.•••..•.••••••••••• 159 
The effect of dexamethasone treatment on cyclooxygenase activity i~ BL6 
cells supplemented with varying levels of combined vitamin E succinate and 
ascorbic acid • • • • . • • • • . . • . • • • • • . • . . • • • • . • • . • • . • • . • • • • • 161 
The effect of dexamethasone treatment on PGEz levels in BL6 cells supplemented 
with varying levels of combined vitamin E succinate and ascorbic acid ••.. 164 
The effect of dexamethasone treatment on adenyl ate cyclase activity and 
cyclic adenosine monophosphate levels in BL6 cells supplemented with 
varying levels of combined vitamin E succinate and ascorbic acid 166 
XVll 
ACKNOWLEDGMENTS 
My sincere appreciation and gratititude are expressed towards the staff members of the 
Biochemistry and Microbiology Department, Rhodes University, for the years of support and 
assistance they have provided. In particular, I would like to thank Professor J. Duncan, my 
supervisor, for his guidance and encouragement during the last few years. 
To all my colleagues in the Department of Biochemistry, Rhodes University, for their 
encouragement and helpful comments. Special thanks goes to Megan van Rooyen for her practical 
assitance and Wade Edwards for his assitance on the High Performance Liquid Chromatography. 
To Paulo Ottino for his support and encouragement through the years. 
My parents, Harold and Wendy Midgley and sister Liesl, for their constant support and 
encouragement throughout my university career. 
I am grateful to Dr Sirion Robertson, Moira Pogrund and Megan van Rooyen for proofreading 
this thesis. 
Lastly, I would like to thank the Foundation for Reasearch Development and the National Cancer 
Association for the funding of this project. 
XVlll 
a-TOH 
AA 
AC 
AMP 
ANOVA 
Asc 
ATP 
BL6 
cAMP 
CDR 
COX- . 
CPM 
DHA 
DMSO 
DNA 
EFA 
FCS 
GAG 
GDP 
Gi 
GLC 
Gs 
GTP 
H20 2 
HDL 
HPLC 
kDa 
LDL 
LLCMK 
LOX 
LT 
ABBREVIATIONS 
Vitamin E = a-Tocopherol 
Arachidonic acid 
Adenylate cyclase 
5' Adenosine monophosphate 
Analysis of variance 
Vitamin C = ascorbic acid 
Adenosine triphosphate 
Murine melanoma cells 
Calcium 
Cyclic adenosine monophospahte 
Calcium-dependent regulatory protein 
Cyclooxygenase 
Counts per minute 
Dehydroascorbic acid 
Dimethyl sulphoxide 
Deoxyribonucleic acid 
Essential fatty acid 
Foetal calf serum 
Glycoaminoglycan 
Guanine diphosphate 
Inhibitory guanine-nucleotide bInding regulatory protein 
Gas-liquid chromatography 
Stimulatory guanine-nucleotide binding regulatory protein 
Guanosine triphosphate 
Hydrogen peroxide 
High density lipoprotein 
High performance liquid chromatography 
Kilodallton 
Low densiity lipoprotein 
Monkey kidney cells 
Lip oxygenase 
Leukotriene 
XIX 
MDA Malondialdehyde 
MEM Minimum essential medium 
Mg2+ Magnesium 
NADH Nicotinamide adenine dinucleotide ~< 
NADPH Nicotinamide adenine dinucleotide phosphate 
NBT Nitroblue tetrazolium 
NO Nitrous oxide 
N02 Nitrite 
NSAID Non steroidal anti-inflammatory drug 
PBS Phosphate bufffered saline 
PES Prostaglandin endoperoxide synthase 
PG Prostaglandin 
PGD2 Prostaglandin D2 
PGE2- . Prostaglandin E2 
PGF2a Prostaglandin F2a 
PGG2 Prostaglandin G2 
PGH2 Prostaglandin H2 
PGI2 Prostaglandin 12 
PHI Physiological hyaluronidase inhibitor 
PLA2 Phospholipase A2 
PUFA Polyunsaturated fatty acid 
RDA Recommended daily dietary allowance 
Ri Inhibitory receptor 
Rs Stimulatory receptor 
SEM Standard error of the mean 
SOD Superoxide dismutase 
Sr2+ Serium 
TBA Thiobarbituric acid 
TBP Tocopherol-binding protein 
TCA Trichloroacetic acid 
TLC Thin layer chromatography 
TX Thromboxane 
VLDL Very low density lipoprotein 
xx 
1 
CHAPTER 1 
LITERATURE<REVIEW 
1.1 CANCER 
Cancer can be defined as a cellular malignancy in which loss of normal controls results in 
unregulated growth, lack of differentiation, and the ability to invade local tissues and metastasize 
(1). Two types of cancers have been identified. Clusters of abnormally proliferating cells can arise 
in any part of the body. Those which are unable to invade the surrounding tissues and so remain 
strictly local growths are called benign tumours. Those that spread from their site of origin, 
disseminating into the bloodstream and lymphatic systems are called malignant tumours (2). The 
transformation of a normal cell into a neoplastic or abnormal cell is thought to proceed through 
three phases: initiation, promotion and progression (3-7) (see Figure 1). 
Chemical carcinogens, viruses, 
radiation, somatic gene mutation. 
Irreversible step 
Normal Cell 
Initiated Cell 
Premalignant Lesion 
Cancer Cell 
Initiation 
Promotion 
Progression 
Figure 1 : A multistep carcinogenesis model (7). 
1. Literature Review 2 
1.1.1 INITIATION 
The stage of initiation that occurs first in the natural· history of neoplastic development reflects a 
permanent and irreversible change in the initiated cell. The efficiency of initiation is related to cellular 
replicative DNA synthesis and cell division (4). The transformation of a normal cell to a cancerous 
cell can be induced by a variety of agents that are generally chemical or physical.in nature. These in 
turn ~ave been grouped into four relatively distinct categories: chemical, physical, biological and 
genetic (4,8,9) (see Table 1) . 
Table 1 : Representative examples of carcinogenic agents (4). 
=========================================== 
Class 
I. Chemical 
II. Radiation 
III. Biological 
IV. Genetic 
Examples 
polycyclic hydrocarbons, aromatic ainines, 
halides, diet, hormones, metals and 
polymers surfaces 
Ionizing ( X and 'Y rays, a partical radiation) 
and UV 
Viruses ( papova, herpes, retro and hepadna 
viruses) 
molecular mass range 
(Daltons) 
(((1-1+ 
Transgenesis by enhancer - promoter- oncogene 
constructs, selective breeding 
The primary action of each of these agents is either to generate or to be metabolically converted to 
electrophilic reactants which bind covalently to cellular DNA and other macromolecules (8). This in 
turn alters the information content or rate of expression of the genetic material. In the case of 
chemically induced cancers, unless the adduct is removed by repair processes, the lesion causes the 
introduction of a permanent genetic mutation. Initiation, the irreversible step, without the following 
steps, promotion and progression, rarely yields malignant tumours (8-10). 
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1.1.2 PROMOTION 
The primary characteristic of promotion that distinguishes it from the stages of initiation and 
progression is its operational reversibility (4). Promotion is a phenomenon of gene activation in which 
the latent altered phenotype of the initiated cell becomes expressed through selection and clonal 
expansion. Tumour promoters are not carcinogenic themselves, but must operate-in succession with 
initiators. In the absence of initiators, promoters can generate reversible changes in cell proliferation 
and phenotypic expression. The molecular mechanisms of tumour promoters are not fully understood. 
However, it is suggested that various promoters override the homeostatic regulatory mechanisms 
utilized by the growth factors (10,11). Proliferation of cells in culture is regulated predominantly by 
extracellular agents of which the polypeptide growth factors are among the most important. These 
factors interact with specific cell-surface receptors which in turn deliver intracellular signals ultimately 
leading to DNA synthesis. The characterization of oncogenes associated with tumourigenesis has 
prompted intensive research into the molecular mechanisms underlying the loss of growth control 
which is characteristic of tumour cells (12,13). 
Oncogenes are modified variants of normal cellular genes which, once activated by a mutation, an 
oncogene promotes excessive or inappropriate cell proliferation. Their products are presumed to 
function at least in part by mimicking the products of the cellular genes from which they arose 
(12,13). When isolated oncogenes from tumours are inserted into normal cells, the latter take on many 
traits of cancer cells. Such gene transfer experiments demonstrate that oncogenes function to 
deregulate the growth of cells into which they are introduced, and so must be accountable at least in 
part for the irregular functioning of the tumour cells from which they were extracted (13). Numerous 
studies have reported that oncogenes are altered versions of normal genes called proto-oncogenes that 
function as focal regulators of growth in normal cells. Various mutations in the course of the normal 
cells existence can convert one of these normal genes into a malignant oncogene (13,14). To date, 
oncogenes have been detected in only 15 or 20% of human tumours. The evolution of a line of 
tumour cells appears to hinge on the accumulation of mutations transforming a number of genes, 
among them oncogenes (15). Cellular antigens encoded by tumour viruses and some antigens encoded 
by cellular oncogenes offer advantages as targets for immunotherapy by being inextricably associated 
with the neoplastic phenotype (16). 
The levels of free radicals may represent an additional or accompanying mechanism for mediating 
some of the actions of tumour promoters. Numerous promoters of carcinogenesis act by the 
1. Literature Review 4 
generation of oxygen radicals, resulting in lipid peroxidation processes. Lipid peroxidation cross-links 
proteins and affects all aspects of cell organization, including membrane and surface structure in 
- -
addition to the mitotic apparatus (17, 18). A number< of cellular defences against these tnmsient but 
damaging radical species exist and can be grouped into enzymic and non-enzymic antioxidant defence 
mechanisms. The non-enzymic agents include minerals as well as the antioxidant vitamins such as 
vitamin E, (3- carotene and vitamin C (16,17). a-Tocopherol (a-TOR) quenches ~inglet oxygen, 
reduces radicals formed from hydroxyl radicals, and protects the lipids from peroxidation by trapping 
peroxide radicals. Ascorbic acid (Asc) scavenges super oxides and in addition helps keep a-TOR from 
being completely inactivated. Rence these two vitamins are most effective in combination (5,16-18). 
1.1.3 PROGRESSION 
Progression is fundamentally typified by its karyotypic instability and· evolution, and the formation 
of irreversible aneuploid malignant neoplasms. Modifications in the structure of the genome of the 
neoplastic cells during this stage are directly related to the growth rate, invasiveness, metastatic 
capability, and biochemical alterations in the malignant cell (4). 
The bulk of cancer deaths are not caused by the primary tumour, but rather by secondary tumour 
growth elsewhere in the body. The ability of malignant tumour cells to disseminate can be considered 
the most lethal aspect of cancer. The spread of cancer from primary to secondary sites is called 
metastasis (19). It is convenient to view the process of metastasis in three phases: i) entrance of-cells 
into the blood stream, ii) circulation of cells to distant organ sites via the blood or lymphatic system, 
iii) arrest and proliferation of tumour cells in a distant organ or regional lymph node (19,20). 
The formation of a metastasis represents the end stage of several highly selective processes. By virtue 
of invasive properties or juxtaposition to the circulatory system in the primary tumour, some cells are 
"selected" for entry into the circulation. In the blood or lymph most tumour cells are destroyed. A 
few resilient cells adhere to capillary endothelium and after passing through other selective steps an 
even smaller number of cells initiate a metastasis. Studies by Boseman et al (cited in 20) showed the 
super metastatic strains exhibited changes in their electrophoretic mobility and, increased activity of 
degradative enzymes, surface glycoproteins and proteases. Immunoselection may also be an important 
aspect of cell selection for metastasis. 
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Organ selection by metastatic cells is not random: experimental observations indicate that 
metastasizing cells "refer" some organs to others. Not much is known about the mechanisms involved 
in organ selection by metastatic cells, however the'h)'pothesis of Green and Harvey (dted in 20) 
suggests that a tumour cell-endothelial cell bond is important in organ selection. 
1.1.4 CHEMOPREVENTION 
Established prevention and therapy approaches have proven unsuccessful in controlling the increased 
incidence of, and low survival rates related to, many solid tumours. Numerous new approaches are 
in progress; one of the foremost is chemoprevention. Chemoprevention is defined as the systemic use 
of specific natural or synthetic chemical agents to reverse or suppress the progression of a 
premalignancy to invasive cancer (6,21). A group of such agents is the antioxidants. 
Many studies have sought to improve our understanding of the role of antioxidants in protecting the 
human body against cancer. Consequently, cancer chemoprevention through supplementation and 
fortification of the diet with micronutrient antioxidants may become an effective strategy for.cancer 
'. 
treatment before the close of the century (22). Benedict et al (6) believe that Asc may play an 
important role in chemoprevention, in addition to identifying events necessary for oncogenic 
progression. Asc has been considered to be of possible chemopreventive use, mainly as a chemical 
block to cancer cell initiation. Furthermore, Asc exhibits antioxidant and antiviral activity, and has 
the ability to block nitrosamine formation (6). Vitamin E (a-TOH) has also generated much attention 
as a protective agent against chemically-induced toxicity to cells (23,24). The principal role of vitamin 
E in enhancing immune responses and phagocytosis is the prevention of lipid peroxidation of cell 
membranes. The rapidly proliferating cells of the stimulated immune and phagocytic systems are 
particularly prone to peroxidative damage by free radical, peroxides and superoxides. The antioxidant 
effect also modulates the biosynthesis and activity of important cell regulators, prostaglandins (PGs), 
thromboxanes (TXs) and leukotrienes (LTs). These studies suggest that vitamin E and vitamin C 
interact positively in enhancing immune responses and protection from infectious diseases and cancer 
(24). 
Since Asc and a-TOH and their role in the neoplastic process is the subject of this thesis, it is 
important to consider the general role of both Asc and a-TOH in cell metabolism. 
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1.2 ASCORBIC ACID 
1.2.1 HISTORY 
Micronutrients, which include vitamins, minerals and some trace elements, are dietary components 
essential to normal metabolic function (25). The term "essential" implies that Aso-bas-to be acquired 
in th~ diet as it cannot be synthesized de novo in Homo sapiens. Asc, commonly known as vitamin 
C, is a water soluble vitamin and is increasingly being recognized as an agent with broad biological 
function and importance (25). 
Asc is essential in the diet of man, other primates, the guinea pig, an Indian fruit- eating bat, the red-
vented bulbul and some related species of the Passeriform birds (cited in 26). All other animal 
species are able to synthesize Asc (26) because they possess the enzyme L-gulono-'Y-Iactone oxidase 
(EC 1.1. 3.8). This enzyme catalyzes the conversion of L-gulono-'Y-lactone to Asc (27). It is 
estimated that primates lost the gene for L-gulono-'Y-Iactone oxidase 70 million years ago (28). 
- ,,'_. 
Scurvy, a disease known since antiquity, is a consequence of an Asc deficient diet which was 
particularly noted in sailors on long voyages in the 15th through to the 19th Centuries (29,30). Sir 
Richard Hawkins in the 16th Century discovered that the juice of fresh citrus fruits cured scurvy. This 
discovery was again used by James Lind in the 18th Century for curing British sailors (29). The active 
agent, the enolic form of 3-keto-L-gulofuranlactone or hexuronic acid, was later named Asc or 
vitamin C. It was first isolated from oranges, cabbages and adrenal glands in the late 1920s by Albert 
Szent-Gyorgi (29,31,32). 
1.2.2 STRUCTURE AND METABOLISM OF ASCORBIC ACID 
Asc is synthesized from D-glucose as shown in Figure 2. In man, due to the absence of the enzyme 
L-gulono-'Y-Iactone, the last step in the Asc biosynthetic pathway involving the oxidation of L-
gulonolactone to Asc cannot occur (28,29). 
Thus Asc is shown to be a 'Y-Iactone, although other tautomeric forms may exist in small quantities. 
The configuration at C-5 is L- (or S-, using the Cann-Ingold-Prelog system). The acid nature in 
aqueous solution derives from the ionization of the enolic OH on C-3, with the resulting Asc anion 
being localized (33). It has been estimated that about forty thousand tonnes of the vitamin are now 
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manufactured annually. In addition to the precursor D- glucose, the synthesis of Asc from C-5 sugars 
is now well established with xylose, lyxose, and recently arabinose being used as precursors (33). 
VitamIn C is the most commonly available singfe nutrient supplement used in the US (30); 
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Figure 2 : The metabolic pathway of L-ascorbic acid biosynthesis in animals (28). 
1.2.2.1 Metabolism 
The recommended daily dietary allowances (RDAs) over the past few decades have varied from as 
little as lOmg to a thousand times as much. The recommended RDA for an adult is 60mg, while the 
RDA for the aged is 150mg (33). Milk is the only animal produce that provides a significant amount 
of the vitamin (1-5mg per lOOg) , although there is some in liver. The best sources are fresh fruits 
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(particularly citrus, tomatoes and green peppers), baked potato (17mg per lOOg) and leafy vegetables. 
Compounds which are incapable of being syntliesized within the cell need to be transported in two 
ways: across cell membranes and through biological fluids. Transportation through biological fluids 
can involve simple diffusion, hydrodynamic flow and protein binding (34). 
It is believed that protein binding is of little significance in the transport of vitamin C in biological 
fluids and its retention in cells (34,35). Vitamin C can be filtered by the kidney and ultra filtered from 
plasma suggesting that protein binding in the blood is minimal (34,35). In addition, vitamin C is 
rapidly lost from energy-depleted cells, suggesting that binding within the cell is also probably 
limited. On the other hand, studies have shown binding of Asc to serum albumin and that this plasma 
protein can increase the stability of vitamin C (34). No more can be deduced as the full extent of 
associat.ions and binding strength remain to be determined (34). 
The polarity of Asc, which favours its presence in aqueous fluids, also hampers its passage across the 
hydrophobic cell membrane. This, and the high concentrations, make it almost certain that the vitamin 
needs carrier mechanisms to enter the cell (34,35). Unfortunately, understanding of the-transport 
mechanism into the cell remains unclear. Most cells appear to be able to transport dehydroascorbic 
acid (DHA), the oxidized form of Asc. The process involves facilitated diffusion, i. e. with a carrier 
but not against the an electrochemical gradient or requiring energy. Continuous uptake of 
dehydroascorbate is due to the cells ability to rapidly reduce it to Asc and hence conserve_ a_ low 
intracellular concentration of the oxidized form of the vitamin. The possibility of co-transport of Asc 
by this system provides an additional mechanism for moving Asc across cell membranes (34). Once 
in the cell, transportation down the concentration gradient into the blood via facilitated diffusion 
occurs. 
Asc can act as a reducing or oxidizing agent depending on the reaction and circumstances. One of the 
principal reasons for the great interest in this aspect of vitamin C function, is that the role of vitamin 
C in living systems is undoubtedly connected to its oxidation-reduction behaviour. This phenomenon 
may ultimately be the key in understanding the biological mechanisms of the actions of vitamin C 
(33,36). L-Asc is oxidized by dioxygen to dehydroascorbic acid (see Figure 3), and both have 
antiscorbutic and other physiological functions of vitamin C. Both Asc and DHA are ultimately 
excreted in the urine as oxalic acid (31,37). 
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Figure 3 : Vitamin C metabolism in humans (37). 
1.2.3 _ FUNCTIONS OF ASCORBIC ACID 
9 
Asc is of enormous biological importance. Functions include involvement in enzyme reactions, 
synthesis of hormones, neurotransmitters, collagen, carnitine, detoxification of exogenous compounds 
and cytochrome P450 activity. In addition, it plays a major role as an antioxidant and free radical 
scavenger, protecting cells against lipid peroxidation. Furthermore, it has been shown to function in 
reconstituting vitamin E for protection of lipid membranes (38). 
Uncertainty exists regarding the actual concentrations of intracellular Asc but it has been esti~~ted 
to be as high as several millimolar (39). In man, the highest concentration of Asc is located in the 
adrenals, ovaries, brain, pituitary gland, liver, spleen, blood cells and extracellular fluid surrounding 
the lung and eye (33). In this thesis, discussions of functions or suggested functions will be limited 
to the areas of relevance to cancer. 
1.2.3.1 Ascorbic acid in enzyme reactions 
Reactions primarily involving Asc are hyroxylations requiring molecular oxygen (see Figure 4). These 
reactions usually involve Fe2+ or Cu2+ as a cofactor (29). Asc is known to stimulate numerous 
dioxygenases that contain prosthetic Fe2+ and monooxygenases with prosthetic Cu2+. Although other 
reducing agents may replace Asc, at least to some extent, Asc shows the greatest stimulation of these 
activities. 
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Asc is believed to play one of two roles: (i) as a source of electrons for reduction of 02; i.e. as a 
cosubstrate (see Figure 4), or (ii) as a protective agent, ip that it provides electrons to keep prosthetic 
metal ions in the reduced ·state (29,40). These enzymatic reactions are important to many biochemical 
processes, for example hydroxylation reactions. 
Enzyme-Fe3+ + Asc....,. Enzyme-Fe2+ + DHA 
Figure 4: The suggested role of ascorbic acid as a cosubstrate in an enzyme reaction (40). 
1.2.3.2. Ascorbic acid in the extracellular and intracellular matrix and collagen biosynthesis 
Most cells in the body are firmly embedded in a highly viscous ground substance. The ubiquitous 
ground material infiltrates every interspace and sequesters every stationary cell from its 
neighbours. It forms the immediate contact environment of all cells and it must be travers.,ed by 
molecules entering or leaving the cell. Evidence suggests that the interface between a cell 
membrane and its immediate extracellular environment is the vital factor in the whole proliferative 
process (31,41). Variations in the composition of the extracellular environment exert a significant 
effect on cell behaviour, hence the cells obtain a powerful means of modifying their immediate 
surroundings. Thus a proliferating cell and its contact environment comprise a balanced scheme in 
which each component influences the other; this synergism is involved in all forms of cell division 
and is of particular importance in cancer. Until recently, emphasis on cancer research tended more 
towards the cell, neglecting the other half of the proliferation equation (31,41). 
The ground substance of the intercellular matrix is a complex aqueous gel containing electrolytes, 
metabolites, dissolved gases, trace elements, vitamins, enzymes, carbohydrates, fats and proteins. 
The characteristic viscous property is dependent on the abundance of specific long chain acid 
peptidoglycan polymers, the glycoaminoglycans (GAGS) and the proteoglycans. This network of 
high-molecular weight polymers form the structurally stable hydrophilic mesh, which in turn is 
fortified at the microscopic level by a 3-dimensional web of collagen fibres (31,41). The single-
stranded long chain polymers comprising GAGs have molecular weights ranging from 101 - 106 . 
Hyaluronic acid (comprising repeating molecular units of N-acetylglucosamine and glucuronic 
acid), chondroitin (built up from N-acetylgalactosamine and glucuronic acid), and sulphate esters 
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(chondroitin sulphate) are the standard forms. Proteoglycansare macromolecules of a more complex 
multibranched structure. Present evidence (41) suggests a primary GAG core exists, to which 
secondary protein cores are attached at spaced intervals by link proteins. 
A notable property of the intercellular substance is its very high viscosity and cohesiveness, which 
in turn is dependent upon the chemical integrity of the large molecules. The structural integrity and 
visco~ity can be eliminated by the hydrolyzing action of certain related enzymes known by the generic 
name hyaluronidase. Most cells in the body are able to synthesize hyaluronidase. The network of the 
intercellular ground substance is in dynamic equilibrium with GAG and its breakdown products via 
the catalytic action of hyaluronidase and subsequent excretion (41). Claude Bernard (cited in 41) states 
that it is in this slowly changing environment that all cellular activity takes place. Depolymerization 
of matrix proteoglycans is initiated by the combined action of the glycosidases and neutral proteases. 
Both of-these are believed to be released simultaneously from lysosomes during cell division. It now 
seems reasonable to suggest that continuous release of these hydrolytic enzymes from neoplastic cells 
is responsible for their invasive capability, for the selective routing by increased diffusion of nutrients 
towards the tumour cell, and perhaps for even sustaining the whole momentum of autonpmous 
neoplastic proliferation (31). 
The collagen component of the extracellular matrix is also vulnerable to the same hydrolytic enzyme 
activity. Collagen synthesis is a complex process of protein synthesis, postranslational modifications, 
protein secretion and extracellular matrix formation. Collagen is a unique animal protein:g.lycine 
comprises up to one third of its amino acid residues with an abundance of proline or 4-hydroxyproline 
and a few of 3 hydroxyproline and hydroxy lysine residues (27,29,31,40). Hydroxylation of prolyl and 
lysyl residues in collagen is catalyzed by the respective hydroxylases. The enzyme prolyl 4-
hydroxylase requires ferrous ion, a-ketoglutarate, oxygen, correct substrate peptide and Asc for 
maximum activity (27,29,31,40). 
The exact role of Asc in collagen synthesis has been the focus of numerous studies. Lack of Asc 
dramatically reduces hydroxylation ofprolyJ and lysyJ residues into hydroxyproline and hydroxylysine 
of mature collagen during ribosomal assembly, leading to the instability of the triple helix of collagen. 
This instability results in increased collagen catabolism which is demonstrated in scurvy and in 
cancer (27,29,31,42) in a variety of cell types. Addition of Asc has brought about increased 
transcription, translation, and stability of mRNA for procollagen. Assuming cell proliferation is reliant 
on the depolymerization of the ground substance by cellular hyaluronidase, it can be seen that there 
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are two methods of exerting some therapeutic control of cancer and other disease states in which 
extreme cellular proliferation is a harmful feature. An attempt to strengthen the ground substance is 
one such way and the other is to directly neutralIze the cellular hyaluronidase by limiting or inhibiting 
its action (41). There is strong evidence (41,43) to suggest that Asc is in some way involved in the 
synthesis of a physiological hyaluronidase inhibitor (PHI). Thus if the elementary theory of cellular 
proliferation is correct, hyaluronidase catalyzes the hydrolysis of the GAG)n Jhe immediate 
environment allowing cells freedom to divide and migrate. PHI might then prove to be a valuable 
therapeutic agent in controlling numerous forms of excessive proliferation, including cancer. It may 
not be necessary to synthesize PHI, but rather it may be possible that the body, given enough Asc, 
could synthesize a sufficient quantity of PHI (41). Thus in summary: in cancer, to obtain sufficient 
inhibition of cell migration, an excess of Asc maybe essential and is one factor open to therapeutic 
intervention. 
1.2.3.3 Ascorbic acid and nitrosamines 
N-Nitroso compounds are known to induce a wide variety of tumours in most species of animal~. This 
suggests that N-nitroso compounds are important in human carcinogenesis. Such nitrosalriines are 
thought to come from exogenous and endogenous sources (29,31,44-46). 
Asc is a potent inhibitor on N-nitrosamine formation (7,47), the precursors being nitrates and nitrites 
and secondary or tertiary amines (47). Nitrites are present in water and foods, particularly vegetaples, 
in addition to cured meat products and cheese. Bacteria in food and in saliva convert the nitrates from 
these sources to nitrite, which is the important nitrosating agent. On the other hand, nitrogen oxides 
produced in flame ovens, cigarette smoke and other atmospheric pollution can act as nitrosating agents 
(44). Nitrosamines are formed by reaction of nitrite (N02) with amines under conditions of low pH 
(PH 2-4) as is present in the stomach (29,31,46). A number of the cancer cases in humans may be 
attributed to the action of these agents. 
In cancer cells Asc, has the ability to react with the nitrosating agents, converting them to products 
which do not nitrosate. The reactions involve nitrous oxide (NO) with either Asc or its anion (DHA) 
therefore competing with amine-nitrosation reactions (29). Dietary supplementation with Asc was also 
been carried out to determine its effectiveness in inhibiting cancer by these preformed chemicals. 
Studies (cited in 46) showed protective effects of vitamin C against skin, respiratory tract, and kidney 
cancer; either inhibition, enhancement or no effect in the mammary gland and colon cancer, and no 
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effect of Asc supplementation in the urinary bladder. 
1.2.3~4 H20 2 formation by and antioxidanf rolep( ascorbic acid 
It is suggested in the literature that Asc can generate hydrogen peroxide (H20 2) upon oxidation by 
molecular O2 in biological systems (36,48). Asc oxidation involves single electron transfer reactions, ~- -
which result in the formation of H20 2 (49). 
This highly reactive H20 2 is termed a reactive molecule and is capable of causing cellular damage. 
The sites of formation of this molecule include all cellular constituents in addition to the cytosol. 
Deleterious effects caused by these molecules involve H20 2 reactions with polyunsaturated fatty acid 
(PUFA) intracellular membranes, nucleotides in DNA and critical sulfhydryl bonds in proteins (50). 
Peterkofsky et al (51) proposed that the antitumour effect of Asc was mediated by H20 2, as the latter 
was found to be toxic to fibroblast cultures. Benade et al (48) found Asc to be toxic to Ehrlich ascites 
carcinoma cells in vitro and proposed that the toxicity is linked to H20 2 formation. It has been 
suggested that the toxicity of Asc to tumour cells may be due to low catalase levels in tumour cells. 
The catalase enzyme is responsible for the detoxification of H20 2 within cells (52,53). Asc inhibits 
catalase activity, hence supplementation of tumour cells with Asc will result in the decreased 
detoxification of H20 2 by catalase ultimately resulting in an accumulation of H20 2 to cause cell death 
(53). 
In contrast, Asc is an excellent water-soluble antioxidant and free radical scavenging nutrient 
protecting cells from destruction by oxidants (33,40,54-57). Free radicals, including hydroxy, 
hypochlorite, peroxy, alkoxy, superoxide, hydrogen peroxide, and singlet oxygen are generated by 
autooxidation, radiation, or from the activities of oxidases, dehydrogenases and peroxidases. Vitamin 
C is known to act as an antioxidant both in vitro and in vivo and its function as a free radical 
scavenger enables vitamin C to become the cells primary defence mechanism against oxidative 
damage. Increasing evidence implies the involvement of free radicals and oxygen species in numerous 
pathological events, cancer and ageing (56). 
1.2.4 ASCORBIC ACID AND CANCER 
As already mentioned, some micronutrients are known to possess anticarcinogenic properties. Vitamin 
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C has been suggested (5,6,11,16,22,26,29,39,40,43-45,48,49,58-62) and disputed (52,63-69) as an 
anticancer agent. The antitumour activity of Asc is reported to be due the its chemical properties, and 
not due to its metabolism (70).< . 
A reduced status of Asc in serum and plasma of cancer patients and tumour-bearing animals have 
been reported in several studies (43,71). The first large-scale trial of Asc supplel!lentation in human 
cancer therapy was reported by Cameron and Pauling (72) in which 22 % of the Asc-treated patients 
-
were alive compared with only 0.4 % of the control group after one year of study. Cameron (73) has 
since published a protocol for the use of vitamin C in the treatment of cancer, emphasing continuous 
use of vitamin C as opposed to intermittent administration. In contrast, Campbell and Jack (74) 
cautioned the use of mega Asc therapy in cancer treatment. 
Immunological studies have reported that Asc can induce imm.unity against some cancers in mice. In 
addition to the immunizing actions are changes in the surface structure of the cancer cells (75). 
Reversion by Asc of transformed cells to normal morphology has been proposed (76-78). These 
studies suggest that low concentrations of Asc in C3H/lOT1h/CL8 cells can be effective in supp~~ssing 
oncogenic progression only prior to a stage where an initiated cell achieves the capacity to grow in 
semi-solid medium and to produce tumours in immunosuppressed animals (76,77). 
Epidemiological evidence links increased intake of fruits and vegetables with decreased risk of most 
cancer types (7). Of 170 epidemiological studies (cited in 79) of cancer at all sites, 132 exhiQited a 
statistically significant protective effect associated with the highest intakes of fruits and vegetables. 
Individuals with low fruit/vegetable intake (approximately 20-30% of the population) have cancer 
rates at least twice that of individuals with high intakes. This is suggestive of an important role for 
vitamin C in cancer prevention. In 90 epidemiological studies by Block (38) in which he examined 
the role of vitamin C or vitamin C rich foods in cancer prevention, the vast majority showed 
statistically significant protective effects. This evidence is particularly strong for the cancers of the 
oesophagus, oral cavity, stomach and pancreas, while other studies have suggested protective effects 
in cancers of the cervix, rectum and breast. Graham et al (cited in 80) suggest a protective role for 
Asc in laryngeal cancer. Although there are encouraging data on the anticarcinogenic effects of Asc, 
higher than recommended levels have been shown to produce adverse effects under some conditions 
(80). 
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1.3 VITAMIN E 
-
1.3.1 HISTORY 
Studies by Osborne and Mendel and by Matti! and Conklin in 1922 (cited in 81) demonstrated that 
laboratory rats fed a semi-purified diet providing an abundance of the vitami~ A, B, C and D 
exhibited good growth and stamina but often failed to support reproduction. At this time Evans and 
his coworker Bishop (81) undertook studies in which it was reported that reproduction failed in 
pregnant females fed diets containing all of the then known nutrients. Although oestrus, mating and 
every recognizable phase of the beginning of a normal pregnancy had resulted, the foetuses soon died 
and were resorbed. It was against this background that Evans and Bishop (82) demonstrated the 
evidence of an unknown dietary factor, initially named factor X. Wheat germ, lettuce and dried alfalfa 
leaves_were recognized as sources of this fat soluble factor (81,.83). Single daily drops of wheat germ 
oil completely prevented this gestation resorption, whereas rich sources of vitamins A, D and cod 
liver oil not only failed to prevent resorption but also increased the severity of the defect. Barnett Sure 
(cited in 82), in 1924, confirmed Evans's finding in independent studies, concluding that t9is fat 
soluble reproductive factor was a new vitamin. In 1925, Evans adopted the letter E as the next serial 
alphabetical designation. Thus the first five years of vitamin E history was that of its recognition 
solely as a dietary factor necessary for fertility in the male and female rat. 
During the next decade or two fruitless attempts were made to acquire evidence of practical 
applications of this discovery in terms of reproductive failures in vetinary and clinical medicine. In 
1931 Adamstone (83) recorded mortality in vitamin E deficient chick embryos, while Pappenheimer 
and Goettsch described vitamin E deficient encephalomalacia in the chick and nutritional muscular 
dystrophy in guinea pigs and rabbits, hence confirming Evans and Burr's idea (1928) that vitamin E 
was not implicated only in anti-sterility (81,83). 
Vitamin E research had been severely impeded by the lack of a more potent source of the vitamin 
than wheat germ oil, and by dependence upon time-consuming and incompletely reliable bioassays 
for determining the vitamin E content of plants and animals. Evans et al (82-84) at Berkeley isolated 
an active substance from wheat germ oil and found it to have very high vitamin E activity. Fernholz 
(cited in 82) in 1938 undertook thermal degradation of the vitamin, demonstrating that it contained 
a phytyl chain and a hydroquinone moiety, and suggested a structure of the vitamin later proven to 
be correct. The structure of vitamin E was subsequently determined and given the name tocopherol. 
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1.3.2 STRUCTURE AND METABOLISM OF VITAMIN E 
Vitamin E refers to a family of fat soluble phenolic <c0mpounds called tocopherols (85,86). Eight 
forms of vitamin E are known to exist in nature: a-, {J-, 'Y-, and 0- tocopherols contain saturated 
phytol side chains, while a-, {J-, 'Y-, and 0- tocoti-ienols possess three double bonds in the side chain 
(82,85-87), o-tocotrienol is the first member of the group to be formed by biosynthetic processes in 
plants, after which methylation occurs leading to the consecutive formation of A-, {J-, and a-trienols 
and hydrogenation of these produce the respective tocopherols. The tocopherols possess three 
asymmetrical carbon atoms located at C-2, C-4' and C-8' (82) (See Figure 5). 
;;o~ ly!l~CH3 
c~ 0 . c~ 
5 TccC':;!".ercl 
Figure 5: Chemical structures of naturally occurring tocopherols and tocotrienols (82). 
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The most biologically active form of vitamin E is a-tocopherol (a-TOH) (82,85,86,88-90). a-TOH 
(see F~gure 5) is a 6-hydroxychroman derivative with methyl groups in positions 2,5,7 and 8 and a 
16-carbon aliphatic side chain attached at carbon 2. The'phytyl side chain at position 2 facilitates the 
incorporation and retention of the a-TOH molecule in biological membranes, so that the biologically 
active site of the molecule in the 6-hydroxyl position is optimal (85,86,90). 
Two 12rimary sources of vitamin E in commercial use are d-a-tocopherol and dl-a-tocopherol, in 
addition to the acetate and succinate esters of these compounds. The acetate esters are prepared 
commercially by reaction of the alcohol forms with acetic acid and they do not exist in nature (82). 
Vitamin E is a potent anticancer agent in terms of both cancer prevention and regression. This has 
been verified in various animal experiments and cell culture studies (49). Of the various forms of 
vitamin E tested for antiproliferative effects on tumour cells - namely D'-a-tocopherol nicotinate, DL-
a-tocopherol free alcohol, Aquasol DL-a-tocopherol acetate and D-a-tocopherol succinate, the 
succinate form of natural D-a-tocopherol (see figure 6) (1), has been shown to be the most effective 
form in vitro (49,91-98). Although the precise reasons for this are unclear, the following possibilities 
,-
have been suggested: (a) vitamin E succinate may be marginally more soluble and stable in growth 
medium or solution; (b) it may easily cross the cell membrane, and (c) it may be converted to a-TOH 
more slowly, so that the intracellular level of a-TOH remains high for a longer period of time (49). 
Figure 6: a-Tocopherol acid succinate (1). 
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Vitamin E is an essential nutrient for man as it cannot be synthesized de novo and is therefore 
obtailled from the diet (99). The required dosage for most vitamins is based on the level at which 
deficiency becomes clinically evident. The minimum~utritional requirement for adults is in the range 
5-13mg of d-a-TOR or its equivalent (99-102). The average intake of a balanced adult diet ranges 
from 7 to 9mg, and the RDA is 8-lOmg per day (99,102). Vitamin E is a fat-soluble vitamin found 
in the diet primarily in vegetable oils, cereal grains, green plants, egg yolk, milkTat,~liver, nuts and 
vegetables (100-102). TORs occur as free phenols in most food sources, however a-TOR esters are 
widely used in pharmaceutical formulations and dietary supplements because the esters are much more 
resilient to oxidation (81,102,103). 
The mechanism by which vitamin E is absorbed and transported in plasma is well understood, but its 
intracellular transport is not well recognized. Due to its hydrophobicity, vitamin E requires a special 
transport system in aqueous environments of the plasma, extracelhilar space and cell cytoplasm. 
Unlike other vitamins, vitamin E does not have a special carrier protein in plasma but is transported 
in plasma by lipoproteins such as high density lipoprotein (RDL), low density lipoprotein (LDL), and 
very low density lipoprotein (VLDL) (104,105). Dietary studies have indicated that no discrimination 
between the homologues in the intestine occurs, as TOR is absorbed from the gut in micelles in which 
the formation depends on bile salts and pancreatic lipase (86,104-107). Absorption of TOR occurs 
mainly in the upper and middle thirds of the small intestine of animals and is enhanced by medium 
chain triglycerides but inhibited by long chain polyunsaturated fatty acids (PUFAs). Micelles 
containing TOR, free fatty acids, monoglycerides and other fat soluble vitamins passively diffuse 
through the brush border (82,104). Transfer of micelles from the cell thus requires several stages. 
In mammals, it must proceed through the lateral or basal plasma membrane of the cell and through 
the basal lamina and then enters the fluid of the lamina propria. It is from here that the vitamin enters 
the capillaries of the lymph and is transported in the intestinally-derived chylomicrons which in turn 
are swiftly catabolized in the circulation by lipoprotein lipase bound to the endothelial wall (107). 
FAs and TOR are transferred to tissues during lipoprotein lipase-catalyzed hydrolysis of 
triacylglycerols to free FAs and monoglycerols. Resulting chylomicron components, including 
apolipoproteinic cholesterol, phospholipids and TORs are delivered to plasma RDLs, while 
apolipoprotein E is transferred in the reverse reaction, i.e. from RDL to the chylomicrons. The 
binding of apolipoprotein E to chylomicron remnants leads to a rapid clearance of the chylomicron 
remnant particles from the plasma by the liver via specific apolipoprotein E receptors (108). 
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Studies by Behrens and Madere (l09) demonstrated the involvement of a low molecular weight (about 
32 KDa) TOH -binding protein (TBP) which was extremely specific for the a-form of the vitamin. The 
cytos-olic liver TBP may serve as an intracelhilar tIansfer protein (cited in 108) shuttling a-TOH 
between subcellular components particularly to proximal VLDL. In addition, evidence suggests (cited 
in 108) that the liver TBP may play a part in maintaining plasma a-TOH levels and controlling 
excretion of vitamin E via the bile. How vitamin E is returned from the tissues tOJhe_ circulation for 
reprocessing and recirculation or removal by liver, still remains to be answered (104,108). Vitamin 
E is secreted from the liver into the plasma in triacylglycerol-rich VLDLs. Hydrolysis of VLDLs by 
lipoprotein lipase delivers FAs and vitamin E to tissues and yields LDL. LDL carries the major 
portion of plasma vitamin E and appears to exchange vitamin E readily with HDL, providing a further 
means for the delivery of vitamin E to tissues via the LDL receptor-mediated uptake pathway (108). 
1.3.3 FUNCTIONS OF VITAMIN E 
Functions to be considered are those relevant to cancer. Cancer is believed to be a consequence of 
external factors combined with a hereditary predisposition for cancer. Increased cancer incidenc.~ with 
the onset of age may be due in part to the increased level of free radical reactions with age: together 
with the dwindling ability of the immune system to eliminate altered cells. Several functions of 
vitamin E are relevant in considering its role in cancer (110). In a addition to enhancing the humoural 
and cellular immune responses (111) vitamin E's reactivity with free radicals is considered to be its 
major biochemical function (88,110,112,113). Furthermore vitamin E is also known to inhibi.t- the 
conversion of nitrites to nitrosamines in the body. 
1.3.3.1 Vitamin E and nitrosamines 
Vitamin E shares with vitamin C the ability to inhibit nitrosamine formation in the stomach (18,25, 
45,76,102,110,113,114). Vitamin E also acts in the lipid membrane where nitrosation occurs more 
readily. a-Tocopherol prevents nitrosamine formation in vitro by destroying nitrite anions and in vivo 
by preventing the nitrosative cleavage of the amine to a nitrosamine (25,76,115). Since 80% of 
nitrosamines are carcinogenic, the prevention of nitrosamine formation has potential significance for 
the prevention of cancer. 
1. Literature Review 20 
1.3.3.2 Vitamin E and p53 
p53 is- a gene that has received vast attention as -a tUIllOl,lr suppressor gene since its discovery in 1979 
(116-120). p53 encodes a 53 KDa protein that arrests the growth of cells containing damaged DNA, 
thereby helping to conserve genetic stability. It functions as a transcription factor with high affinity 
for specific DNA target sequences, and in response to DNA damage, p53 up regulates the expression 
r- -
of target genes such as the gene encoding p21, which in turn blocks cell proliferation in G 1 of the 
cell cycle or functions as an essential trigger of apoptosis (117,118). The p53 protein is composed 
of 393 residues and is divided into three structural domains. These three structural domains are known 
as the amino-terminal trans-activation domain, the central "core" domain and finally the carboxyl 
terminus (117). This "wild type" of p53 may be converted by mutation to a "mutant type" of p53 
that can act as an oncogene, perhaps alone or together with other oncogenes. Mutant forms not only 
deprive_ cells of the "wild types" beneficial effects in cells but can spur abnormal cell growth. The 
"mutant type" of p53 is expressed in various forms of malignant tumours including carcinomas of 
breast, lung, colon, stomach, oral mucous membrane and osteogenic sarcoma (116,119). There is 
evidence (117) to suggest that mutations in the central core domain are linked with cancer. Such 
cancers are particularly difficult to treat, since mutant p53 confers resistance (117) to radiation and 
chemotherapy. Tumours containing abnormal forms of the p53 protein are the most aggressive and 
are particularly prone to spread and cause death quickly. Numerous pharmaceutical companies already 
have teams working on cancer therapies that target p53. 
Since vitamin E has potent activity in cancer inhibition in vitro and since the concept of cancer 
suppressor genes has been established, Schwartz et al (116) undertook an experiment using the 
hamster buccal pouch model to seek the mechanism of vitamin E's anticancer action in the stimulation 
of a cancer suppressor gene or inhibition of related oncogenes. They found stimulation of "wild type" 
p53 by vitamin E and decreased "mutant" p53 expression by vitamin E. They propose three 
suggestions for vitamin E anticancer action: stimulation of a cancer repressor gene; prevention ofp53 
mutation to oncogenic forms by promoting DNA repair and by preventing mutation of other proto-
oncogenes which may function together with "mutant" p53 (116). 
1.3.3.3 Vitamin E and membranes 
Mammalian cell membranes consist of a lipid bilayer primarily of phospholipids and cholesterol. 
Proteins having vital cellular functions, such as receptors, transporters and enzymes, are embedded 
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in the lipid bilayer (121). The oxidation of PUFAs associated with membranes can result in the 
. - disruption of numerous c~llular functions and cause leakage of intracellular contents. This process, 
termed lipid peroxidation, is believed to be a major'factor in causing numerous toxicities. PUFAs 
susceptibility to lipid peroxidation is counterbalanced in biological reactions by numerous endogenous 
antioxidant enzyme systems and antioxidants (122,123).Vitamin E is a potent chain breaking 
antioxidant which inhibits lipid peroxidation in membranes (84,88,107,108,122,1'24-128). Since a-
TOH -is required for protection of mitochondrial and microsomal membranes even when the diet 
contains enough synthetic antioxidant, it is clear that d-a-TOH appears to have the advantage over 
other TOHs and organic antioxidants by having the best access and longest retention in the tissues 
(82). Lucy (125) suggested that vitamin E stabilizes membranes by virtue of specific physicochemical 
interactions between its phytyl side chain and the fatty acyl chains of polyunsaturated phospholipids 
particularly derived from arachidonic acid. Lucy and Diplock (127) proposed that the interaction of 
a-TOR with phospholipids containing arachidonyl residues comprises two reactions. The methyl 
group at C4' of a-TOH can fit into a pocket provided by the cis double bond nearest the carboxyl 
group. The methyl group at C8' of a-TOH is then aligned and can interact similarly with the third 
cis double bond. Thus in the complex formed, the hydroxyl group of the chromanol ring ~td-TOH 
and the polar groups of the phospholipid all lie at the same end of the complex where they are thought 
to participate in polar interactions at the membrane surface (82,127). Therefore membranes lacking 
vitamin E would be expected to be less stable. In addition, according to Lucy and Diplock (125,127), 
vitamin E in the membrane would reduce membrane permeability and vitamin E deficiency would 
increase permeability. Scott et al (cited in 129) agree with the postulations of Lucy (127f who 
suggests that the formation of a vitamin E-arachidonate complex in the lipid membranes may have 
three functional consequences: (i) inhibition of peroxidative destruction of PUFAs in cells and 
subcellular membranes, (ii) prevention of permeability in biological membranes containing relatively 
high levels of PUFAs, and (iii) possible prevention of degradation of the membrane phospholipids 
by membrane-bound phospholipases (82). 
1.3.3.4 Antioxidant role of vitamin E 
Free radical-mediated lipid peroxidation has been suggested to be critically involved in numerous 
toxicities, and post ischemic reoxygenation injury, in addition to the degenerative processes associated 
with ageing (110,130,131). The close relationship between free radical activity and malignancy has 
also been well documented (132). The hypothesis appears to be that free radical damage of cellular 
materials would result in triggering or transforming non-malignant cells to malignant ones (133). An 
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increase in the activated forms of oxygen in the cell due to overproduction or/and the inability to 
destrQ¥ them may leadto.severe damage of cell molecules and structures (130). It is well known that 
-~ ~ 
vitamin E (a-, (J-, 'Y- and 0 tocopherol) acts as an antioxidant in protecting PUFAs and other lipids 
from peroxidation (134). a-TOH is chemically and biologically the most active lipid-soluble, phenolic 
antioxidant present in mammalian tissue (135-140). Dam (cited in 141) suggested that the principal 
role of vitamin E as an antioxidant may be to neutralize free radicals which could initiate a chain 
reaction, largely in highly unsaturated lipids, bringing about the formation of peroxides and products 
of their subsequent degradation. Studies have shown a-TOH to be a potent inhibitor of the 
propagation step of lipid peroxidation (138,142). The antioxidant properties of TOHs have been 
ascribed to hydrogen transfer from the OH group in the TOH (138). Each TOH molecule can react 
with two peroxyl radicals (LOO') (135,136,143), as shown in Figure 7. 
a-tocopherol + LOO' ...... a-tocopherol' + LOOH 
a-tocopherol' + LOO' ...... LOO-a-tocopherol 
Figure 7 : a-Tocopherol inhibition of phospholipids (135). 
The first product is the a-tocopheroxyl radical (a-tocopherol'), which is a resonance-stabilized, 
oxygen-centred radical. The a-tocopheroxyl radical can react with another peroxyl radical to form 
a stable adduct (136). From the high affinity of a-TOH for peroxyl radicals it would appear that 
the structure of the head has been optimized to obtain maximum antioxidant effectiveness,-while 
the phytyl chain gives the compound its lipophilicity and solubility in biomembranes (139). 
Though it is a major, if not the only chain-breaking antioxidant in mitochondrial membranes, 
vitamin E is present in extremely low concentrations, normally less than O.lnmol per mg of 
membrane protein, in other words one molecule per 1000 to 2000 membrane phospholipid 
molecules. On the other hand, lipid peroxyls can be generated in membranes at a rate of 1 to 
5nmol per mg of membrane protein per minute. However, destructive oxidation of membranes 
rarely occurs, nor is vitamin E rapidly depleted (84). An exceptionally efficient mechanism for 
regenerating or recycling vitamin E must exist in order to sustain such small but effective 
concentrations. Recycling of vitamin E by enzymatic and non-enzymatic means have been 
demonstrated, with vitamin C being implicated in the recycling of vitamin E (14,49,84,143,144). 
Since reactive oxygen species have been implicated in cancer initiation and promotion, evidence 
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(144) suggests that vitamin E and other antioxidants alter cancer incidence and growth by functioning 
as anticarcinogens, quenching free radicals or reacting with their products. 
1.3.4 VITAMIN E AND CANCER 
Vitamin E has been suggested (145-160) and disputed (58,161-164) as an anticanter agent. The 
antitwnour activity of vitamin E has been reported to be due to its chemical properties and not to its 
metabolism (135-137). 
A reduced status of vitamin E in serum and plasma of cancer patients and tumour-bearing animals has 
been reported in several studies (113,130,145,146,151,155), suggesting that a deficiency in vitamin 
E could ultimately lead to diseased states. Immunological studies have reported that vitamin E can 
induce immunity against infection (20,111,112,158,159). In addition to its immunizing actions, 
vitamin E can induce morphological alterations and growth inhibition in melanoma cells (94), mouse 
and human neuroblastoma cells, and rat glioma cells in culture (92). These studies suggest that 
vitamin E can induce multiple effects during the management of tumours including celLdeath, 
differentiation, inhibition of cell division, reduction of the toxic effects of certain chemotherapeutic 
agents and stimulation of the hosts immune system (94). These effects of vitamin E are dependent 
upon the type of cancer and the type of therapeutic agent. 
Influences of vitamin E in cancer, using epidemiological data, are difficult to assess due to a number 
of factors: 
i. The vitamin is present in a wide variety of food items in low quantities and it becomes difficult to 
group individuals according to their level of intake. Moreover, not all dietary vitamin E consumed 
is available for absorption and storage and this again varies among individuals. 
ii. The vitamin is relatively unstable during storage and can vary greatly within any individual 
foodstuff. 
iii. No specific and clear-cut vitamin E deficiency has been established. 
Hence, epidemiological data on the association of vitamin E and cancer risk are not vast, and those 
that are available are inconsistent. In 1984 two groups (cited in 160) reported an association between 
serum vitamin E levels in women and their risk of developing breast cancer. While one reported that 
low serum vitamin E was related to a significantly high risk of breast cancer, the other failed to note 
such an association. Menkes et al (155) also reported a significant association between the vitamin 
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E level and risk of lung cancer, while Norma (161) assessed the serum of 6 800 men and failed to 
- find any correlation betwe_en vitamin E and cancers of the colon, lung, stomach, rectum and urinary 
-~ . 
bladder. Xuan et al (cited in 159) suggested after studies done on miners at high risk of lung cancer 
that vitamin E in combination with other nutrients could be used for chemoprevention. Packer (110) 
. . 
also indicated that adequate intake could provide protection against diseases including cancer caused 
by pollutants and lifestyle patterns. Knept (113) also suggests that vitamin E may h;ve anticancer 
propenies as a lipid antioxidant and free radical scavenger, thus supporting the hypothesis that dietary 
vitamin E is associated with decreased cancer risk in man. 
Since the combined supplementation of vitamin E succinate and Asc are to be examined in this thesis, 
it is important to consider their synergistic action in vivo and in vitro. 
1.4 SYNERGISTIC ACTION OF VITAMIN E AND VITAMIN C 
In 1941, Goulmbic and Matill (29), demonstrated that although vitamin C alone was not effective in 
preventing the autooxidation of fat in vitro, it could, in the presence of vitamin E, greatlye~teriQ the 
inhibition period produced by vitamin E alone. In 1968, Tappel (cited in 162), suggested that Asc 
may reduce the tocopheroxyl radical back to the starting TOH. Subsequent in vitro (29,163-172) and 
in vivo (173) experiments demonstrated that vitamin C can indeed reduce the a-tocopheroxyl radical 
(Figure 8). 
i 
LOOH 
ii 
~H2-~H 
OH OH 
Figure 8 : Regeneration of vitamin E from vitamin E radical by vitamin C (18). 
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The sparing action of vitamin E by vitamin C is attributed to the reduction of the vitamin E radical 
by vitamin C to regener~te vitamin E. As depicted in Figure 8, vitamin E (i) scavengers the lipid 
-~ w 
peroxyl radical (L02·) to halt the chain propagation and the resulting vitamin E radical (ii) is reduced 
by Asc (iii) to regenerate vitamin E (18). This suggests that vitamin C represents a pool of antioxidant 
potential which could be delivered to peroxidized membranes through the regeneration of lipid-
soluble vitamin E (103,143,167,168). The delayed consumption of vitamin E is knowri"as the "sparing 
effect-" (exerted by vitamin C) and is defined as the ability of one antioxidant to slow the depletion 
of another (103). Although vitamin E and C have been proposed to act synergistically, the question 
that remains is how a lipid-soluble membrane-bound antioxidant such as vitamin E can interact with 
a water-soluble cytosolic bound antioxidant such as vitamin C. It has been shown (174) that in a 
membrane system, the phenolic group of the vitamin E is located near the polar heads of the 
phospholipids that comprise the lipid layer, and the phytyl chain of vitamin E lies parallel to the 
phospholipid fatty acyl chains. During lipid peroxidation, resulting lipid peroxyl chains create a 
significant dipole within the membrane that allows the peroxyl radical moiety on the lipid chain to 
partition to the membrane-water interface. This facilitates repair of the lipid peroxyl radical by 
vitamin E and results in the production of a stable vitamin E radical at the membrane-water interface. 
- "'-' 
This in turn allows water-soluble vitamin C access to the membrane-bound vitamin E radical for 
recycling (174). 
1.4.1 VITAMIN E AND C AND CANCER 
As indicated there is some uncertaintity about the role of vitamin E and C in carcinogenesis and a 
possible synergistic effect of the two vitamins in regulating tumour cell growth has not been 
investigated to date. A possible effect of Asc and a-TOR on tumour cell growth maybe mediated 
through numerous metabolic pathways which influence cell growth. One such pathway is the 
arachidonic acid cascade pathway (Figure 9) which involves the cleavage of AA from the sn-2 
position of the membrane phospholipid via the action of the enzyme phospholipase A2 (PLA2). The 
conversion of AA to prostaglandins (PGs) and the effect of the latter on adenylate cyclase (AC) 
activity influences the production of cyclic adenosine monophosphate (cAMP), a known regulator of 
cell growth. This pathway is also influenced, by exogenous essential fatty acids (EFAs), 
cyclooxygenase (COX) and a calcium (Ca2+) requirement of a number of the enzyme reactions. Since 
this study involves an investigation of the influence of Asc and a-TOR on the various AA metabolites 
in the above mentioned pathway and their relationship and possible association with tumour cell 
growth, a review of the pathway and its metabolites is necessary. 
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Figure 9 : Schematic representation of the AA cascade pathway investigated in this study. 
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1.5 CELL MEMBRANES AND FATTY ACIDS 
1.5.1 FLUID MOSAIC· MODEL OF BIOLOGIC:<\.L MEMBRANES 
The dynamic state of the lipids in the bilayer of cell membranes was described in 1972 by Singer and 
Nicolson (121,175-177). They proposed the fluid mosaic model of membrane structure and proposed 
that t~is was applicable to most biological membranes. 
The accepted model of membrane structure is a dynamic, asymmetric lipid matrix of phospholipds 
and cholesterol with globular proteins embedded across the membrane to various degrees (178). Most 
phospholipids are in the bilayer arrangement and may be closely associated with the integral 
membrane proteins or loosely associated with peripheral proteins, in which the integral proteins are 
critical to the integrity of membranes (175,178). The peripheral proteins are associated with the 
membrane surface and hence are easily released from the membrane (179). Several forms of non-
covalent and covalent forces are involved in the interaction of membrane protein with membrane lipid 
(180). Major features of the model include the following: 
i. membranes are two dimensional protein solutions in a fluid lipid bilayer phase, in which the 
"membrane fluidity" refers to the physical state of the central core of fatty acyl chains comprising the 
bilayer structure. The central core of fatty acyl chains serves the dual purpose of being a solvent for 
the integral membrane proteins and a permeability barrier (121,175,178,181,182). 
ii. a small proportion of membrane lipids interacts specifically with particular membrane proteins in 
which the association reflects the specific function of the protein (121,175,183-185). 
iii. membrane proteins possess unique characteristics that distinguish them from other globular 
proteins (176). Membrane proteins are free to diffuse in the lipid matrix, however, there appear to 
be areas of restricted mobility, due to special protein-protein, lipid-protein or lipid-lipid interactions 
(175,176,180). 
Membrane fluidity is influenced by temperature, drugs and nutrition (176,186). Thus biological 
membranes are changing, dynamic and responsive structures in terms of their constituents. This vast 
diversity brings about unique differences among similar membrane types of different cells (180). 
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1.5.2 BIOSYNTHESIS OF FATTY ACIDS 
Phospholipids and cholesterol are the main forms of lipid present in cell membranes. Lipids also serve 
as the metabolic fuel for the cell, with fatty acids being one of the main oxidative substrates (121). 
Another form of lipid, triacylglycerol, is a storage form of fatty acid within the cell, in which its FA 
content can be used either for energy or for membrane lipid synthesis (187). Most -ofthese saturated 
and monosaturated fatty acids are derived from the diet or from de novo synthesis by the condensation 
of acetate units followed by direct oxidative desaturation of the long fatty acids. In contrast, PUF As 
can be derived only from dietary lipids since mammalian tissues lack the enzymes capable of 
synthesizing linoleic acid and a-linoleic acid which are the precursors of all the PUFAs found in 
animal cells (188). 
1.5.2.1° Unsaturated fatty acids 
In 1930, Burr and Burr (cited in 189-191) first suggested that some mammalian tissue could not 
synthesize certain unsaturated F As and needed to be acquired from the diet. These are termed 
essential FAs (188,192), in which there are two families of essential FAs, the n-6 (w 6) and n-3(w 
3) family. The n-6 EFAs have considerably more biological activity, and there is a debate as to 
whether the n-3 family are in fact essential. 
Dietary n-6 EFAs are supplied abundantly in the diet in the form of linoleic acid which iIi rum is 
converted to arachidonic acid via desaturase and elongase enzymes (193-196). The available n-6 fatty 
acids are stored as esters of glycerol and cholesterol and are the in vivo precursors for the PGs. 
1.5.3 FATTY ACIDS IN THE BIOMEMBRANES 
Membrane fluidity now appears to be of general importance for processes ranging from passive 
permeability and lateral diffusion to cell recognition, differentiation and malignant transformation 
(181). The FAs esterified to form complex lipids constitute the hydrophobic core of the membrane 
that provides anchorage for the numerous integral and intrinsic proteins that function as enzymes, 
transporters, and ion channels. The FA profiles of complex lipids vary with the type of lipid, position 
within a phospholipid, body organ, organ region, cell type, and in some cases, even to selective 
domains within the plasma membrane (73). FA components of the membrane lipids could affect 
membrane function in one of four ways: (i) effects on lipid fluidity (184,186,190,197) (ii); effects 
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on lipid thickness (184,197); (iii) effects on lipid phase (175,186,197); and (iv) by specific interaction 
with membrane proteins. Such effects may influence enzymes such as AC which is particularly 
sensitive to changes in membrane fluidity, hence i~creased membrane fluidity augments enzyme 
activity whereas activity is reduced when membranes become more rigid (121,186,198). This is a 
result of the membrane F As directly affecting the dynamic properties of a protein through their 
influences on the bulk physical characteristics of the hydrophobic core of 'Uie -bilayer (184). 
Modifications of the phospholipid fatty acyl composition can also effect cellular functions such as PG 
synthesis and cell growth. Furthermore, the increase in lipid peroxidation that can result from PUF A 
supplementation may have effects on other cellular processes besides inhibiting cell proliferation as 
discussed earlier (121). 
1.5.4 MEMBRANES AND CANCER 
Interest in the physical and chemical properties of cellular membranes in cancer research has been 
steadily growing (199). Neoplastic transformation leads to dramatic change in the lipid structural 
organization within tumour membranes (199,200). Tumour plasma membranes generally' exhibit 
decreased fluidity, in that they are structurally changed towards a higher rigidity (199,201). The loss 
of fluidity is often caused by free radical and lipid peroxidation processes in which the unsaturated 
bonds are the prime targets (53,202-204). Furthermore, alterations in certain cellular functions 
including carrier-mediated transport receptor binding, ion channels and eicosanoid production have 
also been observed (200). 
The functioning of the cancer cell is determined in part by peculiarities of its external surface. Cancer 
cells are unable to bind calcium adequately, and do not adhere to one another tightly, but tend to 
separate and disseminate to the surrounding tissues. Hence, many of the malignant features of cancer 
cells may be attributed to the cell surfaces. Studies by Coman and Anderson (205) showed that when 
comparing the ultrastructure of normal squamous epidermal and Vx2 epidermoid carcinoma cells, vast 
differences in the ultrastructure were noted. The significance of difference in surface structure to the 
neoplastic state of the cells remains unknown, but, implies that membranes are credible targets for 
neoplastic therapy, a possibility that has generally been overlooked (200). 
1.6 FREE RADICAL FORMATION AND LIPID PEROXIDATION 
Living systems have evolved to survive in the presence of molecular oxygen, and for most biological 
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systems, life depends on it. Although critical to the maintenance of life, exposure to oxygen is not 
without risks. It is extremely toxic at concentrations slightly higher than that in air, and this toxicity 
may be important in several biological processes induding cancer. Hence, life in the presence of 
oxygen involves a delicate balance between the obligatory role of oxygen in respiration and the need 
to protect biological systems from the detrimental effects of the partially reduced intermediates (206). 
These intermediates include superoxide, anion, radical, hydrogen peroxide and-hydroxyl radical 
(55,l~3,136,206-210). Autooxidation is a free radical chain process consisting of chain initiation, 
propagation, and terminal steps (133,136,211) 
A free radical can be defined as a chemical species possessing an unpaired electron, hence it can be 
referred to as a fragment of a molecule. Free radicals can be formed in three different ways (54,211) 
(Figure 10). 
Radical formation by electron transfer 
Radical formation by homolytic fission 
Ion formation by heterolytic fission 
:A+e~A-
: X:Y ~ X, + y. 
: X:Y ~ X- + y+ 
Figure 10 : Three different ways of free radical formation (54). 
Electron transfer is by far the most common process in biological systems. Free radicals can be 
negatively charged, positively charged or electrically neutral (54). Initiation of peroxidation occurs 
by the attack of a species capable of abstracting hydrogen atoms from fatty acid side chains (212). 
Species capable of doing this are hydroxyl (OH·), peroxyl (LOO·), alkoxyl (LO') and alkyl radicals 
(V). Hence the first step in the initiation of lipid peroxidation from a PUFA is attack by a free radical 
species (R') which is capable of abstracting one of the doubly allylic hydrogen atoms on the carbon 
atom between two double bonds (See figure 11). 
Propagation follows initiation, The product of the radical attack upon a polyunsaturated fatty acid 
(LH) is a delocalized pentadienyl radical (L') which in turn reacts rapidly with oxygen to form the 
peroxyl radical (LOO'). The peroxyl radical can then extract a hydrogen atom from a PUFA to yield 
yet another free radical (V) and a peroxide (LOOH) (136). Singlet oxygen which can initiate lipid 
peroxidation from PUF A, may represent one of the ways that this electronically excited species of 
oxygen is toxic to biological systems (136,210). One of the most common ways of initiating lipid 
peroxidation is by means of the metal-catalyzed breakdown of peroxides already present in the system. 
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Both oxidized and reduced transition metals (iron or copper), can catalyze the decomposition of 
_ peroxhles to form either alkoxyl, alkyl or hydroxyl radicals. These species can in turn re-initiate the 
peroxidative process (Figure 11). 
Compounds that react with chain-propagating ra'dical species and result in the formation of species 
no longer capable of hydrogen abstraction are considered chain breaking antioxidantS"'. Termination 
of chain propagation (Figure 11) involves a variety of compounds which function as chain-breaking 
antioxidants such as phenols, aromatic amines and conjugated polyenes (136). Apart from these 
antioxidants, most cell types possess proteins and enzymes that can specifically remove reactive 
species (210). These proteins include superoxide dismutase (SOD), catalase, peroxidase and the 
glutathione-dependent systems (136,210,213). 
(1) INITIATION (2) PROPAGATION 
R- RH 
~~.. 
LH 
(3) SINGLET OXYGEN INITIATION 
--~ .. ~ Lcx::>H 
( 4) RE-INITrATION 
LOOH + Fe2+ 
LOOH + 
(5) PRODUCT REMOVAL 
LOOH + 2 GSH ~LOH + GSSG + H2 O 
(6) TERMINATION 
LOOo/Lo/LO· + IH .. LOOH/LH/LOH + I· 
LOa· + LaO· .. L=O + LOH + O2 
LOO· + I- .. LOO-I 
Figure 11: Lipid peroxidation and sites of action of antioxidants in lipid peroxidation (136). 
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Of special interest to this study is the involvement of lipid peroxidation in cancer. The major effects 
of the_products of lipid peroxidation are the inl1ibition of DNA synthesis, cell division, and tumour 
growth (123). Substantial evidence on the other hand has reported that active oxygen species including 
free radicals playa role in the tumour initiation and promotion processes in multistage carcinogenesis 
(3,4,8-11,54,133,211,214). However, studies by Salim (215) illustrated that by removing oxygen-
derived free radicals, the development of hepatic metastases is impaired and survIval-is prolonged in 
rats with 1,2-dimethylhydrazine-induced colonic cancer. In contrast, Das et al (216) showed that 
human breast carcinoma (AR-75-1) exhibited increased superoxide production which may be attributed 
to SOD and glutathione peroxidase activities. Lipid peroxidation products a consequence of free 
radical reactions have been suggested to influence the way in which signals for proliferation cross 
membranes. It is not yet known whether the observed increased resistance to lipid peroxidation is a 
property of malignant cells or whether it is simply a feature of rapidly dIviding cells in proliferating 
tumours. Goldring et al (214) have proposed that lipid peroxide levels are inversely related to cell 
growth, irrespective of whether the cells are malignant or not. Studies by Cheeseman et al (217) 
showed reduced rates of lipid peroxidation in Yoshida hepatoma cells while Slater (218) reported that 
liver tumours undergo lipid peroxidation very slowly and have noted a number of contributory factors 
- ,.--" 
viz; lower content of PUFAs which are substrates for PUFA-peroxidation; enhanced cholesterol 
levels; decreased NADPH-cytochrome P450 reductase activity which donates electrons to reducible 
substrates which serve to initiate peroxidation; and low cytochrome P450 content which is known to 
act as a source of new radicals for chain propagation. 
It has also been observed that enhanced lipid peroxidation in vitro induced by the addition of PUFAs 
to the culture medium resulted in a cytotoxic effect in cancer cells. This led (219) to the proposal that 
specific PUF As may be used to treat patients with cancer on the assumption that there is reduced 
tumour lipid peroxidation in the first instance. Some patients, however, have reduced antioxidant 
levels and exhibit increased lipid peroxidation-malondialdehyde (MDA) which has mutagenic 
properties. MDA is generated during peroxidation of PUFAs in the cell membranes by free radicals 
and the breakdown of prostaglandin H2 (PGH2), the immediate precursor of other PGs (219). 
1.7 PROSTAGLANDINS 
PGs consist of a large group of cyclic derivatives of C20 oxygenated unsaturated FAs (196,220) and 
have been detected in virtually all cells and tissues of animals (220,221). PGs augment a variety of 
biological effects and appear to playa regulatory role in a number of systems (220). The term 
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"prostaglandin" is a misnomer: it was coined by von Euler in 1935 in the belief that this active 
subs1a!1ce emanated from the prostate gland (222,223). Today, PG is a term applied to a series of 
compounds derived enzymatically and non-enzymatically from C20 FAs such as AA (Figure 12) (9). 
PGs are not stored in tissues (9,224-227) but' are formed upon stimulation of cells. Figure 12 
summarizes the three phases of prostanoid formation: (a) mobilization of APr from membrane 
phosppolipids; (b) sequential conversion of released AA to the prostaglandin endoperoxides PGG2 then 
PGH2; and (c) isomerization/reduction of PGH2 to the various prostaglandins (224,227). To fulfil a 
function, the PGs have to be synthesized at rates sufficient to overcome inactivation (228). 
1 
C
PHOSPHO'..JPIO 
ACTIVATION OF ____ ---;) 
PHOS?HOUPASES 
~H 
Figure 12: Biosynthetic pathway for prostanoid formation (229). 
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cis-PUFAs in which the conjugation is interrupted by methylene groups, belong to the group of 
essential FAs which can be converted into PGs with the help of enzyme systems (230). AA is by far 
the most biologically important EF A of the w6 series. Besides normal ,a-oxidation; die common fate 
for all FAs in the body, AA can be enzymatically oxygenated by three different enzyme types: (i) by 
lipoxygenases to form hydroperoxyeicosatetraenoic acids; (ii) by COX to form PG endoperoxides 
and (iii) by monooxygenases (231). AA can interact with prostaglandin endoperoxide synthetase (PES) 
(E.C. 1.14.99.1) (also referred to as FA COX and PGH synthase), a membrane-bound multi-enzyme 
complex (222,232). The ubiquitous PES catalyzes the first committed step in the formation of PGs 
and TXs from AA. 
PES has two activities, a cyclooxygenase which converts AA to PGGz and a peroxidase which reduces 
PGGz to form PGHz (233-237). PGHz is converted to a combination of prostanoids by numerous 
synthases depending on the cell or tissue type (238,239). 
The PES is a glycoprotein with two identical heme-containing subunits (240,241) in which the 
primary site of action for the enzyme in the endoplasmic reticulum (ER) has an abundance of heme 
(242-244). The synthase has been purified to homogeneity as a dimer of 70kDa subunits (239,242). 
The amino acid sequence has been deduced from the nucleotide sequence of the cloned synthase -gene 
(245,246). The 2.7 Kb cDNA encodes a protein of 600 amino acids including a signal sequence of 
24 amino acids. The glycosylated enzyme (232,247) has three potential sites for N-glycosylation 
(248). A hydrophobic region (amino acids 267-282) may be a site of a transmembrane domain (246). 
Based on experimental observations, a model predicting COX topology in the ER with different 
putative functional domains has been proposed (246). The amino-terminal and the carboxy-terminal 
end of the protein are separated by one transmembrane-spanning region (Figure 14). Distinct 
peroxidase and dioxygenase domains are predicted to be cytoplasmic and in the COOH terminal half 
of the protein. The NHz-terminal portion of the protein has three glycosylation sites, in addition it has 
been speculated that there is an epidermal growth factor-like domain on the NHz-terminal side of the 
protein (247). Serine 530 is the "active site serine" on the membrane. 
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Figure 13: A predicted model for the cyclooxygenase enzyme. Cyclooxygenase (solid line) is shown 
traversing the membrane (interrupted lines) once. Carboxy-terminus is cytoplasmic and contains 
putative dioxygenase domain and peroxidase domain (247). 
Two COX enzymes have been described which ~re almost identical at the protein level but which 
differ markedly at the gene level (249). The first isoform (COX 1) is constitutively expressed, that 
is messenger RNA (mRNA) is constantly transcribed from the gene and the protein is synthesized at 
a steady rate independent of extracellular signals (249,250). The second isoform (COX 2) is an 
inducible form (248-254) in which the gene is said to be sensitive to extracellular signals and its 
expression may be increased by activation of cell surface receptors (249). 
This finding led to interest in the mechanism of non steroidal anti-inflammatory drugs (NSAIDS). The 
NSAIDS are known to exert their effects through the inhibition of PG synthesis by interaction with 
CO2 (256). In addition to NSAIDS, glutathione peroxidase also suppressed PGH synthase activity 
(257,258). On the other hand, lipid hydroperoxides serve as essential activators of PES. Peroxides 
activate COX, leading to several metabolic events linking the regulation of cellular peroxide levels 
to an indirect regulation of the production of PGs by COX (242,259), while phenol and tryptophan 
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are known to stimulate the peroxidase of the PES (241,260). 
1.7.2 MECHANISM OF ACTION OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE 
Biosynthesis of PGs is initiated by PES, a dioxygenase which incorporates two moles of oxygen into 
each mole of AA to form PGG2 (234). This same enzyme then converts the PG02 to PGHz by 
reducing the hydroperoxy group into a hydroxyl moiety in a peroxidase-type reaction (235,260,261). 
(See figure 14). 
~OH 
8.11.14. Eicosa trie noie acid 
Fatl"), acid 
cyclo-ox yge na se 
In··~COOH 
o-~ 
60H 
PGG. 
PG hydroperoxidase 
'V 
rl'r,·~COOH 
O~ OH 
PGH. 
PG endoperoxide 
synthetase 
Figure 14: Reactions catalyzed by prostaglandin endoperoxide synthetase (262). 
The COX reaction requires the continued presence of hydroperoxides, and much evidence (263) 
suggests that peroxidase plays an important role in the hydroperoxide-dependent initiation of the COX 
(263,264). The hydroperoxide and ferriheme interact to form a hydroperoxy radical (probably enzyme 
bound) in an initiation step for the overall reaction. This radical, with the help of the COX enzyme, 
propagates the reaction by abstracting the 13-S hydrogen (258). Oxygen then reacts with the alkyl 
radical at carbon 11 and cyclization occurs (265), hence one molecule is retained as a peroxide linking 
C9 and Cll, while the second molecule of oxygen appears as a hydroperoxide at C18 (258,265,266). 
Experiments with 180 have shown that both oxygen atoms at 9- and 11- positions originated from the 
same molecule of oxygen, demonstrating that the incorporation of oxygen involves a dioxygenase 
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reaction (267). Peroxidation of the 15-hydroperoxy group ofPGGz to a 15-hydroxy group, producing 
PGHZ! is catalyzed by the hydroperoxidase activity of the PES (237). In addition PG hydroperoxidase 
is capable of oxidizing NADH and NADPH in a series· of reactions which involves the formation of 
radicals ·NAD and ·NADP (268). These radicals readily react with oxygen to form the superoxide 
anion. Thus superoxide generation is a product of a side-chain reaction, dependent on the presence 
of suitable reducing co-substrates (268). ~ ~ -
COX has an obligatory requirement for a hydroperoxide activator. Any modification which reduces 
hydroperoxide concentrations below about lOnM can inhibit COX activity (229). A peculiar 
characteristic of the COX is the time course of the enzyme reaction. The COX activity slows down 
gradually as soon as the reaction commences and ceases after 1-2 minutes. The cessation of the 
reaction is neither due to exhaustion of substrate nor accumulation of an inhibitor since the reaction 
can be tesumed by the addition of fresh enzyme, but not by the further supply of substrate. Such a 
phenomenon has been observed by many investigators (258,260,268,269) and is referred to as a self 
catalyzed destruction or self-deactivation. The enzyme may be inactivated by an active oxygen species 
which is released during the hydroperoxidase reaction. Reduction of the 15-hydroperoxide group of 
'.-
PGGz to a hydroxyl may produce an active oxygen species if the hydroperoxide is not fully reduced 
to water, resulting in the destruction of the enzyme (237). Vitamin E, like phenol, may provide 
additional reducing equivalents to generate PGHz and vitamin E radicals, without the concomitant 
release of oxidizing equivalents. 
1.7.3 BIOSYNTHESIS OF PROSTAGLANDINS D2, E2, Fza, and Iz 
Biosynthesis of PGs requires the release of the esterified precursor AA from tissue lipids, AA in turn 
is converted to PGH2 by PES, the central enzyme in the PG biosynthetic pathway. PGH2 is at a 
pivotal point in the divergent pathways leading to the synthesis of various types of PGs and 
thromboxanes TX (237,270) (see Figure 15). 
Although products are derived from a common cyclic endoperoxide intermediate, differences in 
optimal conditions for the formation of each, and differences in the effects of inhibitors on each, show 
that separate enzymes are involved in the formation of the different products from the endoperoxide 
intermediate, PGHz (271). 
Enzymes utilizing PGH2 as substrate, are isomerases which attack the 9,1l-endoperoxide bridge of 
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PGH2• PGH2 is the substrate for the enzymes PGD, PGE; PGF and PGr synthases (237), and 
depen~ing on the cell or tissue type, PGH2 is converted to a combination and varying concentrations 
of the prostanoids PGD2, PGE2, PGF2a and PGI2 (238): 
1.7.3.1 PGD synthase 
The cQnversion of PGH2 to PGD2 is an isomerization of the 9 ,11-endoperoxide moiety to 9a-hydroxyl 
and II-keto groups of PGH2 (Figure 15) (237). The enzyme is found predominantly in the cytosol 
(237) and can be purified to homogeneity. A survey done on rat tissue indicated that PGD isomerase 
activity was higher in the brain and spinal cord than in other tissues (232,237). PGD2 is the principal 
COX product of rat and human mast cells (232). 
o-z:('~ I - - eOOH 
0-. ~ PROSTACYCLIN 
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HO ~ PGHz 0-~~H i, 
6 OH GSH ~/'-........... ~ -PGE HO - Y ~ ~ 
SYNTHAS~ OH.. - -
eOOH 
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o \\ . /I'~eooH 
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OH 
(Jr'~eOOH ~:A~ o . 
OH 
Figure 15: Modified biosynthetic pathway for prostanoid formation (229). 
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1. 7 .3.2 PGE synthase 
The conversion of PGH2- to PGE2 is an isomerization -of the 9, ll-endoperoxide to 9-keto and lla-
hydroxyl groups (Figure 15). Initially, the enzyme system catalyzing the overall synthesis of PGE2 
from AA was referred to as PG synthase (E.C. 1.14.99.1). Glutathione is required as a specific 
coenzyme for the reaction, in which glutathione is believed to act as a nucleophile iB a 1,2-hydride 
shift during the isomerization of endoperoxide (272). 
1.7.3.3 PGF synthase 
There are three possibilities for the synthesis of PGF2a• Firstly the conversion of PGH2 to PGHZa can 
involve a net two-electron reduction of PGH2 (229,266). Thus the overall reduction is a reductive 
cleavage of the 9, 11-endoperoxide of PGHz. The second pathw-ay is the conversion of PGEz to PGFza. 
The 9-keto group of PGEz can be reduced to a hydroxyl group. This conversion occurs in various 
tissues (273,274). The third mechanism of PGF2a synthesis is the reduction of ll-keto of PGDz 
(275,276). 
1.7.3.4 PGI synthase 
The formation of PGIz is an isomerization of the 9, ll-endoperoxide of PGHz into a 6,9-epoxide and 
an lla-hydroxyl group (Figure 15). PGIz is unstable, especially at acidic pH, and is· readily 
transformed into 6-keto-PGFza> a stable but inactive product (235). PGI synthase is inhibited by 
hydroperoxide of various unsaturated FAs (277-279), while Asc is thought to protect PGI synthase 
by scavenging hydroxyl radicals which are produced from hydroperoxides (280,281). 
1.7.4 FUNCTIONS OF PROSTAGLANDINS 
PGs have interested investigators ever since their initial discovery in the 1930s, (282), of their 
remarkable versatility and wide range of effects (223). 
PGs are cell-to-cell messengers produced by eukaryotic cells in response to extracellular stimuli (283). 
Many of the effects of PGs are manifested via changes in the intracellular concentration of cAMP 
(283). PGEz, PGFza (284,285) and PGI2 (286,287) all enhance the formation of cAMP. PGs can 
either inhibit or facilitate tumour metastasis (9,288), host immunoregulation (289), tumour promotion 
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(276), and cell proliferation (226,290), depending on the cell system examined. PG production is 
related to cell growth, and cells in the quiescent state (Go phase) are the most active PG producers 
(291). 
PGs are transported actively into cells by a specific carrier on cell membranes and the growth 
inhibitory effects of these PGs is closely related to this uptake (292). Prostanoids-loove the cell by 
facili!ated diffusion (239). 
1. 7 .4.1 Functions of prostaglandin D2 
Although the biological function of PGD2 is not fully understood, PGD2 has been described as an 
antithrombotic agent (293,294), and a neufomodulator (295,296). 
1. 7 .4.2 Functions of prostaglandin E2 
The pharmacology of PGE is quite diverse. PGE2 is known to be a vasodepressor (223,27{») and 
bronchodilator (270). In the kidney, PGE2 can increase sodium excretion and decrease vasopressin-
mediated water reabsorption. Both of these responses appear to involve interactions with AC (280). 
Furthermore low doses of PGE2 were shown by Bygdeman (cited in 223) to stimulate contraction of 
the uterus. 
1.7.4.3 Functions of prostaglandin F2« 
PGF2«, a closely related member of the PGE family, also raises blood pressure and PGF2a , in addition 
to PGE2 , PGF2a was shown to stimulate contraction of the uterus (223,297). 
1. 7 .4.4 Functions of prostaglandin 12 
Prostacyclin (PGI2), produced by the blood vessel wall, is the most potent natural inhibitor of platelet 
aggregation known (298,299). Furthermore, PGI2 is a potent pulmonary vasodilator, where it binds 
to specific platelet receptors and activates AC, raising the cAMP level in the platelets. 
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1.7.5 PROSTAGLANDINS AND CANCER 
Eicosanoids can influence the carcinogenic process ip yarious ways. PG levels can either. inhibit or 
stimulate tumour growth or influence tumour migration and the metastatic potential (200,289). 
PGs, especially of the E series, have been shown to be elevated in a large number of tumours 
.- - '" 
(9,220,228,300-304). Uncertainty remains as to whether the increase in the synthesis and release of 
-PGs is the cause or the effect of increased proliferation rates, or whether it merely accompanies this 
phenomenon (305). Two mechanisms have been proposed for the increased PG production by 
tumours: tumour tissue could contain elevated amounts of PG synthetic enzymes and/or increased 
substrate may be available due to altered enzyme activities within the PG biosynthetic pathway (306). 
Interaction of PGs with growth factors has been reported and may contribute to the ability of the 
tumour .cells to establish themselves at a metastatic site (300,~03). In contrast, PGs in a number of 
situations have been shown to elicit a bell-shaped dose response curve with low concentrations 
stimulating and higher concentrations inhibiting cell proliferation (307). 
With respect to the PGs to be considered in this study, in 1979, studies by Fitzpatrick et al{308,309) 
demonstrated that PGDz had an antimetastatic effect on mouse melanoma B16FlO cells. In 1982, 
Fukushima et al (310) presented evidence that PGD2 had potent cytotoxic activity on several lines of 
tumour cells such as mouse leukaemia and several human leukaemia cells in vitro. In 1983, studies 
by Simmet and Jaffe (311), Bregman and Meyskens (312) reported that PGD2 was a potent i~i~itor 
of mouse melanoma growth in vitro. The antineoplastic PGD2 is thought to exert its effects by 
inhibiting DNA synthesis (313,314) and through its inhibition of platelet aggregation which is not 
favoured in the metastatic process (309). PGs of the E series are known to inhibit the growth of a 
number of tumour cell lines (315). Numerous in vitro (257,316,317) and in vivo studies (318,319) 
have demonstrated PGE2 inhibitory effect on cell growth which is thought to be mediated via the 
cAMP-AC linked system (320). PGFZa production is increased in several cell lines transformed by 
chemicals or oncogenic viruses (321). PGF2a has been reported to increase proliferation of cultured 
Swiss 3T3 and Raj Leukaemia cells (cited in 322), while PGF2a had no effect on cell growth in 
murine mastocytoma cells (323). However, in human gastric carcinoma cell line Kato III, PGF2a 
significantly and dose-dependently inhibited cell growth. The study by Nakamura et al (285) suggested 
that inhibition of growth was mediated via the stimulation of cAMP. PGI2 is known to be both a 
negative and a positive modulator of tumour growth. PGI2 production inhibited the growth of 
subcutaneous B16 tumours (324). However, Honn and Meyer (324) suggest that the modulation of 
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PG~/TXAz ratios may be an important therapeutic locus in the control of tumour growth. PG~ is a 
powerful antimetastatic agent against B16 melanoma cells. This effect, which may result from the 
platefet anti-aggregatory action ofPGI2 is potendatedby a PDE inhibitor. Inhibitors ofPG!zsynthesis 
increase metastasis (325). PGIz and agents that may increase endogenous PGIz synthesis or prolong 
its activity are suggested as new antimetastatic agents (325). 
1.8 CALCIUM 
Caz+ is the most abundant cation in vertebrates (326) and Ca2+ is both an essential structural body 
component and a functional clement in living cells. It is a key component in conserving the membrane 
integrity in addition to being a pivotal regulator for a wide variety of cell functions in its role as a 
second messenger (327). Of particular interest in this study is the associ4tion of Caz+ with PLAz and 
AC activity. 
1.8.1 CHARACTERISTIC PROPERTIES OF CALCIUM 
Calcium is characterised by its charge, co-ordination number and unhydrated radius (328). The 
concentration of Ca2+ ions in the resting cytoplasm of cells is very low (10-7 M or less) (329), while 
that of the extracellular free Ca2 + concentration is in the region of ImM. Hence a very steep 
electrochemical gradient of Ca2+ exists across the plasma membrane for most animal cell types. 
Together with the concentration gradient, an electrical driving force for Ca2 + entry prevails, si~c:e the 
intracellular space is usually found to be at a potential of about -60mV relative to the outside 
(326,330). The Ca2+ concentration in the cytosol rises to about IJLM following a Caz+ mobilization 
stimulus. Ca2 + is involved in electrical signalling processes as well as transmembrane chemical 
signalling (330). 
Ca2+ cannot be synthesized or broken down, the only mechanisms available for causing large-scale 
changes in Ca2 + concentration involve alterations in compartmentation and movements across 
membranes. Ca2 + ions are "sticky", which enables it to bind to various ligands such as proteins and 
phosphate groups. Ca2 + bound to such ligands enables the ion to regulate metabolic processes (330). 
One such protein is the calcium-dependent regulatory protein (CDR,calmodulin) which is an acidic, 
low molecular-weight, ubiquitous Ca2+ binding protein of mammalian cells. Calmodulin is recognized 
as the mediator of Ca2 + dependent control of an increasingly large number of enzymes (331). 
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1.8.2 INTRACELLULAR TRANSPORT OF CALCIUM 
Given the extreme electrochemical gradient of Ca2 +< ~cross membranes, two systems exist for the 
active outward transport of Ca2+. The two well documented systems are the Ca2+ -stimulated ATPase 
and a Na+ -Ca2+ exchange systems, in which many but not all cell types seem to contain both systems. 
The level of activity ofthe Na+ -Ca2+ exchange system varies considerably from tissue to tissue, being 
r - M 
weak or absent in erythrocytes and liver cells and highly active in excitable cells such as those of 
heart -and nerve. A detailed account of these systems is given by Dawson (330). 
1.8.3 FUNCTIONS OF CALCIUM 
1.8.3.1 Calcium and cell proliferation 
Ca2+ availability is the key controller of cell proliferation in multicellular organisms and a defect in 
the Ca2+ levels appears to be the common determinant of unrestrained proliferation in cancer cells. 
Durham and Walton (329) suggest that the proliferation rates of both normal and cancer cells is 
-,-
controlled by the availability of Ca2+ ions from the stores inside the cell at a particular timeand place 
(329). 
Malignant cells lose the ability to maintain cytoplasm Ca2+ concentrations below a critical point. As 
a result, in contrast to normal cells they can proliferate when extracellular fluid Ca2+ ion 
concentrations are very low (328,332). These findings are substantiated by Swierenga et al (cited in 
333) who showed that neoplastic cells with high tumourigenicity were able to proliferate in a low 
Ca2+ medium whereas proliferation of non-neoplastic cells in low Ca2+ medium was much lower, 
suggesting that proliferation is controlled by extracellular Ca2+ (328). Thus the Ca2+ requirement of 
neoplastic cells is very low in comparison to that of normal cells (329). This is consistent with the 
observation that hepatoma cells contained at least 100% more Ca2+ than normal liver. In addition, 
the Ca2+ content was found to escalate progressively with increasing age of the tumour (334). 
Ca2+ and lor calmodulin play significant inhibitory roles in DNA synthesis and cell proliferation (335-
337). cAMP has the ability to mediate Ca2+ levels (188) with cAMP regulating the cell cycle at the 
various phases (338). 
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1.8.3.2 Calcium and enzymes 
Many-key enzymes which are involved in AA esterification or release are dependent on metal ions. 
Ca2+ stimulates acyl hydrolase activity (339), while PLA2 requires elevated cytosolic Ca2+ for the 
activation and subsequent release of AA from tissue lipids in numerous stimulated cell types 
(339,340). The role of Ca2+ in PLAz regulation of AA release is three-fold, in th,at Ca2+ is involved 
in the activation of protein kinase C (PKC) and subsequent phosphorylation of PLAz due to prior 
activation of phospholipase C (PLC) (339,341). Hence, Ca2+ becomes directly stimulatory to PLAz 
as exhibited in cell homogenates and isolated membranes. Thirdly, Caz+ is required for the activation 
of PLAz by G proteins (339,342,343). Following release of AA from precursor lipid stores, 
prostanoids are formed by oxygenation of free AA by prostaglandin endoperoxide synthase (PES). 
Caz+ also acts as a second messenger in eliciting a physiological response via Ca2+ -modulated 
proteins. AC forms reversible Ca2+ -dependent complex with calmodulin, with calmodulin-Ca2 + 
interacting directly with the catalytic subunit of AC (344). The various hormone-responsive AC 
systems, including the B16 melanoma (345) are Ca2 + dependent. However, comparatively fe~ have 
been shown to be regulated by calmodulin. Voltage-gated Ca2+ channels in atrial membranes; cardiac 
sarcolemmal, and skeletal muscle T tubule membranes, are positively modulated by a G protein. The 
latter is a stimulator of AC. However, G proteins are also involved in the action of certain receptors 
that inhibit Ca2 + channels (346). Thus G proteins have direct effects on plasma membrane Ca2+ 
channels (330). 
1.8.4 PHOSPHOLIPASE A2 
Studies over the last several years have led to the expansion of knowledge on the diversity of forms 
and function of mammalian sn-2 acylhydrolases. The release of FAs from phospholipids by these 
enzymes although proposed over a hundred years ago has only recently been more defined. Of 
particular interest in this study is AA release. 
1.8.5 CLASSIFICATION AND PROPERTIES OF PHOSPHOLIPASE A2 
Phospholipases Az (PLAz; phosphatide sn-2-acylhydrolases; EC 3.1.1.4) catalyze the hydrolysis of 
the sn-2 fatty acyl chain of various phospholipid (PL) substrates to yield F As and lysophospholipids 
(347-349). PLA2s are a heterogenous family of enzymes that can be classified into two classes based 
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on their molecular weight (350,351). Secretory PLAzs (sPLA2) are small proteins (about 14 KDa) 
which unselectively cleave any FA from the sn-2 position of phospholipids. sPLA2 requires millimolar 
levels-of Ca2+ for activity- and have a high sulphide cQntent (352-354). The sPLAz are further divided 
into three groups based on their amino acid sequence, namely group I, II and III. Pancreatic PLAz 
is in Group I (347,353,355), Group II includes human synovial fluid and platelet PLAzs 
(347,353,356) and Group III includes bee venom PLAz (347). Group IV, the high molecular mass ~ ~ ~ 
(80-11OkDa) cytosolic PLAzs (cPLAz) are activated by submicromolar amounts of Ca2+ and 
preferentially hydrolyse phospholipids that have AA at the sn-2 position (347,352,357). This enzyme 
is present in the cytosol and trans locates to membranes in response to physiological concentrations 
of Caz+ (352-354,357-359), thus mediating transient physiological eicosanoid synthesis. cPLAz lacks 
disulphide bonds and exhibits no amino acid sequence homology with Type I and II although it does 
have a Caz+ binding domain like that of PKC (353). cPLAz is of particular interest in this thesis due 
to its AA selectivity, which is the key substrate involved in the regulation of eicosanoid synthesis via 
the cyclooxygenase pathway. 
A number of factors influence PLAz activity. Acidic phospholipids are generally hydrolysed faster 
than neutral ones (360). Studies have shown that the cPLA2 activity is stimulated· by anionic 
phospholipids which act to increase the affinity of PLA2 for Ca2+ (361-364). The activity of this 
enzyme is influenced by the rate of enzyme attachment and release of AA from the phospholipid 
monolayer where cPLAz carries out its hydrolyzing activity (357,362). Most PLA2s show an absolute 
requirement for Ca2+ but some intracellular enzymes are activated substantially by Sr2+(362,365). The 
concentration of free AA within resting cells is unknown but is believed to be maintained at low 
levels. An increase in the release of free AA from phospholipids has been observed in many cell types 
(366) upon stimulation. PLAz, is competitively inhibited by unsaturated FAs, particularly AA. Hence 
FA inhibition may represent one mechanism of regulation for PLA2 and thereby eicosanoid production 
(367-370). Subsequently to these findings, researchers have reported that AA metabolites are potent 
mediators of cell proliferation, glucocorticoids and allergic and inflammatory reactions, PLA2 
inhibitors are expected to have a variety of therapeutic effects on cell proliferation, glucocorticoids, 
allergic and inflammatory reactions (357,371,372). 
1.8.6 FUNCTIONS OF PHOSPHOLIPASE Az 
The presence of PLAz in biological membranes is a prerequisite for proper membrane turnover in 
cellular metabolism and is considered to be involved in membrane remodelling (349,373), exocytosis 
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(374) and the repair of oxidative damage (349). Membrane-associated PLA2 prevents membrane 
oxidative damage by providing a membrane sparing effect by the elimination of lipid peroxidation 
- -
products (375). In addition, PLA2 activity leads to a rapid release of large amounts of PGs (376), 
which in turn stimulate second messengers. 
1.8.7 G PROTEINS AND PLA2 MECHANISMS 
Two major routes of receptor-mediated regulation have been implicated in the control of AA 
mobilization and release. One route is activation ofPLA2 via a receptor linked G-protein not requiring 
PLC (342,347,377-379), and the other is indirect activation through a PLC-mediated pathway 
increasing Ca2+ and activating PKC (347,353,380-382). In the first route, PLA2 is directly linked to 
a G-protein and hence dependent on GTP(343,346,367,376-378). This leads to a direct release of 
AA, without prior activation of other phospholipases. 
Termination of a receptor-mediated signal transduction is a vital requirement. The system in which 
PLA2 activity is linked to G proteins, reassociation of the inactive heterotrimer following act!yation 
of the GTPase associated with the a-subunit of the G-protein occurs (367). In addition to snutting off 
the signal at the G protein level other mechanisms exist which could turn off the systems at the 
receptor level of the G-protein(s). These include reduction of cytosolic Ca2+ levels, activation of 
protein kinases, feedback inhibition as well as the second messenger, cAMP (366,367). 
1.9 ADENYLATE CYCLASE AND CYCLIC ADENOSINE MONOPHOSPHATE 
AC was discovered by Sutherland and RaIl in 1957 (383). AC (ATP pyrophosphate-Iyase[cycling] EC 
4.6.1.1), the catalytic protein converts ATP to adenosine 3' ,s"-cyclic monophosphate (cAMP) and 
pyrophosphate (331,384,385). cAMP acts as a second messenger for many systemic and local 
hormones and consequently controls many physiological processes at the cellular level (198,386). 
1.9.1 STRUCTURE AND PROPERTIES OF ADENYLATE CYCLASE 
AC occurs in both prokaryotic and eukaryotic organisms and most probably in plants (331,383). AC, 
a glycoprotein, is a single subunit enzyme of either 115kDa or 150kDa (346). However, this 
polypeptide exists with the AC system which is ubiquitous, multi-component and membrane-bound 
(198,331,383). The AC system is composed exclusively of intrinsic membrane proteins and depends 
1. Literature Review 47 
on their proper integration in a membrane for hormonal regulation and hence adequate functioning 
(331). 
-< 
Initially, the hormone response AC system in the cell membrane exhibited a three component model 
comprising a hormone receptor, a catalytic unit, and a guanine nucleotide-binding regulatory protein 
(198,331,387-390). However, research has shown that the receptor and the GTP~inaing regulatory 
prote~n components are more complex. The hormonally regulated AC system is now shown to 
comprise of five main components: the stimulatory receptor Rs, the stimulatory guanine-nucleotide 
binding and hydrolyzing regulatory protein Gs, which itself is composed of three subunits (a,{3,'y), 
the catalytic moiety of the AC, the inhibitory receptor Ri and the inhibitory GTP-regulatory protein 
Gi, which also consists of three subunits (346,388,391,392). AC stimulation via hormones appears 
to be a transmembrane phenomenon (393)~ as the various components are asymmetrically arranged 
in the-membrane (198). The catalytic site on the enzyme, which is responsible for the formation of 
cAMP from A TP. is thought to face the inside of the intact cell, while the receptor site, which 
interacts with specific circulating hormones, faces the external medium (393). AC, like many integral 
membrane-bound enzymes, is regulated by the nature of its membrane lipid environment (12tI98). 
1.9.2 PROPERTIES OF THE ADENYLATE CYCLASE COMPONENTS 
1.9.2.1 The receptor component 
Various hormones have their own specific receptor sites on the receptor component, of which 
glucagon and epinephrine are the best documented (178,394). Some receptors, however, are known 
to recognize more than one hormone (198). The receptor-hormone complex acts by facilitating the 
binding of a guanine (or related purine) nucleotide to the regulatory site (198). Hormonal stimulation 
of AC is observed only in intact membranes. 
1.9.2.2. The regulatory component 
Nucleotides, particularly guanine nucleotides, playa vital role in regulating the function of hormone-
sensitive AC systems (395). Two major subunits suggest two distinctly separate guanine regulatory 
sites for AC. One site appears to mediate inhibition of AC, and is denoted the Gi or Ni site 
(388,396,397), while occupancy of the Gs leads to AC stimulation (387,388,396,397). 
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The regulatory protein is essential to functionally couple agonist occupancy of the receptors with 
activation of the catalytic moiety. Hence guanine nucleotides not only modulate the catalytic activity 
of AC but also exert specific regulatory effects on agohist binding to receptors (389). 
1.9.2.3 The catalytic component 
LittleJs known about the physical properties of the catalytic component of AC, however it is known 
that this component has a relatively hydrophobic surface area (198,331). In addition, the catalytic 
component must have a substrate site for A TP as well as a binding site for the cation. Hence, this 
component presumably binds to a divalent cation-ATP complex (198,398). 
1.9.3 MECHANISM OF ADENYLATE CYCLASE ACTIVITY 
In 1971 it was reported that the receptor-sensitive signal transduction was not only regulated by 
hormones but also guanosine triphosphate (GTP) as originally suggested in 1956 by Sutherland (citen 
in 346). The progress that led to the discovery of hormone signalling is reviewed in Pertseva.{399). 
The transmembrane signalling systems usually consist of two major components: the specific binding 
site (receptor) and the effector components-namely the enzymes or channel proteins (391). GTP is 
an essential cofactor for hormonal stimulation of AC. The actions of GTP require interaction of the 
nucleotide with specific guanine nucleotide-binding proteins, which in turn serve as regulators of the 
appropriate catalytic entity (400,401). Hence regulatory proteins function as transducers· of 
information between receptors for hormones and the ultimate effector (402). AC has a type II 
signalling mechanism, generating second messengers (399). The binding of an agonist to the receptor 
is followed by an interaction of the Rs complex with the stimulatory G-protein (Gs) (391) (See figure 
16). 
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Figure 16 : Mechanisms involved in the regulation of the adenylate cyclase activity by stimulatory 
(s) and inhibitory (i) processes (391). 
Gs binds to GTP and cations in addition to linking the receptor Rs to the catalytic unit 
(198,387,388,403). AC is essentially inactive in the absence of the divalent cation Mg2+ (~39;404). 
The activated GTP-bound Gs induces an active conformation in the catalytic unit of AC, resulting in 
the formation of cAMP (391). The presence of high levels of GTP ( ;;::: IJLM), activates the catalytic 
unit in the conversion of ATP to cAMP (198,391). The activation of intracellular cAMP-dependent 
protein kinases results in the phosphorylation of specific protein substrates. Stimulation of the 
inhibitory receptor Ri induces dissociation of the {3- and "1- subunits from as and the subsequenf tight 
binding to ai, brings about the inactivation of the catalytic unit (391) due to the binding of GDP 
(346). 
1.9.4 FACTORS INFLUENCING ADENYLATE CYCLASE ACTIVITY 
1.9.4.1 Membrane lipid composition 
AC is sensitive to changes in membrane fluidity. Increased membrane fluidity enhances enzyme 
activity whereas activity is reduced when membranes become more rigid (178,198). AC activity is 
affected by changes in the composition of the phospholipid fatty acyl chains and polar head groups 
(121), hence modification of AC activity is influenced by the nature of the dietary fat (405). To 
explain this phenomenon, it has been suggested that AC can exist in numerous different conformations 
exhibiting varying activities, and that changes in membrane lipid composition cause the enzyme to 
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shift from one conformation to another (121). 
AC activity is also affected by changes of membranedipid environment (406). Lipid peroxidation in 
membranes is known to decrease membrane tluidity, exerting a negative effect on the enzyme activity 
and in doing so inhibits AC activity (407,408). In contrast, Canuto et al (409) found that in AH-130 
Ascites Hepatoma, enhanced AC activity was not only related to membrane fluidity ~but also to the 
increase of lipid peroxidation. 
1.9.4.2 Prostaglandins 
Regulation of the AC system appears to involve PGs (410), which have been shown to be associated 
with activation of AC and an increase in cellular cAMP concentrations (411). Stimulation of AC 
activity.by PGs is initiated through the binding of these agonists to their specific receptors on the 
outer surface of the membrane bilayer (341,412-415). PGE2 (416-421), PGD2 (286,422) and PGIz 
(286,287,422) are reported to have both stimulatory and inhibitory effects on AC activity, henc~ 
altering cAMP production accordingly, while PGFzc< (415,423,424) has been reported to hav~ only 
a stimulatory effect on AC activity. Separate receptors are present for each PG suggesting the effects 
brought about by PGs are independent of each other (415). 
1.9.4.3 Calcium-dependent regulatory protein 
The calcium-dependent regulatory protein (calmodulin) is recognized as the mediator of Ca2+-
dependent control of an increasingly large number of enzymes (331). AC has demonstrated a need 
for CDR for the stimulatory effects of Ca2+ on AC activity (426). CDR-Ca2+ is however found to 
activate some ACs but not all of the AC types (331,345,426). 
1.9.5 CYCLIC ADENOSINE MONO PHOSPHATE 
cAMP is a ubiquitous molecule in which numerous activities are facilitated by hormonal actions which 
utilize cAMP as a second messenger or mediator (427). The magnitude of the effects of cAMP 
depends on its concentration (428). Since the discovery of cAMP by Earl Sutherland (cited in 
392,429), cAMP has attracted much attention for the explanation of a variety of cellular phenomena. 
The conversion of A TP to cAMP by AC takes place in the presence of a divalent cation, such as 
Ca2+, Mg2+ or Mn2 + (404,430,431). The enzyme phosphodiesterase (PDE) is instrumental in 
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controlling the concentration of cAMP within cells, and in doing so altering the biological activity 
of cAMP (432). cAMP is converted to 5· adenosine mOBophosphate (AMP) by PDE in the presence 
-- -
of Mg2+ (433-435). Numerous forms of PDEs are krlown to exist (436-439). 
1.9.5.1 Biological functions of cyclic adenosine monophoshate 
An il1}portant property of cAMP is that it affects the activity of different cell types in various ways 
(431). cAMP not only mediates the actions of most biogenic amines and polypeptide hormones but 
also influences such fundamental processes as cell division, cell motility, morphology, contact 
inhibition and the synthesis ofproteoglycans (431-433,440,441). Furthermore, in cancer, cAMP may 
be a modulator of the activity of several oncogenes (429). 
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Figure 17: cAMP regulation of the cell cycle (442). 
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Three observations provide evidence for the role of cAMP in the control of cellular growth: (i) cAMP 
levels are lower in transformed cells than normal cells (443), (ii) agents which increase cellular levels 
suppress growth and (iii) agents which decrease cellular cAMP levels stimulate growth (444,445). 
cAMP concentrations vary within the cell during the different phases of the cell cycle. These 
fluctuating levels of cAMP in turn playa significant role in controlling the cell cycle (394,442).The 
life cycle can be divided into four phases (See Figure 17). 
The cell cycle begins at cytokinesis or cell division. As the cell matures it goes through a G 1 (Gap 
1) phase, during which it prepares to replicate its chromosomes; it then progresses through to an S 
(for DNA synthesis) phase, during which it replicates its chromosomes. Thereafter it pauses in a 
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second gap, or G2 phase, during which it prepares for mitosis and cytokinesis; finally it ends its life 
as an individual upon dividing into two new individuals during the D phase (328,394,446). The length 
of these periods depends -on the cell type and conditions of growth. Mitosis (D phase) is usually the 
shortest phase (394). 
The G 1 phase is the most susceptible to inhibition by shortages of essential nutritmtsand is the most 
respopsive to growth factors and hormones. This is due to the fact that the conditions must be optimal 
before the cell will risk starting the chromosome subcycle. In the G 1 phase there is a prolonged 
cAMP surge in a variety of cells (394,423,446). A further prolonged surge occurs in the late S phase 
or G2 phase of some cells (431,445-447). These elevated levels of cAMP keep the cell in the 
quiescent state and it is only once the cAMP levels drop, that the cell is then stimulated to resume 
cycling. Hence, elevated levels of cAMP in the S phase, prevent DNA synthesis (442,446). 
Therefore, cAMP functions as a negative regulator of DNA synthesis (328,446). 
1.9.5.2 Cyclic adenosine monophosphate and prostaglandins 
Various effects of PGs on the regulation of growth, morphology and functional differentiation on 
several cell lines in culture appear to be mediated through the cellular concentrations of cAMP (447) 
as they can alter the intracellular levels of cAMP and/or Ca2+(448). 
PGE2 (420,421,449), PGD2 (386,422,447), PGI2 (387,405,422) and PGF2a (415,423,449) are known 
to increase cAMP accumulation in various cell lines. In mastocytoma cells (447) PGI2 was the most 
potent PG in elevating cAMP within the cells, with PGF2a being the least potent, whereas in dog 
thyroid, PGF2a was the most potent PG (423). Cell proliferation shows an inverse relationship with 
these PG-induced changes in cAMP levels (450). 
PGE2 can activate cAMP formation in normal cells (451), hence elevated PGE2 levels resulted in 
increased cAMP formation which suppresses DNA synthesis (416). Furthermore cAMP acts as the 
second messenger for PGE2-mediated modulation of biological functions in various cells (452,453). 
PGE2 at concentrations greater than 1O-6M stimulated platelet AC and raised cAMP synthesis (454), 
whereas concentrations as low as 1O-6M inhibited AC and cAMP, reducing the platelet content below 
controls (449). In general, it appears that PGE2 (449,455), PGD1 (447), PGI1 (287,447) and PGF1a 
(415,449) stimulate cAMP formation directly via association with their respective receptors resulting 
in cAMPs regulation of various biological functions. 
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1.9.6 ADENYLATE CYCLASE ACTIVITY, CYCLIC ADENOSINE MONOPHOSPHATE 
AND CANCER 
In general, tumour and transformed cells have levels of cAMP significantly lower than those of 
normal cells (427 ,456-461). Low intracellular levels of cAMP in transformed and malignant cells may 
be due to alterations in the activity of AC and/or PDE (386,462), hence altering t\le pattern of cAMP 
metabolism (458). AC has two binding sites for Mg2+. One is the catalytic site and the other is the 
Gi site. In transformed cells, the second regulatory site is altered such that high concentrations of 
Mg2+ are unable to enhance catalytic activity (398). Furthermore, cAMP itself is an inducer of PDE 
(386). Moreover, lower cAMP content in transformed cells may also be attributed to some 
modification of the plasma membrane (398). 
In transformed cells, various modifications are known to occur in the plasma membrane. Since AC 
is associated with the plasma membrane, altering its AC receptor sites results in decreased activity 
and hence decreased cAMP levels (453,462). Furthermore, lipid peroxidation decreases membrane 
fluidity inhibiting AC activity (415). It has been reported (386) that during oncogenesis AC a.~tivity 
is always elevated, resulting in enhanced cAMP levels in these cells. This alteration 'in cAMP 
metabolism during tumour development could have a functional role in oncogenesis or could just be 
an accompaniment to the cellular changes (386,429). However, cAMP does not appear to function 
as a second messenger for oncogenes (386). 
The concentration of cAMP appears to control the growth rate of cells. Numerous in vitro studies 
have shown an inverse correlation between the growth rate and intracellular cAMP levels 
(442,443,459,462,463). Hence, it has been suggested that the abnormal properties of transformed 
cells, e.g. growth rate, morphology and loss of contact inhibition, can be reverted towards those of 
normal cells by treatment with agents that raise cAMP levels (435,464,465). Such agents could be 
PDE inhibitors, such as theophylline, caffeine (466,467) and Asc (464) which increase the endogenous 
intracellular cAMP pool size. This implies that many of the abnormal properties of transformed cells 
may be due to decreased cAMP levels (462), as a result of decreased AC activity. However, 
numerous in vivo studies with animal tumours have also shown increased cAMP levels in the cells 
(447,468). Hence there is some uncertanty regarding the exact relationship between cAMP levels and 
tumour cell growth. 
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1.10 OBJECTIVES 
As indicated earlier there is some uncertaintity" about the role of vitamin E and C in 
anticarcinogenesis, although it has been suggested that these effects maybe due to their synergistic 
antioxidant properties and/or their combined effect on various metabolic pathways such as the AA 
cascade pathway shown in Figure 9 (repeated on this page). 
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Figure 9: Schematic representation of the AA cascade pathway investigated in this study. 
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The principal objective of this dissertation was to investigate the effect and role of combined vitamin 
E succinate and Asc supplementation over a nutritional range on the growth and cellular functions of 
- . 
in vitro cultured normal and malignant cell lines. 
The effect of vitamin E succinate and Asc on malignant BL6 and non malignant LLCMK cell growth 
could possibly be mediated through metabolic pathways which influence this cell growth. The pathway 
that was studied in this regard was that of the AA cascade pathway (Figure 9, repeated on page 55), 
which involves the cleavage of AA from esterified phospholipid stores via the action of PLA2• The 
conversion of AA to PGs and the effect of the latter on AC activity and cAMP (a known regulator 
of cell growth) was also determined. The pathway is also influenced by exogenous EFAs, 5-LOX, 
COX and Ca2+ levels. In addition to the role of 5-LOX and COX activity in AA metabolism, their 
role in free radical formation and lipid peroxidation was also examined. 
Hence, the effect of combined vitamin E succinate and Asc supplementation on the activity and the 
metabolism of this pathway, in addition to AA metabolites which influence this pathway, was 
investigated. 
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CHAPTER 2 
COMBINED -NUTRIENT SUPPLEMENTATION AND CELL GROWTH 
2.1 INTRODUCTION 
The technique of in vitro culture of animal cells has expanded considerably over the past few 
years, and is now widely used in many disciplines (469)_ The properties of individual cell lines 
makes them useful for a wide variety of purposes in biological research, diagnosis and commercial 
applications (470). The development of continuous cell lines has attained great importance in 
research and has numerous advantages over a finite cell line (469). Finite and continuous cell 
culture techniques allow for the supplementation of the cultures with· various nutritional factors 
and the monitoring of the effects of these factors on cell growth and cell metabolism. 
In attempts to find a treatment for cancer, cultured malignant cell lines have proved invaluable: 
These cell lines have been supplemented with various anticarcinogenic chemical compounds, in 
addition to various natural biological substances as a means of halting or delaying tumour cell 
growth (80). The potential of these natural substances as a preventative measure against neoplasia 
development is of paramount importance as numerous sources clearly indicate that natural foods 
contain factors that protect against cancer (7,80). Thus a relationship between diet and cancer 
incidence is clearly indicated in human populations (7,80) and the role of vitamins· in - the 
prevention and management of neoplasms is becoming increasingly evident. 
For example the beneficial effects of vitamin e in the prevention (31) and management (31,52) of 
neoplasms has been extensively reported. Supplementation of a mixture of vitamin e with B12 
increased the survival rate of mice bearing P388 leukaemia and Ehrlich carcinoma (471). Sodium 
Asc, in combination with some tumour therapeutic agents, namely 5-fluoro uracil, bleomycin 
sulphate, sodium butyrate, cAMP-stimulating agents and X-radiation, has been found to potentiate 
the growth inhibitory effect on neuroblastoma cells in culture (53). Furthermore, vitamin e 
supplemented to eRO clone A cells in vitro inhibited cell growth (472). Results of administration 
of Asc as a therapeutic agent to cancer patients suggests that it could assist in overcoming Asc 
deficiency and assist in stabilizing malignant cell development, hence halting further metastasis 
(31,68,473). 
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Vitamin E succinate has also been shown to induce differentiation and growth inhibition in certain 
animal and human tumour cells in culture (49,93). Numerous studies have been conducted to evaluate 
the role of vitamin E in experimental carcinogenesistS), although the studies that have been carried 
out (cited in 80) have reported decreased tumour growth with o:-TOH supplementation. 
Supplementation of vitamin E succinate reduced the growth of transplanted mouse melanoma and 
neuroblastoma cells in vivo (49). Furthermore, supplementation of vitamin E succinate to melanoma 
cells ~n vitro induced morphological changes and growth inhibition (94), while vitamin E succinate 
has been reported to inhibit cell growth of glioma and neuroblastoma cells in culture (92). Treatment 
of vitamin E succinate and PGs such as PGEz have been shown to act in an additive manner to inhibit 
the proliferation of human oral squamous carcinoma cells (SCC-25) (91), while vitamin E succinate 
enhances the growth inhibitory effect of vincristine in a synergistic fashion (474) in neuroblastoma 
and glioma cells in culture. 
These findings suggest that the inability of tumour cells to maintain biochemical processes may be 
partly due to the deficiency or increased requirement of essential nutrients such as Asc and vitamin 
E. Emphasizing this possibilty, tumour cells lose their ability to maintain the complex intrac011ular 
and extracellular matrix (31) as well as cell membrane integrity (123,199). Furthermore, 
administration of 0:-TOH to cancer patients could aid in overcoming the cellular damage caused by 
active oxygen, preventing the promotional phase of carcinogenesis and stabilizing cell membranes 
(5,475). The suggestion that vitamin E and C can modify the effect of pharmacological agents on 
tumour cells in culture is somewhat unique (52,49). The extent of modification depends upon the type 
of tumour, vitamin and the pharmacologictll agents. As a result of the growing evidence for vitamins 
A, C and E as nutritional adjuncts in the treatment of cancer in one study, patients with disseminated 
malignancies were placed on large doses of A, C and E. Results from this study suggest that doses 
of A, C and E are of great value in the treatment of these cancer patients (476). 
While the inhibitory effects of Asc and vitamin E succinate on the growth of numerous cell lines in 
vitro have been well documented, the addition of combined Asc and vitamin E to cell lines and the 
subsequent growth effects has not. A synergistic action of these two vitamins has, however been 
reported (103,143,167,168). 
In addition to vitamin supplementation of tumour cell lines , other nutrients which can induce changes 
in fluidity and stability of all membranes are the essential FAs (121,184,186). In tumour cells, there 
may be substantially reduced quantities of n-6 EFAs (193). Supplementation with EFAs has been 
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shown to inhibit the growth of malignant tumours in vitro, enhancing EFA levels resulting in 
increased PG production (194). Eicosanoid production, in turn, is essential in the generation of 
- . 
secondary metabolites, eg cAMP (see Chapter 1), wIi'ich control metabolic pathways including those 
associated with the control of cell growth. 
In this study, cells were supplemented with combined vitamin E succinate and Asc-aIfd the influence 
of th~ combination of these compounds on the growth of non malignant LLCMK (monkey kidney) 
and malignant BL6 (murine melanoma) cell lines was monitored. In addition, the effects on cell 
growth combinations of vitamin E succinate, Asc and 3H vitamin E succinate, 14C ascorbic acid and 
AA, respectively were also determined since supplementation of the two cell lines with these 
combinations of nutrients and their derivatives was the subject of subsequent studies described in this 
thesis. 
2.2 MATERIALS AND METHODS 
MATERIALS 
Basal Minimum Essential Medium (MEM) , L-serine, L-ascorbic acid (reduced form-99%),( + )-a-
tocopherol acid succinate and succinic acid disodium salt were purchased from Sigma Chemical Co., 
USA. LLCMK (monkey kidney) and BL6 (murine melanoma) cells were obtained from Stellenbosch 
University, South Africa. Foetal Calf Serum (FCS) and sterile tissue culture flasks were purchased 
from Elabtec, Port Elizabeth, South Africa. Novo streptomycin (1g/3ml) and novo penicillin (2 
million U) were purchased from Novo Industries (Pharmaceuticals Ltd), South Africa. Unilab, 
SAARCHEM, South Africa, supplied the NHC03 and dimethyl sulphoxide (DMSO). Glycine, D-
glucose, phenol red, KH2P04 and NazHP04. 2H20 were purchased from BDH Chemicals Ltd, 
England. Trypsin was purchased from Boehringer Mannheim, Germany, while ethylenediamine-
tetraacetic acid (EDTA) was purchased from Holpro Chemical Co., South Africa. L-[carboxyl-14C] 
Ascorbic acid, [U-3H] vitamin E acid succinate and 15-[3H] arachidonic acid were purchased from 
Amersham International, England. A haemocytometer was purchased from Neubauer, Germany. 
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METHODS 
2.2.1 PREPARATON OF CULTURE REAGENTS 
2.2.1.1 Preparation of the medium 
The following compounds were added to Basal MEM, which contained Hank's salts and glutamine 
but no NaHC03 : 
O.Olg/l Serine 
0.006g/1 Glycine 
1.68g/l NaHC03 
5mlll Novo-Strep and Novopen Mixture 
(1 Vial of sodium benzylpenicillin (106U) and one vial streptomycin sulphate (106 JLg) were combined 
and then made up to 100ml with milli Q water). Ten litres of media were prepared at a time. 
2.2.1.2 Filtration of the medium 
The medium was filtered through a millipore filtration unit (Millipore Corporation, USA), using the 
following three filters: a prefilter, type AW 03 "Membr filter" 50k (size 130); a 0.45JLm type HA 
filter (HAWP 14250); and a 0.22JLm type GS filter (GSWP 14250). Initially 500ml of milli Q water 
was pumped through followed by 200ml of medium, both of which were discarded, while- the 
remaining medium was sterile-filtered into autoclaved Schott bottles. The bottles of medium were 
incubated at 37°C for 7 days, to test for contamination, before being used. 
2.2.1.3 Preparation of growth and freezing media 
Growth medium was prepared by filtering FCS through a 0.45JLm Millipore filter using a Swinnex-25 
holder (Millipore Corporation, USA), until the medium contained 10% (v/v) FCS. Thereafter, all 
medium was incubated at 37°C for 48 hours to test for contamination. 20% (v/v) FCS medium was 
prepared for use in the first 24 hour growth period for vials of cells thawed from storage. Freezing 
medium was prepared by adding 10% DMSO and 20% FCS, before being frozen until required. If 
the pH of the growth medium was too acidic, a few drops of sterile 1M NaOH solution were added 
to return it to physiological pH. 
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2.2.1.4 Preparation of trypsin solution 
The t~yPsin solution required was a 0.33 % sohltion.< T.he trypsin solution contained the following: 
8.0g/1 NaCI 
0.4g/1 KCI 
1.0g D-glucose 
o .58g/1 NaHC03 
0.2g/1 EDTA 
33.33mg/l Trypsin 
0.02g/l Phenol Red 
10ml Novo-Strep and Novopen solution (prepared as in 2.2.1.1) 
The trypsin was filtered directly into the culture flask, through a 0.45jLm Millipore filter using a 
Swinnex-25 holder. The trypsin solution was stored at -20°C until required. 
2.2.1.5 Preparation of media containing vitamin E succinate and ascorbic acid 
Stock solutions of vitamin E succinate, 5-20mg/ml were freshly prepared in absolute ethan?l and 
diluted 1: 1000 in media containing 10% PCS, to give final concentrations of 5, 10, 20 jLg/rril vitamin 
E succinate respectively, in 0.1 % final concentration of ethanol. Stock solutions of Asc, 25 and 
50mg/ml were freshly prepared and diluted 1: 1000 in media containing 10 % PCS to give a final 
concentration of 25 and 50jLg/ml, respectively. 
Thus four different batches of medium were obtained containing the following combined vitamin E 
succinate: Asc concentrations: 5:25; 10:50; 10:25 and 20:25jLg/ml. The concentrations were chosen 
following preliminary range-finding experiments to determine the most effective cell growth inhibitory 
concentrations of combined vitamin E succinate and Asc. 
Vehicle controls were prepared with equivalents amounts of succinate (succinic acid) and absolute 
ethanol as follows: Stock solutions of succinic acid 3.78mg/ml were prepared in milli Q water and 
diluted 1: 1000 in media containing 10% PCS and 0.1 % absolute ethanol to give a final volume of 
3.78jLg/ml. Other concentrations of succinic acid (1.89 and 0.98jLg/ml) were prepared by serial 
dilution from the 3. 78mg/ml stock solution. 
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2.2.1.6 Preparation of phosphate buffered saline solution 
Phosphate buffered saline (PBS), pH 6.6 in mil1i Q w~ter, was prepared as follows: 
8g/1 NaCI 0.2g/1 KCI 
0.15g/1 NaHP04.2H20 
-2.2.2 CELL CULTURE 
2.2.2.1 Routine cell culture procedures 
All procedures were carried out on a laminar flow bench which had previously been sterilized by 
expOSUl:e to ultra-violet light and all the equipment used was ~ither purchased sterile or autoclaved. 
Sterile techniques employed included regular swabbing of the hands and bench surface with 70% 
alcohol, while all equipment was swabbed prior to use. Non-malignant LLCMK (monkey kidney) and 
malignant BL6 (murine melanoma) cells were maintained at 37°C in 75 cm2 flasks containing 30ml 
10% (v/v) growth media, when they were not required for experimental purposes. The medium was 
changed approximately once a day. 
To passage cells, the growth medium was decanted and lOml sterile trypsin solution was added to 
each flask. The flasks were incubated at 37°C for ten minutes to allow the cells to detach from the 
flasks surfaces. The cells were then passaged into three or four flasks to which was added growth 
medium containing 10% PCS. 
2.2.2.2 Freezing of cells 
The storage of either cell line involved the cells being harvested with 10ml sterile trypsin and then 
centrifuged, and the cell pellet reconstituted with 2ml freezing medium in a cryogenic vial. The cells 
were stored in liquid nitrogen until required. 
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2.2.3 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON CELL GROWTH 
-;: . 
2.2.3.1 Experimental cell culture procedure 
Large flasks of near confluent cultures of either LLCMK or BL6 cells were trypsinised with 10ml 
r- -
sterile trypsin. The flasks were incubated at 37°C until the cells had detached from the flask surfaces. 
Once -the cells had lifted off, they were poured into sterile tubes with caps and centrifuged at 3 OOOg 
(Eppendorf Centrifuge 5403, Germany) for 10 minutes. Thereafter, the trypsin solution was poured 
off and the pellet resuspended in 2ml 10% (v/v) PCS medium. The cells were counted using a 
haemocytometer. The cell counts allowed calculation of the volume of cell suspension required per 
flask in order to seed 500 000 cells per 75cm2 flask, or 300 000 cells per 25cm2 flask. In 
experiments relevant to 3.2.2 and 3.2.3, for which furthe~ analytical procedures and data are 
described in Chapter 3, (the numbers denoting the relevant experiments), 3x105 LLCMK or BL6 cells 
were seeded into 6 sets of 5 25cm2 flasks. To each of 4 of the 6 sets of flasks was added 10ml 
medium, containing 10% (v/v) PCS and the varying levels of combined vitamin E succinate (5-
20/Lg/ml) and Asc (25-50/Lg/ml). The fifth set of flasks, referred to as the contwl cultures (0) 
contained only lOml, 10% PCS medium, while that of the sixth set received lOml 10% PCS 
containing 0.1 % final volume of ethanol and is referred to as the ethanol control cultures (OE). In 
experiments relevant to 3.5#, 4.1#, 4.2#, 4.3#, 4.4#, 4.6#, 4.7.2# and 4.7.3# for which further analytical 
procedures and data are described in Chapter 3 and Chapter 4 respectively (the numbers denoting the 
relevant experiments), 5x105 LLCMK or BL6 cells were seeded into 6 sets of 3 75cm2 flasks. Exactly 
the same procedure was carried out as that for the 25cm2 flasks except that 30ml medium, containing 
10% (v/v) PCS was added. 
2.2.3.2 Harvesting of the experimental· cell cultures 
When the first flask reached confluency (± 5 days) (determined under a microscope), the cells in all 
the flasks were harvested under non-sterile conditions using 10ml or 5ml trypsin depending on flask 
size. The cell suspensions were centrifuged for 10 minutes at 3 OOOg. The pellet was resuspended in 
2ml PBS buffer, unless otherwise stated, and enumerated using a haemocytometer. The cell counts 
were used as a measure of cell growth, enabling the effect of combined vitamin E succinate and Asc 
on cell growth to be determined. The counted cells were then used for further experimentation and 
analysis. 
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2.2.4 THE EFFECT OF COMBINED VITAMIN E SUCCINATE, ASCORBIC ACID AND 
3H VITAMIN E SUCCINATE SUPPLEMENTATION ON CELL GROWTH 
-:; I 
2.2.4.1 Experimental cell culture procedure 
The experimental procedure described below is relevant to experiment 3.3 in Chapter 3. 
r~ -
Non-malignant LLCMK or malignant BL6 murine melanoma cells were seeded into 6 sets of 3 75 
cm2 flasks, at 5x105 cellslflask. Basal MEM, 30ml containing 10% PCS, and the varying combined 
vitamin E succinate (5-20JLg/ml) and Asc (25-50JLg/ml) concentrations respectively were added to 
four sets of flasks. The fifth set of flasks received 30ml 10% (v/v) PCS medium containing 0.1 % 
final concentration of ethanol, and was referred to as control cultures (OE) The sixth set of flasks 
contained 30ml 10% (v/v) PCS medium and was referred to ~s control cultures (0). The six sets of 
flasks were incubated at 37°C, with one media change. During the media change, O.lJLCi of 3H 
vitamin E succinate was added to all flasks containing the varying combined vitamin concentrations 
and the control culture set (OE), while control cultures (0) received 3H vitamin E succinate. 
The flasks were once again incubated at 37°C and harvested as described in 2.2.3.2. 
2.2.5 THE EFFECTS OF COMBINED VITAMIN E SUCCINATE, ASCORBIC ACID AND 
L-[CARBOXYL-14Q ASCORBIC ACID SUPPLEMENTATION ON CELL GROWTH 
2.2.5.1 Experimental cell culture procedure 
The experimental procedure described below is relevant to experiment 3.4 in Chapter 3. 
The method outlined in 2.2.4.1 was repeated for 14C ascorbic acid supplementation of the cells with 
the following changes. During media change, 0.15JLCi 14C Asc was added to all flasks containing the 
varying levels of combined vitamin E succinate and Asc concentrations and the control cultures (OE). 
The control culture (0) was again the sixth set of flasks, with no combined vitamin concentrations or 
14C Asc supplementation. 
The cells were harvested as described in 2.2.3.2. 
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2.2.6 THE EFFECT OF COMBINED VITAMIN E SUCCINATE, ASCORBIC ACID AND 
3H ARACHIDONIC ACID SUPPLEMENTATION ON CELL GROWTH 
-~ , 
2.2.6.1 Experimental cell culture procedure 
The above experimental procedure is relevant to experiment 4.3 in Chapter 4. 
Non-malignant LLCMK or malignant BL6 murine melanoma cells were seeded into six sets of 3 
75cm2 flasks, at 5x105 cellslflask. Basal MEM, 30ml containing 10% PCS and the varying levels of 
combined vitamin E succinate and Asc concentrations (5:25; 10:50; 10:25 and 20: 25/Lg/ml) 
respectively were added to four sets of flasks. The fifth set of flasks received 30ml of 10% PCS 
medium containing 0.1 % final concentration of ethanol and was referred to as control cultures (OE), 
while the sixth set of flasks contained 30ml 10% (v/v) PCS llledium and was referred to as control 
cultures (0). The sixth set of flasks were incubated at 37°C, with one media change. During the 
media change, 5/LCi 15-3H AA was added to all flasks containing the varying combined vitamin E 
succinate (5-20/Lg/ml) and Asc (25-50/Lg/ml) concentrations respectively, and the control cultures 
.. ' 
(OE). The control set (0) was again the sixth set, to which no combined vitamins Of 15-3HAA was 
supp lemented. 
The above methods were repeated for AA supplementation, with the following changes. During the 
media change, 2.5/LM AA was added to all flasks containing the varying combined vitamin E 
succinate and Asc concentrations, and the control set of cultures (OE). The control set (0) was once 
again the sixth set of flasks, with no combined vitamin or AA supplementation. 
The cells were harvested as described in 2.2.3.2. 
2.2.7 STATISTICAL ANALYSIS 
The results obtained were analysed using a one- way analysis of variance (ANOV A) followed by the 
Student-Newman Keuls Multiple Range Test. 
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2.3 RESULTS 
2.3.C THE EFFECT OF COMBINED VITAMIN.E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON LLCMK AND BL6 CELL GROWTH 
Cell growth of LLCMK and BL6 cells found in the relevant experiments in whi~h sombined 5:25; 
10:50; 10:25 and 20:25fLg/ml vitamin E succinate and Asc supplementation, respectively, was 
-
performed are presented in Table 2a and Table 2b. Relevant to the discussion in this chapter, for both 
cell types, is the mean percentage of growth inhibition relative to untreated controls that was obtained 
in all the experiments. Growth inhibition for each individual experiment will be discussed in Chapters 
3 and 4 with respect to the relevant data obtained on cell metabolism in these experiments. 
The ov~rall mean growth inhibition, recorded in Table 2a, indicates that combined vitamin E 
succinate and Asc did not have a significant inhibitory or stimulatory effect on LLCMK cell growth. 
Combined vitamin E succinate and Asc supplementation at 5:25 and 1O:25fLg/ml resulted in slight 
increases in cell growth relative to that of the control cultures (OE), however not significantly so. At 
10:50 and 20:25fLg/ml combined vitamin E succinate and Asc supplementation, cell growth -decreased 
compared with control cultures (OE), although again no significance was found. 
Supplementation of BL6 cells with combined vitamin E succinate and Asc resulted in an overall 
significant (p sO. 00 1) decrease in cell growth when compared to control cultures (OE) (Tabl_e)b). 
When comparing 20:25fLg/ml combined vitamin E succinate and Asc to 5:25fLg/ml (psO.OOl), 
1O:50fLg/ml (p s 0.01) and 1O:25fLg/ml (p s 0.001) a significant decrease in cell growth was again 
found. Thus, the most significant decrease in cell proliferation (Table 2b) was observed at combined 
20:25fLg/ml vitamin E succinate and Asc supplementation relative to control cultures (OE) and the 
other combined vitamin concentration groups. 
TABLE 2a : The effect of combined vitamin E succinate and ascorbic acid supplementation on LLCMK cell growth. Results are the mean oCfive' or three 
cultures ± SEM. 
[vitamin E 
succinate: 
ascorbate] 
p.g/ml Exp Exp 
3.2.2· 3.2.3· 
OE 100 100 
±4.81 ±3.7 
5:25 100.8 99.9 
±2.0 ± 1.2 
10:50 87.8 87.5 
± 14.1 ± 11.2 
10:25 97.7 93.5 
± 1.2 ±2.2 
20:25 86.8 85.4 
±3.3 ±2.7 
a - p:::;; 0.001 relative to control cultures (OE) 
b - p:::;; 0.01 relative to control cultures (OE) 
c - p:::;; 0.05 relative to control cultures (OE) 
Exp 
3.5 
100 
± 12.2 
73.5 
±7.6 
70.0 
± 13.0 
68.9 
±6.4 
78.5 
±7.3 
LLCMK CELLS 
Growth inhibition [% of untreated controls] 
Exp Exp Exp Exp Exp Exp 
4.1 4.2 4.4 4.5 4.6 4.8 Mean 
100 100 100 100 100 100 100 
±6.5 ±6.9 ±22.1 ±3.5 ±1.7 ±2.7 ±7.12 
95.2 274.3b 201.Y 77.0a 121.8 65.1a 123.2 
±7.7 ±1O.6 ±1O.6 ±0.5 ±5.6 ±5.3 ±t3.2 
104.5 77.9 82.7 31.7a 121.8 34.4a 77.6 
±7.5 ±12.4 ±2.7 ' ± 1.2 ±4.3 ±1.4 ±9.8 
107.4 235.2b 146.8c 54.5a 141.2a 43.93 109.9 
±4.9 ±9.2 ±4.9 ±3.6 ±7.0 ±5.8 ± 19.6 
98.49 90.2 94.7 33.6a 87.33 25.1a 75.6 
±8.1 ± 14.0 ± 1.3 ±2.9 ±16.6 ±4.l ±9.0 , 
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TABLE 2b : The effect of combined vitamin E succinate and ascorbic acid supplementation on BL6 cell growth. Results are the mean of five" or three 
cultures ± SEM. 
[vitamin E 
succinate: 
ascorbate] 
p.g/ml Exp Exp Exp 
3.2.2' 3.2.3" 3.5 
OE 100 100 100 
±2.2 ± 1.2 ±1O.5 
5:25 85.1b 88.0b 
±3.3 ±3.2 
10:50 64.6a 66.0a 
±5.5 ±4.8 
10:25 67.2a 69.8a 
±0.5 ±1.2 
20:25 13.9a 15.9" 
±0.8 ± 1.1 
a - p ~ 0.001 relative to control cultures (OE) 
b - p ~ 0.0 I relative to control cultures (OE) 
c - P ~ 0.05 relative to control cultures (OE) 
87.1b 
±3.2 
60.8a 
±2.6 
68.0a 
±2.5 
30.2a 
± 1.7 
BL6 CELLS 
Growth inhibition [% of untreated controls] 
Exp Exp Exp Exp Exp 
4.1 4.2 4.4 4.5 4.6 
100 100 100 100 100 
±7.9 ±0.8 ± 1.7 ±5.8 ±3.9 
105.6 . 49S 25.8a 76.4b 81.3b 
±5.1 ±3.8 ± 1.3 ±2.6 ±1.7 
70.7b 12.1a 17.5b 48.3a 74.6b 
±3.1 ±1.5 ±0.3 ±3.0 ±3.6 
81.4c 40.7a 26.7a 45.2a 130.6a 
±5.4 ±2.2 ±1.9 ±6.4 ±1.8 
63.7a 3.6a 1.6a 24.49a 15.13a 
±6.1 ±0.2 ±6.1 ±3.0 ±0.4 
Exp Exp Exp 
4.7.2 4.7.3 4.8 Mean 
100 100 100 100 
±5.6 ±4.2 ±3.4 4.5 
85.6c 107.9 77.0h 79.0b 
±4.1 ±5.2 ±4.8 :± 7.1 
81.7b 87.7 52S 57.5a 
±3.2 ±1.4 ±6.4 ±7.3 
76.8b 90.3 51.2a 68.0b 
±3.1 ±4.5 ±4.0 ±8.5 
57.1a 69.6a 20.5a 28.7a 
±2.6 ± 1.6 ±2.2 ±7.2 
, 
!'J 
Q 
::::::: 
~ ~ 
s. 
0\ 
-..J 
TABLE 3a : The effect of vehicle treatments on LLCMK cell growth. Results are the mean of five' or three cultures ± SEM. 
---~ ... --.- ..... -- .... - .. --.- ... - ~ --
II LLCMK CELLS 
Treatmentsa Growth inhibition [% of untreated controls] 
Exp Exp Exp Exp Exp Exp Exp Exp Exp 
3.2.2" 3.2.3" 3.5 4.1 4.2 4.4 4.5 4.6 4.8 
0 100 100 100 100 100 100 100 100 100 
±S.l ±0.2 ±2.[ ±3.7 ±3.7 ±8.2 ±2S.2 ±2.2 ± 1.3 
OE 99.0 lOS.9 99.6 102.9 90.8 [01.9 96.3 102.9 100.6 
±9.6 ±8.6 ±3.2 ±2.2 ±6.7 ±3.2 ±6.9 ±2.2 ± [S.2 
a - cells cultured in the presence (OE) or absence (0) of ethanol 
TABLE 3b : The effect vehicle treatments on BL6 cell growth. Results are the mean of five' or three cultures ± SEM. 
~ -
BL6 CELLS 
Treatmentsa Growth inhibition [% of untreated controls] 
Exp Exp Exp Exp Exp Exp Exp 'Exp Exp Exp Exp 
3.2.2" 3.2.3" 3.5 4.1 4.2 4.4 4.5 4.6 4.7.2 4.7.3 4.8 
0 100 100 100 100 100 100 100 100 100 100 100 
1 
±7.0 ±23.0 ±7.3 ±6.3 ± IS.1 ±11.0 ±8.3 ± 17.1 ±S.6 ±3.7 ' ±3.4 
. 
OE 103.3 88.7 98.4 92.6 110.4 lO1.S 100 101.7 96.3 137.4 99.1 
±7.9 ±22.7 ±4.7 ±7.2 ±7.6 ±36.4 ' ±2.7 ± 1.9 ±3.6 ±2.7 ±3.9 
a - cells cultured in presence (OE) or absence (0) of ethanol 
Mean 
100 
±S.7 
100.S 
±1.4 
Mean 
100 
±9.8 
102.7 
±3.9 
!'l 
Q 
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Tables 3a, 3b and 4 represent the control experiments using the solvent ethanol and succinic acid. 
A control experiment using the solvent of vltamila E succinate (absolute ethanol) was done to 
determine the effect of ethanol on the parameters measured in this study. In both the LLCMK (Table 
3a) and BL6 cells (Table 3b), no trend of increased or decreased cell growth was observed when 
compared with control cultures (0). 
A further control experiment (Table 4) was set up with the equivalent concentrations of succinic acid 
as those present in the vitamin E succinate supplemented cultures and an equivalent amount of 
ethanol. Supplementation of equivalent amounts of succinic acid and ethanol as present in the vitamin 
E succinate supplemented cultures did not have a significant inhibitory or stimulatory effect on 
LLCMK cell growth. A general trend of decreased LLCMK cell growth is however apparent. In BL6 
cells, supplementation of succinic acid and ethanol equivalent~ resulted in no significant decreasing 
or increasing trend of cell growth. 
TABLE 4: The effect of succinic acid and vehicle treatments on LLCMK and BL6 cells, respectively. 
Results are the mean of five cultures ± SEM. , .. ' 
Growth Inhibition [% of untreated controls] 
[Succinic acid] [Ethanol] 
p.g/ml % 
LLCMK CELLS BL6 CELLS 
.. - -
oa 0.1 100±7.80 100±9.79 
0.89 0.1 100.62±3.13 86.19±3.66 
1.89 0.1 85.24±5.29 87.26±5.20 
3.78 0.1 86.29±4.30 105.76±6.36 
a - cells cultured in the presence of vehicle control 
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2.3.2 THE EFFECT OF COMBINED VITAMIN E SUCCINATE, ASCORBIC ACID 
AND 3H VITAMIN E SUCCINATE SUPPL~MENTATION ON CELL GROWTH 
-~ , 
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A slight decrease (non significant) in cell growth was found in control cultures (OE) of both the 
LLCMK and BL6 cells, when compared with that of control cultures (0) (Table 5), although not 
significantly so. 
-TABLE 5: The effect of vehicle treatment on LLCMK and BL6 cell growth. Results are the mean 
of three cultures ± SEM. 
Growth Inhibition [% of untreated controls] 
Treatment 
LLCMK CELLS BL6 CELLS 
-
0 100±7.12 100±3.75 
OE' 96.35± 14.05 94.43±6.31 
-.'-
* - control cultures containing 0.1 % ethanol and 3H vitamin E succinate 
TABLE 6: The effect of combined vitamin E succinate, ascorbic acid and 3H vitamin E succinate 
supplementation on cell growth. Results are the mean of three cultures ± SEM. 
PH] 
[vitamin E succinate:ascorbate] [Ethanol] Vitamin E 
Itg/ml % 
0 0.1 
5:25 0.1 
10:50 0.1 
10:25 0.1 
20:25 0.1 
a - p::;O.OOl relative to respective control cultures (OE) 
b - p::;O.Ol relative to respective control cultures (OE) 
succinate 
ItCi 
0.1 
0.1 
0.1 
0.1 
0.1 
Growth Inhibition 
.. - -[% of untreated controls] 
LLCMK BL6 
100 100 
±5.9 ±2.5 
50.0a 15.5" 
±7.3 ±0.3 
64.5b 11.7a 
±9.8 ±1.2 
60.1b 24.2a 
±7.3 ±2.1 
49.4a 18.2a 
±5.2 ±0.7 
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Supplementation of combined vitamin E succinate and Asc (5:25; 10:50; 10:25 and 20:25p,giml), and 
0.1p,Ci 3H vitamin E succinate (Table 6) resulted in a trend of decreased cell growth for both cell 
types~- The decrease in LLCMK cell growth fecordeg was significant at 5:25 (p~O.OO1); 10:50 
(p ~ 0.01); 10:25 (p ~ 0.01) and 20:25p,giml (p ~ 0.001) when compared with control cultures (OE). 
A similar but much more marked inhibitory effect was observed in the BL6 cells. The decreased cell 
growth recorded was significant (p ~ 0.001) for each combined vitamin concentr~tio1} group. 
2.3.3 THE EFFECT OF COMBINED VITAMIN E SUCCINATE, ASCORBIC ACID 
AND 14C_ ASCORBIC ACID SUPPLEMENTATION ON CELL GROWTH 
Cell growth in control cultures (OE) of both LLCMK and BL6 (Table 7), was slightly increased in 
comparison to control cultures (0), although no significance was recorded. 
TABLE 7: The effect of vehicle treatment on LLCMK and BL6 cell growth. Results are the mean 
of three cultures ± SEM. 
~. ' 
Treatment Growth Inhibition [% of untreated controls] . ~~ 
LLCMK BL6 
0 lOO±6.78 lOO±2.31 ~- -
OE* 107.98±7.13 101.25±5.67 
* - control cultures containing 0.1 % ethanol and 14C ascorbic acid 
Supplementation of combined vitamin E succinate and Asc (5:25; 10:50; 10:25 and 20:25p,giml) 
together with 0.15p,Ci 14C Asc resulted a general trend of decreased LLCMK cell growth with a 
significant (p ~ 0.01) decrease at 5:25p,giml vitamin E succinate and Asc (Table 8). On the other 
hand, BL6 cells (Table 8) supplemented with varying levels of combined vitamin E succinate and Asc, 
together with 0.15p,Ci Asc, showed a marked decrease in cell growth at each combined vitamin 
concentration with significant (p ~ 0.001) decreases at 10:50; 10:25 and 20: 25p,giml combined vitamin 
E succinate and Asc respectively. 
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TABLE 8: The effect of combined vitamin E succinate, ascorbic acid and 14C ascorbic acid 
supplementation on cell growth. Results are the mean of three cultures ± SEM. 
'14t 
[vitamin E succinate:ascorbate] [Ethanol] ascorbic 
jtg/ml % acid 
jtCi 
0 0.1 0.15 
-
5:25 0.1 0.15 
10:50 0.1 0.15 
10:25 0.1 0.15 
~ 
20:25 0.1 0.15 
a - p:s;; 0.01 relative to respective control cultures (OE) 
b - p :s;; 0.001 relative to respective control cultures (OE) 
Growth Inhibition 
[% of untreated controls] 
LLCMK BL6 
r ~ ~ 
100 100 
±4.2 ±3.0 
71.4a 75.0 
±7.1 ±5.8 
80.6 53.3b 
±5.2 ±1.2 
77.0 58.2b 
±5.2 ±4.0 
81.1 28.2b 
±6.1 ±0.3 
2.3.4 THE EFFECT OF COMBINED VITAMIN E SUCCINATE, ASCORBIC ACID AND 
3H-ARACHIDONIC ACID SUPPLEMENTATION ON CELL GROWTH 
Combined vitamin E succinate and Asc supplementation together with 5JLCi 3H AA resulted in an 
overall increase in cell growth of LLCMK cells, (Table 9). This increase in cell growth was 
significant at 5:25 (p:S;;O.OOI); 10:50 (p:S;;O.OOI); 10:25 (p:S;;O.Ol) and 20: 25JLg/ml (p:s;;0.05) 
respectively. On the other hand, combined vitamin E succinate and Asc together with 2.5JLCi AA 
supplementation resulted in an overall decrease in cell growth of LLCMK cells (Table 10), although 
not significantly so. Combined vitamin E succinate and Asc together with AA (radioactive and non-
radioactive) resulted in an overall significant (p :s;; 0.001) decrease in cell growth of BL6 cells (Tables 
9 and 10). Supplementation of AA (radioactive and non-radioactive) to control cultures did not have 
any effect on cell growth (Tables 11 and 12). 
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TABLE 9: The effect of combined vitamin E succinate, ascorbic acid and 3H arachidonic acid 
supplementation on cell growth. Results are the mean of three cultures ± SEM. 
[vitamin E succinate:ascorbate] [Ethanol] 
Jig/ml % 
0 0.1 
-
5:25 0.1 
10:50 0.1 
10:25 0.1 
-
20:25 0.1 
a - p:5 0.001 relative to respective control cultures (OE) 
b - p:50.01 relative to respective control cultures (OE) 
c - p:5 0.05 relative to respective control cultures (OE) 
-< 
15-3H AA 
JiCi 
5 
5 
5 
5 
5 
Growth Inhibition 
[% of untreated controls] 
LLCMK BL6 
100 - 100 
±5.4 ±8.2 
154.1" 73.0e 
±8.7 ±12.7 
140.4" 33.8" 
±5.5 ±2.2 
131.6b 34.6" 
±5.5 ±3.1 
--
122.8e 28.1" 
±5.6 ±3.1 
TABLE 10: The effect of combined vitamin E succinate, ascorbic acid and arachidonic acid 
supplementation on cell growth. Results are the mean of three cultures ± SEM. 
Growth Inhibition 
[vitamin E succinate:ascorbate] [Ethanol] [ AA] [% of untreated controlsl- -
Jig/ml % JiM 
LLCMK BL6 
0 0.1 2.5 100 100 
±4.3 ±0.8 
5:25 0.1 2.5 87.5 49.3" 
±4.5 ±2.2 
10:50 0.1 2.5 85.4 44.0a 
± 1.9 ±0.2 
10:25 0.1 2.5 86.3 28.1a 
±3.7 ±0.3 
20:25 0.1 2.5 85.28e 24.1a 
±3.3 ±1.5 
a - p:50.001 relative to respective control cultures (OE) 
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TABLE 11: The effect of 3H arachidonic acid and vehicle treatment on LLCMK and BL6 cell 
growth. Results are the mean of three cultures ± SEM. 
-
Growth Inhibition [% of untreated controls] 
Treatment 
LLCMK CELLS BL6 CELLS 
0 103.7 ±6.0 105.7 ±4.0 
OEo 106.3±2.5 1 04:(j £3.8 
OE* 100±5.4 100±8.2 
o - cultures containing 0.1 % ethanol 
* - control cultures containing 0.1 % ethanol and 5jlCi 3H_ AA 
TABLE 12: The effect of arachidonic acid and vehicle treatment on LLCMK and BL6 cell growth. 
Results are the mean of three cultures ± SEM. 
- Growth Inhibition [% of untreated controls] 
Treatment 
LLCMK CELLS BL6 CELLS 
0 103.7±2.2 101.7 ±3.2 
OEo lOS.7±2.1 104.0± 1.0 .. ' 
OE* 100±4.3 100±O.8 '.' 
o - cultures containing 0.1 % ethanol 
* - control cultures containing 0.1 % ethanol and 2.5jlCi AA 
2.4 DISCUSSION 
Vitamin E supplementation has been shown to have an inhibitory effect on the growth of numerous 
cell lines in vitro (49,91,92,94,96,97,477), while vitamin C has been reported to have both an 
inhibitory and a stimulatory effect on the growth of numerous cell lines in culture (64,69,76,478-480). 
Vitamin E succinate is the most potent form of vitamin E in vitro and is believed by Prasad and Rama 
(49) to be effective in a very narrow concentration range. A concentration of 6jlg/ml was found to 
produce a more marked decrease in cell growth than that produced by a concentration of 5jlg/ml in 
melanoma cells (49). A concentration of lOjlg/ml vitamin E succinate supplemented to melanoma 
cells was lethal. These findings were substantiated by studies by Prasad and Edwards-Prasad (94), 
Rama and Prasad (92) and Kline et al (97). The growth inhibitory effect of vitamin E succinate on 
mouse melanoma in culture was found to be primarily irreversible (94). In summary, from the above 
studies, lOjlg/ml vitamin E succinate was reported as being the most cytotoxic concentration when 
supplemented to various cell lines in culture. Furthermore, vitamin E succinate is known to induce 
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morphological changes in melanoma cells. At high concentrations (lOJLg/ml) of vitamin E succinate, 
cells become round and granulated, which is attributed.to the toxicity of the vitamin (92). 
The effect of Asc supplementation on cell growth appears to depend on the cell type and the level of 
Asc supplementation. Since melanoma cells have been found to preferentially incorporate Asc, in vitro 
studies have shown that Asc is more toxic to melanotic cells than any others studied-(59). The growth 
of BL6 cell melanoma in vitro (481,482) and leukaemic (61) cells was shown to be inhibited at Asc 
concentrations ranging from 25-200JLg/ml, with marked decreases occurring at 50-200JLg/ml. On the 
other hand, it has been reported that non-malignant, osteoblast-like MC 3T3-El cells resulted in 
enhanced proliferation following Asc supplementation (42), while that of Chinese hamster ovary cell 
proliferation (472) was inhibited by Asc. Interestingly, Asc supplementation of up to 200JLg/ml is 
considered not to cause any morphological changes in mouse melanoma (B-16), mouse neuroblastoma 
(NBP2)'. rat glioma (C-6) and mouse fibroblasts (L cells) in culture (49). However, at higher 
concentrations (500-1000JLg/ml) supplementation of Asc was lethal. 
Since the effect of combined vitamin E succinate and Asc supplementation of malignant BL6 murine 
melanoma on cell growth has not been reported, it was important to determine effective inhibitory 
concentrations of combined vitamin E succinate and Asc supplementation on BL6 cell growth. With 
reference to these inhibitory concentrations of vitamin E succinate and Asc, preliminary range finding 
experiments were set up. Results from these studies showed that the most effective cell growth 
inhibitory levels of combined vitamin E succinate and Asc were as follows: 5:25; 10:50; 1O:2S-and 
20:25JLg/ml respectively. 
Since studies by Ottino and Duncan (483) on BL6 cell growth following vitamin E succinate 
supplementation resulted in marked decreases in cell growth, it may be expected that a more 
pronounced inhibitory effect on cell growth of these cells following combined vitamin E succinate 
and Asc since an Asc regenerating capacity of vitamin E (see Section 1.4) could be expected. 
Results from these studies showed that supplementation of combined vitamin E succinate and Asc in 
LLCMK cells resulted in no increasing or decreasing trend in cell growth. However, supplementation 
of combined vitamin E succinate and Asc of BL6 cells resulted in a decreasing trend in cell growth. 
The decrease in cell growth of BL6 cells was significant (p::;; 0.001) at all combined concentrations 
(5:25; 10:50; 10:25 and 20:25JLg/ml). Furthermore, as expected, it was found that the concentration 
of the vitamin E succinate relative to Asc was important for maximum inhibition of BL6 cell growth. 
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When the concentration of vitamin E succinate relative to Asc was increased, a significant inhibitory 
effect on cell growth was observed. This suggests that. the ratio of vitamin E succinate to Asc is a 
major determining factor "for the effectiveness of these vitamins in decreasing cell growth. The reason 
for this is that vitamin E is known to be inhibitory (49,91,92,94,96,477) to growth of various cell 
lines, and the regenerative capacity of vitamin C could in turn enhance the antiproliferative effect of 
vitamin E. 
Supplementation of 3H vitamin E succinate and 14C ascorbic acid respectively, to combined vitamin 
E succinate and Asc supplemented LLCMK and BL6 cells resulted in a significant decreasing trend 
in cell growth for both cell types. Supplementation of BL6 cultures with combined vitamin E 
succinate and Asc together with AA (radioactive and non-radioactive), again resulted in significant 
decreases in cell growth. As the supplemented levels of AA remained constant, it is reasonable to 
conclude that this inhibitory effect on cell growth was due to the combined vitamin E succinate and 
Asc supplementation. 
Control experiments (Tables 3a, 3b and 4) of equivalent amounts of succinic acid and ethanol, were 
set up to determine the effect of the vehicle, ethanol, and succinic acid on the parameters measured 
in this study. None were found to have any effect on the growth of BL6 cells. These findings suggest 
that the growth inhibitory effects observed in BL6 cell are in fact due to combined vitamin E 
succinate and Asc and not the vehicle or succinic acid. The findings in this study on these controls 
were supported by studies of Prasad and Edwards-Prasad (94) and Kline et al (97). 
CHAPTER 3 
THE EFFECT OF COMBINED NUTRIENT SUPPLEMENTATION ON THE UPTAKE 
AND METABOLISM OF THE NUTRIENTS AND ON THE OXIDATION STATES IN 
CELLS 
3.1. -INTRODUCTION 
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Oxygen, a vital element for the life of a cell, is also the source of active species of oxygen which 
can disrupt cell structure and alter cell function (3). Substantial evidence indicates that the active 
oxygen species formed, particularly from molecular oxygen, may play a role in the tumour 
promotion process of multistage carcinogenesis (3,10,11). 
Reactive oxygen species (ROS), which include superoxide anion radicals, hydroxyl radicals, 
hydrogen peroxide, organic peroxide radicals, and singlet molecular oxygen are constant1y.~eing 
generated intracellularly in organisms (484). The aerobic organisms are protected against this 
oxidative damage by an array of defence mechanisms, which under normal conditions appear to 
provide adequate protection for the cell membrane. Cellular defences against these transient but 
damaging species can be grouped under enzymic and non-enzymic mechanisms. These are 
represented by the protective enzymes SOD, glutathione peroxidase and catalase, and non-enzymic 
antioxidants such as Asc, iJ-carotene and (X-TOR (17,210). However, the possibility exists that in 
certain circumstances these defences become defective or even completely overwhelmed, resulting 
in free radicals and active oxygens attacking lipids, proteins, sugars, CHO, and in DNA inducing 
oxidation, cleavage, cross-linking and modifications which eventually leads to extensive damage 
(52-54,210). 
Tumour promoters are known to modulate cellular antioxidant defense mechanisms (10), resulting 
in tumour cells exhibiting decreased enzymatic antioxidant activity (123,485-487). This 
phenomenon leads to tumour cells accumulating free radicals and lipid peroxides. Furthermore, 
some human patients have exhibited reduced antioxidant levels and corresponding increased lipid 
peroxidation-MDA levels which are known to have mutagenic properties (188). 
Numerous studies on the relationship between serum vitamin E and cancer incidence have 
suggested an inverse relationship between the levels of vitamin E and risk of cancer development 
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(110,146,155,488). A similar relationship has been suggested for that of Asc (43,71). As a 
consequence, one would expect tumour cells to have r~duced free radical and lipid peroxide levels 
(123,130). Results from studies in Section 2.3.1 ha~ shown that combined vitamin E sucdnate and 
Asc supplementation significantly reduced cell growth in BL6 cells. The actual mechanism by which 
vitamin E succinate inhibits growth is at present unknown (97), although studies by Prasad and Rama 
(92) have suggested that the inhibitory effects of vitamin E succinate on growth are Illediated in part 
by its antioxidant properties. Vitamin C is reported to regenerate TOR from the tocopheroxyl radical 
thus restoring the antioxidant ability of the fat-soluble vitamin E (36). This would suggest an enhanced 
inhibitory effect on BL6 cell growth following combined vitamin E succinate and Asc. In nature, the 
antioxidant a-TOR is found as free (unesterified) a-TOR (489), while vitamin E esters are non-
physiological antioxidants which require esterase activity in order to liberate the free alcohol, a-TOR, 
with antioxidant properties (93,97,490,491). As yet, no species specific hydrolysis of vitamin E 
succinate has been demonstrated, however it has been suggested that numerous other ester forms 
encounter esterases in association with other hydrophobic membranes and other membranous 
structures present in most cells (490). Uptake mechanisms of a-TOR across plasma membranes are 
presently undefined (107), while the tocopheryl esters, are absorbed into the cell, also by unlg10wn 
transfer mechanisms (490,492). Concerning the uptake of Asc by cells, it appears that more than one 
transport mechanism is operative, although the hydrophilic nature of vitamin C suggests that a carrier 
mechanism is necessary for Asc entry into the cell (34). 
To determine whether the inhibition of BL6 cell growth is the result of a synergistic antioxidant.effect 
of combined vitamin E succinate and Asc, experiments were carried out to examine the effect of 
combined vitamin supplementation on free radical and lipid peroxidation levels in LLCMK and BL6 
cells. In addition, relative uptake of the vitamin E succinate and Asc, as well as the metabolism of 
vitamin E succinate was determined. 
3.2 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON FREE RADICAL AND LIPID PEROXIDATION FORMATION 
3.2.1 MATERIALS 
2-Thiobarbituric acid (98%) (TBA), Nitro Blue Diformazan (NBD), Nitro Blue Tetrazolium (NBT) 
and Butylated Rydroxytoluene (BRT) were purchased from Sigma Chemical Co., USA. 1,1,3,3-
Tetramethoxypropane (98 %)[ malondialdehyde-tetramethyl acetal] was obtained from Fluka, 
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Switzerland. Trichloroacetic acid (98%) (TCA), butanol and glacial acetic acid (99.5%) were 
purchased from Holpro Chemical Co., South Africa. 
3.2.2 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON FREE RADICAL FORMATION 
METHODS 
3.2.2.1 Cell culture procedures 
Refer to 2.2.3.1 and 2.2.3.2. The cell suspensions were centrifuged at 3 OOOg for 10 minutes. The 
cellular pellets were resuspended in 1.0mI of PBS, pH 7.4, for the free radical determination. 
3.2.2.2 Free radical formation 
The principle of this assay is based on the reduction of NBT by the superoxide anion and other free 
radical species to insoluble diformazan. Free radical formation was determined using amodified NBT-
assay as described by Sagar et al (493) and Das et al (494). 
To 1ml cell suspensions, O.4ml of a 0.1 % NBT solution in PBS, pH 7.4 was added and allowed to 
incubate for 2 hours at 37°C. The reaction was then terminated by the addition of 0 .6mI glacial_a~etic 
acid, and the relative absorbance values measured at 560nm. The amount of NBD formed was 
determined from a standard curve generated from NBD as shown in Appendix 1. Final results were 
expressed as nmoles diformazan/1Q4 cells. 
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3.2.3 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON LIPID PEROXIDATION FORMATION 
METHODS 
3.2.3.1 Cell culture procedures for lipid peroxidation experiment 
-Refer to 2.2.3.1 and 2.2.3.2. The cell suspensions were centrifuged at 300g for 10 minutes. The 
cellular pellets were resuspended in 1.0ml of 0.9% NaCI for lipid peroxidation determination. 
3.2.3.2 Lipid peroxidation determination 
Lipid _p~roxidation was determined using the thiobarbituric acid (TBA) assay. The principle of this 
assay involves the reaction of MDA equivalents with TBA to yield a pink complex. A modified 
method of Sagar et al (493) and Drapper et al (495) was used in this assay. 
To 1ml cell suspensions, a 0.5ml aliquot of BHT (0.5g/l) was added followed by the-additioh of 1ml 
of 25% trichloroacetic acid (TCA). The samples were centrifuged at 2 OOOg for 20 minutes at 4°C, 
to remove insoluble proteins. Following centrifugation, 2ml of protein-free supernate was removed 
from each tube and a 0.5ml aliquot of 0.33% TBA was added to this fraction. All tubes were boiled 
for 1 hour at 95°C in a water bath. After cooling the TBA-MDA complexes were extracted wi!h_ 2ml 
butanol. The absorbance was read at 532nm and MDA levels determined from a standard curve 
generated from 1,1,3,3-Tetramethoxypropane as shown in Appendix 2. Final results were represented 
as nmoles MDA/104 cells. 
3.2.4 STATISTICAL ANALYSIS 
The results were analysed using a one-way analysis of variance (ANOVA) followed by the Student-
Newman Keuls Multiple Range Test. Data in all subsequent sections of this chapter were similarly 
analysed. 
3.2.5 RESULTS 
The effect of combined vitamin E succinate and Asc supplementation on the formation of free radicals 
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and lipid peroxidation is shown in Table 13. 
Supplementation of combined vitamin E succinate,aJ)d Asc to LLCMK cells resulted ,in a non 
significant decrease in free radical levels for the combined vitamin concentrations tested (Table 13). 
In BL6 cells, however, supplementation of varying levels of combined vitamin E succinate and Asc 
respectively, resulted in a general increase in free radical levels with a significant (p ::;; 0.05) increase 
~- -
occurring at 20:25JLg/ml. Comparing the levels of free radicals in LLCMK and BL6 control cultures 
(OE), a lower free radical level was observed in BL6 cells, however not significantly so. 
TABLE 13: The effect of combined vitamin E succinate and ascorbic acid supplementation on free 
radical and lipid peroxidation levels in LLCMK and BL6 cells respectively. Results are the mean of 
five cultures ± SEM. 
LLCMK CELLS BL6 CELLS 
- --
[vitamin E Free radical Lipid Free radical 
[succinate:ascorbate] formation peroxidation _ formation 
Itg/ml 
nmoles nmolesMDA/ nmoles 
Diformazan/ 104 cells Diformazan/ 
104 cells 104 cells 
OE 0.058 0.820e 0.032 
±0.005 ±0.031 ±0.002 
5:25 0.044 0.581 0.047 
±0.002 ±0.011 ±0.004 
10:50 0.053 5.643a 0.043 
±0.008 ±0.191 ±0.003 
10:25 0.045 0.646 0.043 
±0.002 ±0.045 ±0.003 
20:25 0.041 6.763a 0.051b 
±0.002 ±0.322 ±0.002 
a - p:::;O.OOl relative to LLCMK lipid peroxidation control cultures (OE) 
b - p:::;0.05 relative to BL6 free radical control cultures (OE) 
c - p:::; O. 05 relative to BL6 lipid peroxidation control cultures (OE) 
d - p:::; 0.001 relative to BL6 lipid peroxidation control cultures (OE) 
e - p:::; 0.05 relative to control BL6 MDA levels (OE) 
Lipid 
peroxidation 
nmoles MDAI 
104 cells 
'--
0.423 
±0.132 
0.412 
±0.025 
. -- -
3.662c 
±0.537 
5.328c 
±0.341 
29.063d 
±2.814 
Supplementation of LLCMK cells (Table 13) with combined vitamin E succinate and Asc resulted in 
no general increasing or decreasing trend in lipid peroxidation levels. Significant increases were, 
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however, detected at 1O:50p,g/ml (psO.001) and 20: 25p,g/ml (psO.001) combined vitamin E 
succinate and Asc, respectively. In BL6 cells, combined vitamin E succinate and Asc supplementation 
resulted in an overall increasing trend in lipid peroxidation levels with significant increases' occurring 
at 1O:25p,g/ml (psO.05) and 20:25p,g/ml (psO.001) respectively, when compared to control cultures 
(OE). From Table 13 it is evident that basal MDA levels in LLCMK cells were significantly (p s 0.05) 
higher in control cultures (OE) than in BL6 control cultures (OE). 
In general, when comparing free radical formation and lipid peroxidation levels in LLCMK and BL6 
cells, it was evident that lipid peroxidation levels were higher in BL6 than in LLCMK cells overall 
following combined vitamin supplementation at higher levels of the two vitamins, while when 
comparing free radical levels, no substantial difference in the levels was detected. 
3.3 EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON [U 3H] VITAMIN E SUCCINATE UPTAKE 
3.3.1 MATERIALS AND METHODS 
MATERIALS 
[U 3H] Vitamin E succinate [lmCi/m] was obtained from Amersham, Int., England. Emulsifier 
scintillator plus™ scintillation cocktail was purchased from Packard Company, USA. 
METHODS 
3.3.1.1 Cell culture procedures 
Refer to sections 2.2.3.1 and 2.2.3.2. 
3.3.1.2 Homogenization of cells and separation of cellular components 
The cell suspensions were poured into a Dounce homogenizer and homogenized 30 times with the 
tight plunger. The homogenizer was rinsed with 1ml PBS solution, pH 7.4. The various homogenates 
were then separated into membrane and stroma fractions by differential centrifugation. Cell 
homogenates were centrifuged (Beckman Model 12-21 Centrifuge) at 480g for 20 minutes, to remove 
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nuclei and non-disrupted cells. The supernatant was retained and centrifuged at 4 OOOg for 20 minutes 
to remove the mitochondrial fraction. Once again, the supernatant was retained and centrifuged at 20 
OOOg for 30 minutes, in 'order to obtain the respectiVe membrane (pellet) and stroma (supernatant) 
fractions of the homogenized cells. The pellet was resuspended in 2ml PBS solution. 
3.3.1.3 Determination of radioactivity in membrane and stroma fractions ~. . 
Duplicate 1ml aliquots of membrane and stroma fractions were removed and added to scintillation 
vials containing lOml of scintillation cocktail. The radioactivity in each membrane and stroma fraction 
was determined by counting in a Beckman (LS 2800) scintillation counter. 
3.3.2 RESULTS 
The total uptake of 3H vitamin E succinate by LLCMK and BL6 cells is presented in Figure 18. 
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Figure 18: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on the uptake of 3H vitamin E succinate by both 
LLCMK and BL6 cells. The bars are the mean of three cultures ± 
SEM. 
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3H vitamin E succinate uptake was significantly (p:::; 0.001) higher in the control cultures (OE) of 
LLCMK relative to the uptake of 3H vitamin E succinate in the control cultures (OE) of BL6 cells. 
Furthermore, 3H Depvitamin E succinate uptake Was significantly higher in the LLCMK cells 
supplemented with combined vitamin E succinate and Asc 5:25 (p:::; 0.001); 10:25 (p:::; 0.01) and 
20:25Ikg/ml (p:::;O.OOI) relative to the corresponding combined vitamin concentrations in BL6 cells. 
Supp!ementation of LLCMK cells with combined vitamin E succinate and Asc together with 3H 
vitamin E succinate resulted in decreased although non significant uptake of 3H vitamin E succinate 
at 1O:25Ikg/ml, with a slight increase in uptake at 5:25Ikg/ml, compared to the relevant (OE) control 
cultures. However, a significantly increased uptake of3H vitamin E succinate at 10:50 (p:::;O.OI) and 
20:25Ikg/ml (p:::; 0.05) was observed following combined vitamin supplementation relative to control 
cultures (OE). 
Supplementation of BL6 cells (Figure 18) with combined vitamin E succinate and Asc together with 
[3H] vitamin E succinate resulted in a general increase in 3H vitamin E succinate uptake which was 
significant at 5:25 (p:::;0.05); 10:50 (p:::;O.OOI) and 20:25Ikg/ml (p:::;O.OI) respectively, relative to 
control cultures (OE). Studies in our laboratory (personal communications) showed that . 3H vitamin 
E succinate uptake increased with increasing concentrations of vitamin E succinate supplementation 
on its own, however no difference in 3H vitamin E succinate uptake beyond 5-10Ikg/ml vitamin E 
succinate is observed. As expected 3H vitamin E succinate uptake in BL6 cells in this study increased 
with increasing concentrations of vitamin E succinate, however at 10:25 and 20:25Ikg/ml combined 
vitamin E succinate and Asc supplementation a decrease in 3H vitamin E succinate uptake was 
observed compared to 10:50Ikg/ml. This suggests that beyond 1Olkg/ml vitamin E succinate, uptake 
of 3H vitamin E succinate is inconsistent although the decrease in Asc concentration may have 
influenced the uptake of 3H vitamin E succinate in these two combined vitamin concentration sets. 
Table 14 shows the relative uptake of 3H vitamin E succinate in membrane and stroma fractions of 
LLCMK and BL6 cells respectively. Supplementation of LLCMK cells with combined vitamin E 
succinate and Asc resulted in a general increase in 3H vitamin E succinate uptake in both membrane 
and stroma fractions when compared to the control cultures (OE) respectively, although no statistical 
significance between the values was recorded. 
Comparison of membrane and stroma fractions in control cultures (OE) and combined vitamin E 
succinate and Asc supplemented LLCMK cells showed a general increase in 3H vitamin E succinate 
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uptake in the stroma fraction. 
Supplementation of BL6 -melanoma cells with combihed vitamin E succinate and Asc resulted in an 
increased uptake of 3H vitamin E succinate in membrane and stroma fractions relative to respective 
control cultures (OE)(Table 14). In the membrane fraction significant uptake of labelled vitamin E 
succinate was observed at 10:50(psO.001); 10:25(psO.01) and 20:25(sO.001) respectively, while 
the uptake in the stroma fraction was only significant (p s 0.001) at 20:25JLg/ml compared to their 
respective control cultures (OE). Comparison of 3H vitamin E succinate uptake in control cultures 
(OE) and combined vitamin supplemented membrane and stroma fractions of BL6 cells (Table 14) 
only showed an increase in uptake of 3H vitamin E succinate in the stroma fraction of the 5:25 and 
1O:50JLg/ml groups. 
TABLE 14: The effect of combined vitamin E succinate and ascorbic acid supplementation on the 
uptake of 3H vitamin E succinate by the membrane and stroma fractions of LLCMK and BL6 cells, 
respectively. Results are the mean of three cultures ± SEM. 
[vitamin E succinate: [U3H] 3H vitamin E succinate 
ascorbate] vitamin E uptake in membrane 
/tg\ml succinate fraction cpm/l04 cells) 
LLCMK BL6 
OE 0.1 1.76 0.21 
±0.34 ±0.02 
5:25 0.1 2.47 0.41 
±0.45 ±0.15 
10:50 0.1 2.00 0.99a 
±0.31 ±0.08 
10:25 0.1 1.08 0.67b 
±0.13 ±0.06 
20:25 0.1 2.23 1.07a 
±0.27 ±0.02 
a - p::;O.OOI relative to BL6 membrane control cultures (OE) 
b - p::;O.OI relative to BL6 membrane control cultures (OE) 
c - p::;O.OOI relative to BL6 stroma control cultures (OE) 
3H vitamin.E succinate 
uptake in stroma fraction 
(cpm/104 cells) 
LLCMK BL6 
3.08 0.34 
±0.12 ±0.01 
.- -
7.03 1.38 
±2.08 ±0.24 
7.92 5.02 
±2.08 ±0.51 
1.96 0.598 
±0.01 0.621 
4.87 1.21 c 
±1.00 ±0.03 
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3.4 EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON [CARBOXYL J4C] ASCORBIC ACID UPTAKE 
-i: • 
3.4.1 MATERIALS AND METHODS 
L-[Carboxyl _14C] ascorbic acid was obtained from Amersham, Int., England. 
METHODS 
3.4.1.1 Cell culture procedures 
Refer to sections 2.2.3.1 and 2.2.3.2. 
3.4.1.2 Homogenization of the cells and separation into cellular components 
Refer to section 3.2.1.2. 
3.4.1.3 Determination of radioactivity in membrane and stroma fractions 
Refer to section 3.2.1.3. 
3.4.2 RESULTS 
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The uptake of 14C Asc by LLCMK and BL6 cells (combined membrane and stroma fractions) is 
shown in Figure 19. 
14C Asc uptake was significantly (p sO. 00 1) increased in the control cultures (OE) of LLCMK cells 
relative to the uptake of 14C in control cultures (OE) of BL6 cells (Figure 19) as was the uptake at 
10:50 (psO.05) and 10:25 (psO.Ol) in the LLCMK cells relative to the corresponding BL6 cells. 
In LLCMK cells (Figure 19) supplemented with combined vitamin E succinate and Asc together with 
14C Asc a significant increase in uptake of 14C Asc was found at 10:50 (psO.001); 10:25 (psO.Ol) 
and 20:25ILg/ml (p s 0.01) compared with control cultures (OE). 
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Figure 19: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on the uptake of 14C ascorbic acid by both 
LLCMK and BL6 cells. The bars are the mean of three cultures ± 
SEM. 
87 
Supplementation of combined vitamin E succinate and Asc together with 14C Asc in BL6 cells (Figure 
19) resulted in a significant (p sO. 00 1) increase in 14C Asc uptake at each combined vitamin 
concentration group relative to control cultures (OE). As expected, an increase in 14C Asc uptake was 
observed with increasing concentrations of cold Asc with the highest magnitude of 14C Asc uptake 
measured at 50JLg/ml Asc. 
Comparison of 14C Asc uptake in control cultures (OE) and combined vitamin E succinate and Asc 
supplemented membrane fractions with corresponding stroma fractions showed an increase (p sO. 00 1) 
in 14C Asc uptake in the stroma fractions of both cell types (Table 15). 
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TABLE 15: The effect of combined vitamin E succinate and ascorbic acid supplementation on the 
uptake of 14C ascorbic acid by the membrane and stroma fractions of LLCMK and BL6 cells, 
respe~tively. Results are the mean of three cultures ± SEM. 
[vitamin E succinate: 14C 14C ascorbic acid uptake in 
ascorbate] ascorbic membrane fraction 
Jlg\ml acid (cpm/l04 cells) 
JlCi 
LLCMK BL6 
- OE 0.15 0.97 0.12 
±0.02 ±0.01 
5:25 0.15 1.43 0.39d 
±0.13 ±0.15 
10:50 0.15 1.19 0.45d 
. ±0.18 ±0.08 
- 10:25 0.15 1.49 0.3Id 
±0.14 ±0.06 
20:25 0.15 1.31 0.51d 
±0.17 ±0.02 
a - p ~ 0.001 relative to corresponding LLCMK membrane fractions 
b - p~O.OOI relative to corresponding BL6 membrane fractions 
c - p ~ 0.001 relative to BL6 membrane control cultures (OE) 
d - p~0.05 relative to BL6 stroma control cultures (OE) 
14C ascorbic acid 
uptake in stroma fraction 
(cpmll04 cells) 
LLCMK r- ~ BL6 
6.66a l.13b 
±0.62 ±0.11 
9.99a 6.61bc 
±1.02 ±1.11 
9.07a 1O.47bc 
± 1.31 ±0.51 
1O.87a 7.14bc 
±0.31 0.621 
10.45" 1O.35bc 
±1.80 ±0.54 
Supplementation of LLCMK cells with combined vitamin E succinate and Asc, resulted in a slight 
but non significant increase in 14C Asc uptake in both membrane and stroma fractions when compared 
to respective control cultures (OE). 14C Asc uptake in the BL6 cells (Table 15), increased significantly 
(p:S: 0.001) in the stroma fractions of supplemented cells when compared to control cultures (OE) , 
while a similar significant (p:S: 0.05) increasing trend in 14C Asc uptake in the membrane fraction of 
supplemented cells was observed. 
3.5 EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON VITAMIN E SUCCINATE METABOLISM 
3.5.1 MATERIALS AND METHODS 
MATERIALS 
A reverse phase lOJLBondaclone ID C18 HPLC column (300x390mm) was purchased from 
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Phenomenex, USA, while the Guard-Pak precolumns. [SfLM, ODS] were obtained from 
Metachemicals, USA. Neostigmine and iminodiacetic ac~d were purchased from Sigma Chemical Co., 
USA. Nitric acid and Potassium Chloride (KC!) were purchased from Holpro Chemical Co., South 
Africa. High Performance Liquid Chromatography (HPLC) grade methanol, acetonitrile, hexane and 
ethanol were supplied by BDH Chemicals, LTD, England. Sodium dihydrogen orthophosphate was 
obtained from Unilab, SAARCHEM, South Africa. r· ~ 
METHODS 
3.5.1.1 Glassware Preparation 
Prior to use, all glassware was treated by the modified method of Buettner (cited in 496). This 
treatment involved the soaking of clean glassware in 2S % nitric acid for 48 hours, followed by 
another 48 hours in milli Q water containing chelating resin (iminodiacetic acid) (Sg/l). 
3.5.1.2 Preparation of Ca2+ and Mg2+ free phosphate-buffered saline solution 
To minimize oxidation of a-TOH to the tocopherylquinone, trace amounts of catalytic transition 
metals such as Ca2+ and Mg2+ were omitted from the assay buffer PBS. This buffer was prepared as 
described by Kelley et al (496) and contained 2.68mM KCI, 1.47mM K2HP02 , 136.8mM NaCI, 
8.06mM NaH2P02 , lOnM neostigmine and O.Smg/ml chelating resin, pH 7.4 
3.5.1.3 Cell culture procedure 
Refer to section 2.2.3.1 and 2.2.3.2, with the following changes. The cell pellets were resuspended 
in 1.0ml ice cold Ca2+ IMg2+ free PBS solution, pH 7.4. To the cell suspension, 20fLI of 200mM Asc 
was added. 
3.5.1.4 Extraction of vitamin E and vitamin E succinate 
The extraction of vitamin E and vitamin E succinate was carried out using a modified method of 
Kelley et al (496). Following enumeration using a haemocytometer, cell suspensions were centrifuged 
(Eppendorf S403 centrifuge) at 7S0g for lOminutes at 4°C. The supernate was discarded and the pellet 
wash repeatedly with the addition of the same amount of Asc. To the final pellet wash SfLl of 200mM 
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Asc was added. The pellet was finger-vortexed and placed Qn ice for 2minutes and then transferred 
in a glass Pasteur pipette to a cold Dounce homogenize~. To the cell suspension was added 500ILI of 
95% -ethanol. The samples were vortexed and homogenized 30 times with a tight plunger; followed 
by the addition of 500ILI of ice cold hexane. The cell suspensions were transferred to precooled glass 
centrifuge tubes and centrifuged at 300g for 3 minutes to separate the phases. An aliquot of the top 
(hexane) phase was placed in a glass storage vial. The head space air was replace(with nitrogen (N2) 
and the vials stored at -70°C until required. 
3.5.1.5 Vitamin E and vitamin E succinate determination 
The extracted samples were analysed by reverse phase HPLC, using a modified method of Scalia et 
al (497). The hexane extracts were dried under a stream of N2 and reconstituted in 100ILI of mobile 
phase containing methanol:acetonitrile (60:40, v/v). Separatiol1 of vitamin E and vitamin E succinate 
was performed on a ILBondclone CI8 column (lOlLm particle diameter, 30cmx3.9mm) fitted with a 
Guard-Pak precolumn (51Lm particle size, ODS) and eluted isocratically with methanol:acetonitrile 
(60:40, v/v) at a flow rate of 1.5ml.min- l . The reconstituted samples were injected (50ILI injection 
volume) onto the column. Vitamin E succinate and vitamin E were detected by a UV-visible 
spectrophotometer (Beckman, System Gold, Programmable detector module, Mode 166, USA). The 
identities of the separated compounds were established by co-chromatography with authentic 
standards, (+) vitamin E and vitamin E succinate, and the quantities of these compounds in the 
extract determined using peak areas and the standard curve recorded in Appendix 3. 
3.5.2 RESULTS 
The effect of combined vitamin E succinate and asc supplementation on cellular vitamin E and vitamin 
E succinate content in LLCMK and BL6 tells is represented in Table 16. 
Supplementation of LLCMK cells with 10:25ILg/ml of combined vitamin E succinate and Asc resulted 
in a marked increase in vitamin E succinate levels being detected, with a significant (p:::;; 0.001) 
increase occurring at 20:25ILg/ml when compared to 5:25ILg/ml combined vitamin supplemented 
cultures. In contrast, vitamin E levels in LLCMK were not detected, suggesting no esterase activity 
in LLCMK cells. 
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TABLE 16: The effect of combined vitamin E succinate and ascorbic acid supplementation on vitamin 
E succinate and vitamin E levels in LLCMK and BL6 <;ells. Results are the mean of three cultures 
± SEM. 
-< 
[vitamin E succinate: vitamin E succinate vitamin E (nmoles/104 cells) 
ascorbate] ( nmoles/104 cells) 
Ilg/m1 
LLCMK BL6 LLCMK ~ BL6 
OE ND ND ND ND 
-
5:25 0.026 0.012 ND 0.002 
±0.003 ±0.007 ±0.002 
10:50 0.009 0.012 ND 0.003 
±0.004 ±0.006 ±0.00l 
10:25 0.0501 0.007 ND 0.004 
±0.017 ±0.00l ±0.008 
--
20:25 0.249a 0.012 ND 0.006 
±0.048 ±0.001 ±0.008 
ND - not detectable 
a - p::;O.OOl relative to 5:251lg/ml LLCMK cells (vitamin E succinate) 
Supplementation of BL6 cells with varying levels of combined vitamin E succinate and Asc resulted 
in no increasing or decreasing trend in vitamin E succinate or vitamin E levels. The levels of vitamin 
E detected in supplemented BL6 cells with combined vitamin E succinate and Asc increased when 
compared to 5 : 25jLg/ml, although not significantly. 
3.6 DISCUSSION 
Ester derivatives of TOR are commonly used for vitamin E supplementation for both experimental 
and therapeutic purposes (95). Studies by Fariss using vitamin E succinate showed complete protection 
from the toxic effects of oxygen, including lipid peroxidation induction (95) and Cd-induced (498) 
toxicity in isolated hepatocytes. Furthermore studies by Pascoe and Reed (492) demonstrated 
protection by vitamin E succinate against the chemical toxicity of the free radical-producing anticancer 
drug adriamycin. The mechanism by which vitamin E succinate acts as an antioxidant protecting 
against toxic effects of free radicals and lipid peroxidation is still unclear, however it has been 
suggested that vitamin E succinate may act as a carrier for the vitamin E enabling the release and 
accumulation of TOR at a particular and critical cellular site within the cell (95,498,492,498). This 
suggests the accumulation of TOR may provide the cells first line of defence against free radical 
3. Cell Oxidation State 92 
attack on membrane phospholipids, and may in turn allow the water-soluble vitamin C access to the 
membrane bound vitamin. E radical for recycling of this ·moiety. This synergistic action would result 
-:; . 
in the delayed consumption of vitamin E, enhancing the antioxidant potential of the two vitamins 
(103,143,167,168). 
Supplementation of non malignant LLCMK cells with combined vitamin concentrations in this study 
resulted in a non significant decrease in free radical formation, while lipid peroxidation states 
exhibited no increasing or decreasing trend. In malignant BL6 cells, however, supplementation of 
combined vitamin E succinate and Asc resulted in a marked increase in both free radical and lipid 
peroxidation levels. One possible explanation for combined vitamin E succinate and Asc 
ineffectiveness in acting as an antioxidant preventing free radical formation and lipid peroxidation 
levels is that the various forms of vitamin E demonstrate different intracellular compartmental 
distrib-ution patterns (95,97), which may vary in different cell types. In LLCMK and BL6 cells, 
studies using radiolabelled vitamin E succinate clearly showed uptake in both membrane and stroma 
fraction. However, supplementation of radiolabelled vitamin E succinate with varying levels of 
unlabelled vitamin E succinate affected its distribution in that the majority of vitamin E suc~inate was 
located in the stroma. This cytosolic accumulation would increase the lipid membrane susceptibility 
to lipid peroxidation. Studies by Stich et al (cited in 58) showed that melanoma cells preferentially 
incorporate vitamin C, supporting the data obtained in our studies in which BL6 melanoma cells were 
shown to incorporate 14C Asc. In BL6 cells it was evident that supplementation of radiolabelled Asc 
resulted in a significant increase in Asc uptake in the stroma fraction when compared to the membrane 
fraction. 
As previously mentioned, vitamin E succinate in this study does not exhibit any antioxidant properties 
unless the succinate group is cleaved by esterase activity, liberating the free alcohol, vitamin E, which 
is an active antioxidant (97). Fariss (498) proposed that the vitamin E succinate cytoprotection may 
be due to vitamin E succinate acting as a carrier for tocopherol enabling the release and accumulation 
of TOH at a unique and critical cellular site. In LLCMK cells, supplementation of increasing 
concentrations of vitamin E succinate resulted in a marked increase in the cellular accumulation of 
the intact vitamin E succinate molecule, however no free vitamin E was detected in LLCMK cells, 
demonstrating the absence of esterase activity. In BL6 cells, supplementation with increasing 
concentrations of vitamin E succinate resulted in an overall increased accumulation of cellular vitamin 
E succinate. Although vitamin E succinate levels in BL6 cells neither increased nor decreased with 
increasing concentrations of vitamin E succinate, increased free vitamin E accumulation was detected. 
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Although these vitamin E levels in BL6 cells may appear very low, vitamin E is present in extremely 
low c_cmcentrations in membranes, normally less than O.lnmol per mg of membrane protein, in other 
words one molecule per 1000 to 2000 membrane phospholipid molecules (84). Results obtained for 
LLCMK cells suggest the absence of specific esterase activities in liberating vitamin E succinate, 
although accumulation of vitamin E succinate was evident. However, results from BL6 cells suggest 
the presence of various esterase enzymes capable of removing succinate from vitamirr E succinate to 
liberate vitamin E. A possible reason for the enhanced hydrolysis of vitamin E succinate as suggested 
by Pascoe and Reed (499) is that the Ca2+ content affects the intracellular metabolism of vitamin E 
and its esters within the cells, which may subsequently govern the outcome of a toxic challenge. 
In summary, the results obtained confirm the uptake of vitamin E succinate and Asc in BL6 cells. 
Furthermore, cleavage of the succinate does in fact occur, thus we propose that vitamin E and Asc 
may act synergistically resulting in the "sparing effect" of vitamin E (see Section 1.4). The inability 
of combined vitamin E and Asc supplementation to reduce free radical formation and lipid 
peroxidation levels within the BL6 cells may not be due to their ineffectiveness as antioxidants but 
rather the presence of other contributing factors which influence the free radical and lipid peroxidation 
- -"'"-" 
tone within the BL6 cells. Another possible source of free radical and lipid peroxidation within the 
cells may be increased eicosanoid metabolism in which COX activity in the pathway is believed to 
be a prime source of intermediatory free radical species (237,242,268). Furthermore researchers 
suggest that reduced levels of antioxidant enzymes may occur in tumour cells which in turn leads to 
elevated free radical and lipid peroxidation levels (185,187). Vitamin E has numerous other-roles, 
once inside the cell, besides its role as an antioxidant. Vitamin E might alter membrane stability or 
function by interacting with the unsaturated EF A portions of phospholipids (lipophilic TOH moiety) 
(95,498). Several studies indicate that administration of vitamin E stabilizes membranes (500) and 
alters membrane enzymatic activities (501,502). In order to explain the lack of antioxidant affect of 
vitamin E succinate and Asc found in the cells used in this study alternative metabolic pathways were 
investigated. Since vitamin E has been suggested to modulate the regulatory proteins in signal 
transduction pathways as well as the modulation of key regulatory enzyme activities in the eicosanoid 
pathway (231,503), the effect of combined vitamin E succinate and Asc supplementation on the 
eicosanoid pathway and its metabolites associated with cell growth were subsequently investigated in 
LLCMK and BL6 cells. 
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CHAPTER 4 
COMBINED NUTRIENT SUPPLEMENTATION AND SECOND MESSENGERS 
As mentioned earlier the mechanism(s) by which combined vitamin E succinate and Asc exert 
anticarcinogenic effects in vitro are unclear, although it has been suggested thaf these effects may 
be due to their synergistic antioxidant properties. Studies in Chapter 3 suggested that the inhibition 
of BL6 cell growth observed in this study was not mediated in part by the synergistic antioxidant 
action of combined vitamin E succinate and Asc but rather mediated through metabolic pathways 
which influence cell growth. This suggestion derives from the fact that free radical formation and 
lipid peroxidation levels increased after combined vitamin supplementation. Since vitamin E has 
been suggested to modulate the biosynthetic pathway involving AA metabolism at various points, 
the AA cascade pathway (refer to Figure 9, page 55), whicli involves the cleavage of AA via the 
action of PLA2 , was investigated. The conversion of AA to PGs and the effect of the latter on AC 
activity and cAMP (a known regulator of cell growth) was also determined. The pathway is also 
influenced by exogenous EFAs, 5-LOX, COX and Ca2 + levels. In addition to this, the role of 
COX and 5-LOX activity in AA metabolism as well as their role in free radical formation and 
induction of lipid peroxidation was examined. Hence we investigated the effect of combined 
vitamin E succinate and Asc supplementation on the activity of the pathway, and of AA 
metabolites which influence it. 
4.1 COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID SUPPLEMENTATION 
AND CALCIUM LEVELS 
4.1.1 INTRODUCTION 
Ca2 + is both an essential structural body component and a critical functional element in living cells 
(327). Ca2+ binds to various ligands such as proteins and phosphate groups (504) which in excess, 
can lead to a decrease in membrane fluidity if such groups form part of membranes (390). The 
function of this Ca2 + -binding is to enable Ca2 + to act as a pivotal regulator in metabolic processes 
(327,329,504) both as a major second messenger, and as free intracellular Ca2 + in cells (504). 
Signal mediation by cytosolic Ca2+ ions within cells plays a vital role in many cellular events 
(505). For example, many of the key enzymes involved in AA esterification or release are 
dependent on Ca2+. PLA2 requires elevated cytosolic Ca2+ for activation and subsequent release of 
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AA from numerous tissue lipids in various stimulated cell types (339,340) as the concentration of AA 
within resting cells is believed to be maintained at low levels (339,366). The regulation of Ca2 + levels 
in cells is mediated by several actions and is very complex. Intracellular Ca2 + concentration in a 
pituitary cell line has been shown to be controlled by second messenger AA and its metabolites. AA 
was shown not only to augment intracellular Ca2 + mobilization within the cells but to stimulate the 
entry of Ca2+ into these cells (506). AA is central to the process of second messeHgermetabolism as 
AA ll}ay serve as a positive or negative feedback regulator of the effects of intracellular c,r. 
The availabilty of Ca2 + within a cell is believed to be a key regulator of cell proliferation in 
multicellular organisms. Defects in Ca2 + control processes are a common determinant of unrestrained 
cell proliferation (329,335,356). Calcium concentrations within tumour cells vary in different cell 
types. Some malignancies are frequently associated with hypercalcaemia rather than hypocalcaemia. 
This phenomenon has been useful in the detection of certain tumour cell types (507-509). 
Since Ca2+ levels play an important role in modulating cell proliferation, and earlier studies in 
Chapter 2 showed significant growth inhibition in BL6 cells following combined vitamin E succinate 
- ,"-,' 
and Asc supplementation, it was necessary to determine the levels of intracellular Ca2 + in non-
malignant LLCMK and malignant BL6 cells, as well as the effect of combined vitamin E succinate 
and Asc supplementation on intracellular Ca2+ levels. 
4.1.2 MATERIALS AND METHODS 
MATERIALS 
A GBC 909 Atomic Absorption Spectrophotometer was used for Ca2+ detection. CaCl2 was purchased 
from Merck, Darmstadt, Germany, while nitric acid (RN03) was obtained from Unilab, 
SAARCREM, South Africa. 
METHODS 
4.1.2.1 Glassware preparation 
All glassware was acid washed prior to use with 25% RN03 solution at 60°C overnight. Thereafter 
it was rinsed with milli Q water. 
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4.1.2.2 Cell culture procedures 
The methods described in 2.2.3.1 and 2.2.3.2 were· repeated, with the exception that the cells 
harvested from this experiment were resuspended in 1ml Tris HCI buffer, pH 7.4 
The cells were not homogenized and fractionated, as Ca2 + concentrations in separate cell fractions 
were below detection limits. 
4.1.2.3 Acid digestion of the cells and calcium detection 
On completion of cell enumeration, the suspensions were centrifuged at 3 OOOg for 10 minutes and 
the supernatant liquid discarded. The cells were washed with 1ml Tris HCI buffer and again 
centrifuged at 3 OOOg for 10 minutes. The supernatant material-was again discarded and the centrifuge 
tubes drained. The remaining pellet was resuspended in 0.2ml concentrated HCI and boiled at 100°C 
for two hours. After acid digestion, a final volume of 1ml w-as constituted using milli Q water. The 
acid-digested fractions were once again centrifuged at 3 OOOg for 10minutes to remove the re§ultant 
debris. The supernate was assayed for Ca2+ content by flame atomic absorption spectroscopy. The 
conditions used for detection were as follows; fuel source air-acetylene; the slit width was 0.50nm; 
the wavelength was set at 422.7nm; and the current was 3mA. 
Standard CaCl2 solutions were also assayed using flame atomic absorption spectroscopy. The Ci+ 
standard curve is recorded in Appendix 4. 
4.1.2.4 Statistical analysis 
The results obtained were analysed using a one way analysis of variance (ANOV A) followed by the 
Student-Newman Keuls Multiple Range Test. Data in all subsequent sections of this chapter were 
similarly analysed. 
4.1.3 RESULTS 
Ca2+ levels in LLCMK cells of control cultures (OE) and 10:50; 10:25 and 20:25fLg/ml combined 
vitamin E succinate and Asc supplemented cells were significantly (p:::;; 0.001) higher than the Ca2 + 
levels detected in corresponding BL6 cultures (Table 17). 
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Combined vitamin E succinate and Asc supplementation of the LLCMK cells (Table 17) resulted in 
a very erratic effect on Ca2 + levels within the cells. relative to the control cultures (OE). At 
1O:25ILg/ml combined vitamin E succinate and Asc supplementation there was a significanf(p::;; 0.05) 
increase in Ca2+ levels was observed while, at 5:25ILg/ml a significant (p::;;0.05) decrease in Ca2+ 
levels relative to control cultures (OE) was observed. At 1O:50lLg/ml and 20:25ILg/ml combined 
vitamin E succinate and Asc supplementation of LLCMK cells resulted in no observed effect on Ca2 + 
level~ relative to control cultures (OE). 
Combined vitamin E succinate and Asc supplementation of the BL6 cells markedly increased the Ca2 + 
levels in these cells relative to control cultures (OE) with significant (p::;; 0.001) increases in Ca2 + 
levels at 10:50; 10:25 and 20:25ILg/ml relative to control cultures (OE). 
TABLE 17: The effect of combined vitamin E succinate and ascorbic acid supplementation on 
calcium levels in LLCMK and BL6 cells respectively. Results are the mean of three cultures ± SEM. 
[vitamin E succinate:ascorbate] 
I'g/ml 
OE 
5:25 
10:50 
10:25 
20:25 
a - p:5: 0.001 relative to corresponding BL6 cells 
b - p:5:0.05 relative to LLCMK control cultures (OE) 
c - p:5:0.001 relative to BL6 control cultures (OE) 
4.1.4 DISCUSSION 
Calcium concentration (nM/I04 cells) 
LLCMK BL6 .. ' 
5.02" 0.49 
±0.46 ±0.04 
1.85b 0.46 
±0.67 ±0.11 
4.33" 1.15" 
-
. 
±0.68 ±0.05 
7.1yb 1.63c 
0.61 ±0.04 
4.34" 1.95" 
±0.61 ±0.02 
The level of free Ca2+ in pancreatic acinar carcinoma cells has been reported to be lower than in 
normal acinar cells (510). Results from this study showed that Ca2+ levels in BL6 cells were lower 
than the Ca2+ levels found in the LLCMK cells, which supports the above finding. Ca2 + levels in 
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different tumour cells vary relative to one another. BL6 melanoma cells have been reported to have 
considerably higher Ca2 + content than normal liver and ~idney cells (504). However, studies by Hill 
(51O)--showed that all H16 melanoma cell lines had . lower intracellular free Ca2+ levels than a 
transformed murine melanocyte cell line, Melan A. Thus it would seem that BL6 melanoma cells are 
characterised by lower Ca2 + content. Despite this, studies (511) on 9 human melanoma cell lines 
suggested that growth was not affected in Ca2+ depleted medium, whereas norijlal £ells ceased to 
proliferate. The mechanism for continued growth of neoplastic cells at low Ca2+ remains unclear 
(511), but the situation is consistent with the suggestion that intracellular Ca2 + in these cells is high 
and requires no extra Ca2 +, or that these cells have adapted to a low extracellular Ca2 + environment. 
Thus a change in intracellular free Caz+ could be relevant to the development of neoplasia (510). 
The effect of combined vitamin E succinate and Asc on Caz+ levels in LLCMK and BL6 cells has not 
previo_usly been reported. High Ca2+ content was detected jn LLCMK cells supplemented with 
combined vitamin E succinate and Asc with no increase or decrease trend in Caz+ levels being 
dectected. As regards the BL6 cells, combined vitamin E succinate and Asc significantly increased 
Ca2 + levels within these cells compared with the control cultures (OE), except for the 5 : 25jlg/ml 
group. The effect of combined vitamin E succinate and Asc supplementation on Ca2+ levels within 
these cells could be due to the ability of vitamin E to modulate membrane fluidity, which could in 
turn account for the observed changes in Caz+ levels. The only mechanism available for causing large-
scale changes in Caz+ concentration involves movement either across the plasma membrane or across 
intracellular membranes (330). 
As Ca2+ levels play an important role in modulating PLAz activity (339,340) and since marked 
changes in intracellular Caz+ have been shown to occur in LLCMK and BL6 cells supplemented with 
combined vitamin E succinate and Asc, determination of the effect of combined vitamin 
supplementation on PLAz activity in LLCMK and BL6 cells required investigation. 
4.2 COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID SUPPLEMENTATION 
AND PHOSPHOLIPASE A2 ACTIVITY 
4.2.1 INTRODUCTION 
Phospholipids are the major structural components of cell membranes (121) and are involved in 
numerous biological responses including signal-transduction, second messenger generation, cell 
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membrane integrity and the activity of membrane bound enzymes (190). It is the fatty acids present 
at the 1 and 2 position on the phospholipid molecule whi~h determine and maintain membrane fluidity 
--
(190). The presence of PLA2 in biological membranes: is a prerequisite for proper membrane turnover 
(changes in chemical and physical properties of the membrane) in cellular metabolism for signal 
transduction and in membrane remodelling (349,373). 
PLA2 removes FAs, mostly AA, from the sn-2 position on the phospholipid glycerol backbone (282). 
The concentration of free AA within resting cells is believed to be maintained at low levels. The 
changes in AA which lead to an increase in the synthesis of the eicosanoids results from receptor-
stimulated lipid hydrolysis as a result of PLA2 activation (366,512). Four types of PLA2 exist, with 
the membrane-bound 85 kDa PLA2 (347,349,352,364) being important in this study, as this particular 
PLA2 cleaves AA from the sn-2 position which is an important substrate in the pathway studied. The 
high molecular mass cPLA2 trans locates to membranes in response to submicromolar changes in Ca2+ 
(513). This observation is of particular significance because many of the ligands that cause rapid 
production of eicosanoids are Ca2 + -mobilizing agents. 
In diseased states such as neoplastic transformation, it has been reported that lipid structUres are 
profoundly altered and hence the membrane fluidity of a number of tissues is modified (123,200). 
This change can affect the activity of membrane-bound enzymes resulting in the possible impairment 
of PLA2 activity in malignant cells. The aim of this part of the study was to determine PLA2 activity 
in LLCMK and BL6 cells, as well as the effect of combined vitamin E succinate and. Asc 
supplementation on PLA2 activity. 
4.2.2 MATERIALS AND METHODS 
MATERIALS 
I-Palmitoyl-2-[1-14C] arachidonyl-sn-glycerol-3-phosphatidyl choline [1-14C-PC] was supplied by New 
England Nuclear Products, Boston, USA. Taurocholic acid, fatty acid-free bovine serum albumin 
(BSA) and phosphatidylcholine (PC) were purchased from Sigma Chemical Co., USA. Silica gel 60 
Aluminium TLC plates were supplied by Merck, Darmstadt, Germany. Chloroform was obtained 
from BDH Chemicals, LTD, England, while Folin-Ciocalteu reagent was purchased from Unilab, 
SAARCHEM, South Africa. 
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METHODS 
4.2.2.1 Cell culture procedures 
Methods described in 2.2.3.1 and 2.2.3.2 were repeated except that cell pellets were resuspended in 
1ml of O.lM Tris HCI buffer, pH 7.4. 
4.2.2.2 Homogenization of cells and enzyme preparation 
The method outlined in 4.2.1.2 was repeated, except that the pellet was resuspended in 2ml of O.lM 
Tris HCL buffer, pH 7.4. 
4.2.2.3. Protein Determination 
Protein determinations were performed using a modified method of Lowry et al (cited in 514). The 
protein standard curve is recorded in Appendix 5. 
4.2.2.4 Determination of phospholipase A2 activity 
Membrane PLA2 activity was assayed using a modification of the methods of Ballou and Cheung 
(369,370), and the method of Krurnhardt and Dupont (515). PLA2 activity was determined by 
measuring the amount of [1-14C] AA released from the substrate 1-palmitoyl-2-[1-14C] arachidonyl-sn-
glycerol-3-phosphatidyl choline (specific activity = 52mCi/mmol). 
A 200111 aliquot of membrane suspension was added to 50111 of substrate and incubated at 57°C for 
10 minutes. The substrate contained Tris-HCI buffer, 50mM taurocholic acid, 20mM calcium 
chloride, 0.05g% fatty acid-free bovine serum albumin and 0.031lCi of radioactive labelled substrate. 
On addition of membrane suspension and after a 10 minute incubation period, lOOll1 aliquots of 
reaction mixture were removed and added to lOOll1 of 100 % ethanol containing 2 % glacial acetic acid 
and 330llM AA, to terminate the reaction. This solution was vortex mixed and lOOll1 applied to silica 
gel 60 Aluminium plates, which separated the [1-14C]AA released from the labelled substrate in a 
mobile phase of chloroform: methanol: H20 (65:25:4, v/v/v). AA and PC were used as markers. After 
the development of the TLC plates, bands of the silica gel were scraped into scintillation vials 
containing lOml of a scintillation cocktail. Radioactivity was determined by liquid scintillation 
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counting. PLA2 activity is determined as the net release of 13C AA from labelled substrate and is 
expressed as pmol of AA released per minute per mg n:tembrane protein. 
4.2.3 RESULTS 
Shown in Table 18 is the effect of combined vitamin E succinate and Asc suppletnentation on PLA2 
activity of both LLCMK and BL6 cells. 
TABLE 18: The effect of combined vitamin E succinate and ascorbic acid supplementation on 
phospholipase A2 activity detected in the respective LLCMK and BL6 cells. Results are the mean of 
three cultures ± SEM. 
[vitamin E succinate:ascorbate] PLA2 activity (pmol AA/min x mg protein) 
Itg/ml 
LLCMK CELLS 
OE 12.78 
±0.48 
5:25 5.67b 
±0.17 
10:50 4.91b 
±0.21 
10:25 8.34b 
±0.31 
20:25 4.44b 
±0.32 
a - p~O.OOI relative to corresponding supplemented LLCMK cells 
b - p~O.OOI relative to LLCMK control cultures (OE) 
c - p~O.OOI relative to BL6 control cultures (OE) 
BL6 CELLS 
11.20 
±0.12 
55. 56'c 
±5.32 
134. 89'c 
±3.63 
139. 92'c 
±2.37 
163.19'c 
±6.13 
.. ' 
'.' 
-
-
A comparison of the PLA2 activity in the two cell types revealed that the PLA2 levels in the BL6 
control cultures were slightly lower than that of the corresponding LLCMK control cultures (OE). 
PLA2 activity in combined vitamin E succinate and Asc supplemented BL6 cells is, however, 
significantly (p::;; 0.001) increased compared with the corresponding LLCMK cells (Table 18). PLA2 
activity in LLCMK cells supplemented with varying vitamin E succinate (5-20p,g/ml) and Asc (25-
50p,g/ml) levels resulted in a significant (p::;; 0.001) decrease in activity relative to control cultures 
(OE). However, in combined vitamin E succinate and Asc supplemented BL6 cells, a significant 
(p ~ 0.001) increase in PLA2 activity was detected relative to control cultures (OE). 
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4.2.4 DISCUSSION 
Studies by Buckley et al (377) demonstrated that bothCa2 + -dependent and Ca2 + -independent pathways 
are involved in PLA2 activation. The 85kDa cPLA2 of interest in this study shows an absolute 
requirement for Ca2+ (360) in the enzyme's translocation from the cytosol to particulate cell fractions 
(347,357,358) and has a substrate preference for sn 2-arachidonyl-containing phospholipids (347). In 
the present study I-palmitoyl-2-[ 1_14C] arachidonyl-sn-glycerol-3-phospatidylcholine was utilized as 
substrate during the PLA2 assay performed. 
A difference exists between soluble PLA2 and membrane-bound PLA2 activity in terms of substrate 
specificity and the rate of catalysis (373). Work by Hendrickse et al (381) demonstrated that PLA2, 
the key enzyme of AA release, was increased in colorectal cancer tissue as compared with that of 
normal tissue. In this study, PLA2 activity in BL6 supplemented cultures was significantly higher than 
the PLA2 activity in the LLCMK cells, which supports the above finding. Comparison of PLA2 
activity found in the control cultures (OE) of LLCMK and BL6 cells, revealed lower PLA2 activity 
in the malignant BL6 cells. Tumour cells are reported to have altered EF A composition in their 
membranes. This in turn modulates the activity of membrane-associated enzymes, such as PLA2 and 
AC (190). Hence, the lower PLA2 in the BL6 cells could be due to changes in the EFA content of 
the BL6 cell membrane. Thus it would seem the PLA2 activity is regulated in part by the EFA 
composition of the phospholipid bilayer in which they reside, and not by substrate availability (515). 
In LLCMK cells, PLA2 activity decreased significantly compared with control cultures (OE), whereas 
in the BL6 cells, PLA2 activity increased significantly with varying levels of combined vitamin E 
succinate and Asc supplementation. The mechanism by which combined vitamin E succinate and Asc 
supplementation increases PLA2 activity in BL6 cells is not clear, although certain factors should be 
considered. Studies by Stoll and Duncan (481) reported decreased PLA2 activity upon Asc 
supplementation in BL6 cells. Since it is believed that tumour cells have altered membrane fluidities 
(123,190), and vitamin E is known to stabilize membranes by virtue of specific physicochemical 
interactions (95,125,127) the significant increase in PLA2 activity observed following combined 
vitamin E and Asc supplementation may be due to the ability of vitamin E to modulate membrane 
fluidity through specific physicochemical interactions in membrane stabilisation. Asc in turn could 
regenerate vitamin E which could also account for the increase in Ca2+ levels observed (Section 4.1) 
and in turn would result in increased PLA2 activity. 
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The reason for the inhibition of PLAz activity in LLCMK cells following vitamin E succinate and Asc 
supplementation is unclear. The effect of vitamin E su.ccinate may be due to indirect inhibition of 
PLA;-through the regulation of intracellular Caz+ ,<as submicromolar changes in Ca2+ 'levels are 
known to regulate PLAz activity. 
In summary, these experiments revealed that when compared with the non malignant.LLCMK cells, 
PLAz activity was significantly higher in supplemented malignant BL6 cells. It was also found that 
-
combined vitamin E succinate and Asc supplementation of BL6 cells resulted in increased PLAz with 
increased vitamin E succinate concentrations, which may in turn affect AA levels within the cells. A 
further factor to consider in terms of cellular AA content is the possible effect of combined vitamin 
E succinate and Asc supplementation on AA uptake into the cells, and the influence that exogenous 
AA in the medium may exert on the cellular levels of AA. 
4.3 ARACHIDONIC ACID LEVELS WITH COMBINED VITAMIN E SUCCINATE AND 
ASCORBIC ACID AND ARACHIDONIC ACID SUPPLEMENTATION 
4.3.1 INTRODUCTION 
AA is esterified to specific phospholipids, most notably phosphatidylcholine and phosphatidylethan-
olamine, hence cells contain only small amounts of free AA (339,366). FA supplementation of cells 
in vitro or changes in dietary fat intake can lead to marked alterations in the FA composition of 
membrane phospholipids (183,184,516) without disrupting basic membrane or cellular integrity (200). 
The activities of membrane-bound enzymes are dependent on the lipid milieu surrounding the protein 
and enzymes, hence alteration in lipid composition may induce changes in the activities of membrane-
bound enzymes (184,198), membrane fluidity and cellular functions such as cell growth (517). 
Membranes isolated from tumour cells are reported to have profoundly alterated the EFA composition 
(123). Neuroblastoma cells in culture are able to rapidly incorporate exogenous FAs from the medium 
(518). The exogenous FAs are incorporated into membrane phospholipids by the action of 
acyltransferases (519). 
AA is a 20 carbon PUF A which is released from the phospholipids after stimulation of PLAz and is 
converted to PGs via the COX pathway (519). AA and its metabolites (PGs) act in various ways as 
intercellular and intracellular messengers (233,366). It is generally believed that changes in free AA 
levels would lead to alterations in eicosanoid synthesis (366). 
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This study examined the ability of the LLCMK and BL6 cells to take up AA from the culture 
medium, together with the effect of combined vitamin E succinate and Asc supplementation on this 
uptake. The effect of combined vitamin E succinate< and Asc supplementation on AA levels in the 
membrane and stroma fractions of these cells was also investigated. 
4.3.2 MATERIALS AND METHODS 
MATERIALS 
Refer to section 2.2. ASP 2330 gas-liquid chromatography (GLC) column manufactured by Supelco 
was supplied by Anatech Instruments, South Africa. Methylated arachidonic acid was purchased from 
Sigma Chemical Co., USA. BF3 methanol reagent (14%) was purchased from Merck, Darmstadt, 
Germany. Potassium Hydroxide (KOH) was purchased from Unilab, SAARCHEM, South Africa. 
METHODS 
4.3.2.1 Preparation of methanolic KOH (10%) 
A 40% KOH solution was prepared. Methanolic KOH (10%) was composed of25% of the 40% stock 
solution and 75% methanol (v/v). 
4.3.2.2 Cell culture procedures 
The relevant methods are referred to in 2.2.6.1 and 2.2.3.2. 
4.3.2.3 Homogenization of cells and separation of cellular components 
The method was repeated as described in 3.2.1.2, except that the pellet was resuspended in 2ml PBS 
solution. 
4.3.2.4 Determination of 15-3H arachidonic acid uptake 
The membrane and stroma fractions, respectively, of the two cell types, supplemented with 15-3H 
AA, were placed into scintillation vials containing 10ml scintillation cocktail. The amount of 3H AA 
4. Second Messenger Metabolism 105 
in each fraction was determined by scintillation counting. 
4.3.2.5 Saponification,' esterification and extraction of fatty acids 
The method used was that of Stoll (520). The various cell fractions were transferred into round 
bottomed flasks and 2ml of 10% methanolic KOH was added to each. The lipids .were saponified by 
heating with reflux under N2 for 45 minutes at 85°C. On completion of saponification, the free FAs 
were acidified by adding 1ml of7N HCI. The acidified FAs were extracted twice with 3ml of distilled 
petroleum ether and vortex mixed for 2 minutes each time. The distilled petroleum ether extracts were 
pooled and evaporated to dryness under N2 at 60°C. The residual FAs were methylated by heating 
with 0.3ml BF3-methanol reagent, with reflux and under N2 for 5 minutes at 100°C. The FA esters 
were again extracted twice using 1ml petroleum ether and shaken for 2 minutes each time. The pooled 
extracts were evaporated to dryness under N2 and stored in darkness at -20°C until required. 
4.3.2.6 Free fatty acid analysis by gas-liquid chromatography 
Separation of the extracted free F As, which were reconstituted in 20/-t1 distilled petroleum ether, was 
achieved by GLC, with a SP 2330 fused capillary column in the Hewlett-Packard 5890 Gas Liquid 
Chromatograph. The temperature programme involved an initial heating of the column at 130°C for 
15 minutes, followed by a rise in temperature of 4°C/minute to a final oven temperature of 220°C. 
The column temperature was held at 220°C for the final 7.5 minutes of the run. A 1/-t1 aliquot-of the 
reconstituted FAs was loaded onto the SP 2330 column. The concentration of AA (20:4), which forms 
part of the n-6 linoleic acid series, was measured. Results are expressed as percentage composition 
of AA relative to the total amount of FA in that sample. 
4.3.3 RESULTS 
3H AA levels in the BL6 control cultures (OE) were significantly (p::; 0.001) higher than the 3H AA 
levels of the LLCMK control cultures (OE) (Figure 20), as was the uptake of 3H AA by BL6 
compared with the corresponding LLCMK cells. Combined vitamin E succinate and Asc 
supplementation in LLCMK cells resulted in a significant (p::; 0.001) increasing trend in the uptake 
of total 3H AA by the cells. In the BL6 cells, combined vitamin E succinate and Asc supplementation 
(with the exception of5:25/-tg/ml) also resulted in a significant (p::;0.001) increase in total 3H AA 
uptake. 
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Figure 20: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on total 3H arachidonic acid uptake by LLCMK 
and BL6 cells. Each bar represents the mean of three cultures ± 
SEM. 
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Uptake of 3H AA in the membrane fractions of LLCMK cells was generally higher than that in stroma 
fractions except in the control cultures (OE). A similar higher 3H AA uptake by membrane fractions 
of BL6 cells than stroma fractions in all cultures was also found. 
Uptake of 3H AA in the membrane and stroma fractions of LLCMK cells was increased in the vitamin 
E succinate and Asc supplemented cells, and this increase was significant in most concentrations as 
can be seen from Table 19. In BL6 cells there was also an increase in 3H AA uptake in both fractions 
as a result of supplementation, but in these cells this was only significant at the 20:25JLg/ml level of 
supplementation in the stroma fraction. 
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TABLE 19: The effect of combined vitamin E succinate and Asc supplementation on the uptake of 
15-3H arachidonic acid by membrane and stroma fractions of LLCMK and BL6 cells respectively. 
Results are the mean of three cultures ± SEM.~ 
-~ . 
[vitamin E succinate:ascorbate] 15_3 H AA 15-3H AA in membrane 
Itg/ml ItCi cpm/l04 cells 
LLCMK BL6 
OE 5 34.97 96.19 
-
±3.72 ±11.92 
5:25 5 54.45' 113.14 
±4.26 ±6.62 
10:50 5 71.71 b 116.42 
2.09 ± 17.50 
10:25 5 71.04b 147.91 
±2.04 ±lL99 
~ ~ 
~ 
20:25 5 125.08b 183.08 
±6.93 ~ ± 14.57 
a - p:S;;O.OI relative to control cultures (OE) in LLCMK membrane fractions 
b - p:S;; 0.001 relative to control cultures (OE) in LLCMK membrane fractions 
c - p :s;;0.05 relative to control cultures (OE) in LLCMK stroma fractions 
d - p:S;; 0.00 1 relative to control cultures (OE) in LLCMK stroma fractions 
e - p:S;; 0.01 relative to control cultures (OE) in BL6 stroma fractions 
15-3H AA in stroma 
cpm/l04 cells 
LLCMK BL6 
-
36.02 72.73 
±2.86 ± 12.29 
41.29 63.13 
±1.02 ±4.55 
54.82 92.40 
±5.95 ±6.65 
70.93c 103.58 
±11.74 ±7.29 
103.63d 122.63e 
±7.37 ± 13.51 
In terms of percentage AA composition the addition of 2.5jlM of AA to the medium had no _effect 
on the amount of AA found in the membrane or stroma fractions of both cell types (Table 19). There 
was also no significant difference in percentage AA found in the membrane versus stroma fractions 
in the control and supplemented LLCMK cells, while in BL6 there was a significantly (p:::;; 0.001) 
higher AA composition in the membrane fraction relative to the stroma fractions. 
Vitamin E succinate and Asc supplementation to LLCMK cells also had no effect on AA composition 
in the menbrane fractions although there was a noticeable increase in the 20:25jlg/ml group. In the 
stroma fractions of the cells, percentage AA composition decreased relative to controls, although not 
significantly so. In BL6 cells the supplementation of combined vitamin E succinate and Asc resulted 
in a significantly (see Table 20) higher percentage AA in all groups, relative to controls, with the 
relative increase being more pronounced in the stroma fractions. 
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TABLE 20: The effect of combined vitamin E succinate and ascorbic acid and arachidonic acid 
supplementation on the percentage arachidonic acid composition in the respective membrane and 
stroma fractions of the LLCMK and BL6 cells. Results· are the mean of three cultures ± SEM. 
[AA] % AA in membrane 
[vitamin E succinate:ascorbate] ,M 
Itg/ml LLCMK" 
OE 0 4.25 
±.3 
-
OE' 2.5 4.1 
± 1.31 
5:25 2.5 3.84 
±1.52 
10:50 2.5 4.25 
± 1.01 
10:25 2.5 4.75 
±.93 
20:25 2.5 6.75 
±0.04 
a - p:::;O.OOI relative to corresponding BL6 stroma fractions 
b - p:::;O.OOI relative to membrane BL6 control cultures (OE') 
c - p:::;O.OOl relative to stroma BL6 control cultures (OE') 
4.3.4 DISCUSSION 
BL6 
3. lOa 
±0.20 
2.17a 
±0.03 
4.07ab 
±0.32 
4.52ab 
±0.03 
-. 
9.12ab 
±0.42 
4. 64ab 
±0.36 
% AA in stroma 
LLCMK BL6 
4.9&- - ~ 0.10 
±2.1O ±0.02 
5.20 0.08 
± 1.71 ±0.01 
4.68 3.82c 
±0.91 ±0.15 
2.94 3.98c 
±1.04 ±0.08 
2.80 4.89c 
±0.05 ±1.1O 
3.93 4.05" 
±.09 ± 1.51 
,-" 
Studies by Denziot et al (519) demonstrated that a human gastric cancer cell line supplemented with 
AA could accumulate exogenous AA in its cellular membrane lipids. This AA is preferentially 
incorporated into phosphatidylcholine, followed by a transfer of AA to phosphatidylethanolamine 
(519). The uptake oeH AA by the LLCMK and BL6 cells in this study indicates the ability of these 
cells to accumulate exogenous AA, however, the mechanism of permeation into the cells remains 
unclear. Vitamin E is believed to have no effect on the uptake and distribution of AA in the major 
cellular lipid fractions of medial cells in culture (501), although vitamin E is known to have profound 
effects on AA metabolism. These effects are exerted on biosynthetic pathways involving AA. Hence 
alternative mechanisms must be involved in the uptake and distribution of AA (503). The AA entry 
step appears to be insensitive to the intracellular metabolism of the substance and hence not driven 
by transmembrane concentration gradients (521,522). It is believed that EFA and AA uptake, at least 
in part, could be carrier-mediated by a membrane fatty acid-binding protein (523,524). In addition, 
because EFAs, at physiological pH, enter cells as anions, their influx should occur coupled to 
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movement of a positive charge (521,52). The potential difference may directly affect the permeability 
of the plasma membrane toward AA in several ways: it r:nay influence AA-lipid partitioning or it may 
supply the energy required (522). However, a ~consi@;tent characteristic of AA transport is that of a 
unidirectional influx exhibiting features of a saturable process (521). 
The BL6 cells supplemented with only 3H AA in this study incorporated a significaptly.greater amount 
of AA than the corresponding LLCMK cells. Due to altered PUFA content in tumour cells (121), it 
-
seems possible that these BL6 cells would incorporate more AA as a result of changes in membrane 
composition. This observation is further substantiated when, on examing percentage AA composition 
in BL6 cells, it was found to be greater than in the corresponding LLCMK cells. 
In both LLCMK and BL6 cells there was agenerally higher uptake of 3HAA found in the membrane 
than str.oma fractions of control and supplemented cells. In both cell types an increase in 3H AA 
uptake in both membrane and stroma fractions, and in total 3H AA, was found as a result of vitamin 
E succinate and Asc supplementation. As regards to AA composition in the cells, combined vitamin 
supplementation resulted in increased levels of AA in both membrane and stroma fractions oJ BL6 
cells. In LLCMK cells, however, an increase (although non-significant) in percentage AA as' a result 
of vitamin supplementation was found only at the 20:25jlg/ml concentration in the membrane fraction, 
while in the stroma fractions (of the supplemented cells) a decrease in percentage AA was in fact 
found. 
The increase in AA levels in BL6 cells as a result of vitamin E succinate and Asc supplementation 
could, partly at least, be accounted for by the increased uptake of the EFA. The fact that the 
increased levels of AA as a result of vitamin supplementation was more noticeable in the stroma 
fraction could be explained by increased AA uptake as well as increased AA release from 
phospholipid by PLA2 , since the magnitude of increase in percentage AA composition in the stroma 
fraction of these cells far exceeded the relative increase in AA uptake found as a result of this 
supplementation. In Section 4.2 supplementation of BL6 cells with combined vitamin E succinate and 
Asc was in fact shown to result in elevated PLA2 activity. 
The mechanism by which vitamin E succinate and Asc influences the activity of PLA2 and subsequent 
release of AA is unclear, however, PLA2 activity may not only be regulated by vitamin E' ,s role in 
membrane stabilization and Asc regenerative capacity of vitamin E but may also be influenced by 
intracellular Ca2+ as elevated levels of Ca2+ are required for PLA2 activation and subsequent release 
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of AA (339,340,347). 
The dependence of 5-LOX activity on Ca2 + and AAJt;vels within a cell, as well as the dependence 
of COX activity on AA levels, led to the further investigation of both 5-LOX and COX activities in 
BL6 and LLCMK cells. 
4.4 COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID SUPPLEMENTATION 
AND 5-LIPOXYGENASE ACTIVITY 
4.4.1 INTRODUCTION 
AA is the key precursor of a large family of potent physiological effectors. It is the branch point 
leading to two important pathways: one involves the enzyme <;OX and leads to the synthesis of PGs 
and TXs, whereas the other involves the lip oxygenase (LOX) enzymes and leads to the synthesis of 
LTs and lipoxins-compounds that regulate cellular responses in inflammation and immunity (525). 
Lipoxygenases are dioxygenases which recognise the 1,4-pentadiene structure of PUFAs and 
incorporate single molecules of oxygen at specific carbon atoms of substrate FAs, resulting in 
hydroperoxy acids containing dienes as reaction products (525). To date three animallipoxygenases 
have been identified, viz 5-, 12-, and 15-lipoxygenases, named after the positions where oxygen is 
inserted into the AA moiety. 5-Lipoxygenase metabolises AA to 5-hydroperoxyeicosatetraenoic acid 
(5- HPETE), which is subsequently transformed to leukotriene A4 (LTA4) (526,237). Lipoxyg~l!ases 
are nonheme, non sulphur-iron dioxygenases which act on fatty acids containing one or more 1,4,2,2-
pentadiene moieties to form 2, E-conjugated hydroperoxides. These enzymes play several 
physiological roles (526), in particular the product hydroperoxides are precursors of specific 
regulatory molecules such as LTs and lipoxins in animals (527). LTs comprise a group of biologically 
highly potent lipid mediators synthesized by Ca2+ -dependent 5-LOX from 20-carbon PUFAs, 
predominantly AA (526,528). 
Since investigations on the metabolism of AA by LOX have revealed that intermediate peroxy 
compounds and hydroxyl radicals are produced in the reactions (237,242,268,529) adding to the 
overall peroxidation state within the cell, the effect of combined vitamin E succinate and Asc 
supplementation on 5-LOX activity in LLCMK and BL6 cells was determined. 
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4.4.2 MATERIALS AND METHODS 
MATERIALS -< 
Adenosine-5'-triphosphate (ATP) and (±) 5-Hydroperoxyeicosatetraenoic acid [(±)-5-HPETE] were 
obtained from Sigma Chemical Co., USA. Calcium Chloride (CaCI2) was purc~ase9 from Merck, 
Darmstadt, Germany, while ethyldiaminetetraacetic acid (EDTA) was purchased from Holpro 
Chemical Co., South Africa. Sucrose was obtained from Riedel-deHaen, Germany. 
METHODS 
4.4.2.1 Cell culture procedures 
The same procedures were used as in 2.2.3.1 and 2.2.3.2, except that the pellets were resuspended 
in 1ml of IOmM Tris HCI buffer, pH 8.0 containing 1mM EDTA and 0.25M sucrose. 
4.4.2.2 Homogenization of cells and enzyme preparation 
The enzyme was prepared using a modified method of Soberman (530). Cell suspensions were poured 
into a Dounce homogenizer and homogenized 30 times with the tight plunger. The homogenizer was 
rinsed with 1ml of IOmM Tris HCI buffer, pH 8.0 containing 1mM EDTA and 0.25M su_c~ose. 
Resulting cell homogenates were transferred to precooled centrifugation tubes and centrifuged 
(Beckman Model 12 21) at 10 OOOg for 10 minutes at 4°C. The resulting supernate was stored at -70°C 
until required. 
4.4.2.3 5-Lipoxygenase assay 
A modified method of Soberman (530) and Furukawa et al (531) was used. The principle of this assay 
is based on the addition of 3H AA to the enzyme preparation, followed by separation of the product 
5 HPETE from substrate 3H AA by TLC and quantitation and determination of the radioactive product 
formed by scraping off relevant areas of TLC plates. A reaction mixture was prepared containing 
10mM Tris HCI pH 8.0, 4mM ATP, 2mM CaCI2, 20JLM 15-3H AA and 75JLI enzyme preparation in 
a final volume of 200JLl. This was allowed to react for 10 minutes at 24°C. Following incubation the 
reaction was terminated by the addition of a 500JLI aliquot of ethyl ether:methanol:2N citric acid 
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(30:4: 1, v/v/v). Terminated samples were centrifuged at 3000g for 5 minutes at 4°C. An aliquot 
(lOOILl) of the upper organic phase was removed using. a graduated capillary tube and spotted onto 
~ . 
precoated silica ge160F2~ TLC plates, and dried under. a stream of N2. AA and 5-HPETEstandards 
were used as markers. The plates were developed in ethyl ether:petroleum ether:acetic acid (50:50: 1 
v/v/v) at 4°C. The silica gel regions corresponding to AA and 5-HPETE of samples were scraped off 
and transferred to scintillation vials containing lOmls of emulsifier scintillator plus~TM scintillation 
cocktail and counted in a Beckman Scintillation counter (LS 2 800). Final results were expressed as 
pmoles 5-HPETEIl04 cells. 
4.4.3 RESULTS 
LLCMK cells (Table 21) supplemented with combined vitamin E succinate and Asc resulted in no 
increasing or decreasing trend in 5-LOX activity, however, a.significant decrease in 5-LOX activity 
was observed at 20: 25ILg/ml(p :::;; 0.001) vitamin E succinate and Asc respectively. 
TABLE 21: The effect of combined vitamin E succinate and ascorbic acid on 5-lipoxygenase activity 
in both LLCMK and BL6 cells. Results are the mean of three cultures ± SEM. 
5-Lipoxygenase activity 
[vitamin E succinate:ascorbate] pmoles 5-HPETE formedJI06 cells 
J.tg/ml 
LLCMK CELLS 
OE 0.691 
±0.017 
5:25 0.571 
±0.003 
10:50 0.613 
±.004 
10:25 0.697 
±0.041 
20:25 0.241" 
±0.021 
a - p::;; 0.001 relative to respective control cultures (OE) 
b - p::;; 0.01 relative to respective control cultures (OE). 
c - p::;;O.OOI relative to LLCMK control cultures (OE) 
BL6 CELLS 
O.013c 
±0.001 
0.037b 
±0.008 
0.055" 
0.003 
0.055" 
±0.003 
0.173" 
±0.007 
-
-
Supplementation of BL6 cells with varying levels of vitamin E succinate (5-20ILg/ml) and Asc (25-
50lLg/ml) resulted in an increasing trend in 5-LOX activity with increasing concentrations of vitamin 
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E succinate (Table 21). The increase in 5-LOX activity was significant at each combined vitamin 
concentration, 5:25 (p ~0.01); 10:50; 10:25 and 20:25JLg/ml (p ~0.001) respectively, when compared 
with control cultures (OE). Comparing basal 5-LOK . levels in control cultures (OE), (Table 21), 
revealed that 5-LOX activity in BL6 cells was significantly (p ~ 0.001) lower than in LLCMK cells. 
4.4.4 DISCUSSION 
5-LOX (EC 1:13:11:14) catalyzes the first two steps in the formation of LTs (532-535). LTs act at 
nanomolar concentrations in intercellular communication, signal transduction, and on host defence 
(528). 5-LOX, like COX, requires Ca2+ (532,535) and hydroperoxides (534,536) for the activation 
of the enzyme. Furthermore, LOX undergoes self-catalyzed inactivation during oxidation offatty acid 
substrates, however, the chemical nature Of this self-destruction phenomenon is not yet clear (536). 
Vitamin E is known to modulate the 5-LOX enzyme in the biosynthetic pathway of AA metabolism, 
however the mechanism is unknown (503,529). Numerous studies investigating the effects of vitamin 
E supplementation on LOX activity are contradictory. Vitamin E added at high concentrations has 
been shown to inhibit platelet LOX (503,528,537), whereas other studies have found no effect. The 
LOX activity of human neutrophils has been reported to be enhanced by physiological concentrations 
of plasma vitamin E, whereas higher concentrations are suppressive (538). 
Results obtained in this study with supplementation of combined vitamin E succinate and Asc to 
LLCMK cells showed no increasing or decreasing trend in 5-LOX, however at 20:25JLg/ml combined 
vitamin E succinate and Asc respectively, a significant decrease in 5-LOX was observed relative to 
control cultures (OE). In BL6 cells however, a significant increase in 5-LOX activity relative to 
control cultures (OE) was observed following supplementation of combined vitamin E succinate and 
Asc. The observed increase in 5-LOX activity was more prominent with the increase in vitamin E 
succinate supplementation in a dose dependent manner. 
The mechanism by which vitamin E succinate and Asc influences the activity of 5-LOX in BL6 cells 
may be similar to that of the PLA2 enzyme. 5-LOX activity may not only be regulated by vitamin E's 
role in membrane stabilization and Asc regenerative capacity of vitamin E, but is also known to be 
influenced by intracellular Ca2 + levels (533,535). 
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Since investigations on the metabolism of AA by LOX have revealed that intermediate peroxy 
compounds and hydroxyl radicals are produced in the reactions (237,242,529) adding to the overall 
peroxidation state, and the fact that these compounds/radicals stimulate COX activity (259); the effect 
of combined vitamin E succinate and Asc supplementation on COX activity in LLCMK and BL6 cells 
was determined. 
4.5 COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID SUPPLEMENTATION 
AND CYCLOOXYGENASE ACTIVITY 
4.5.1 INTRODUCTION 
Prostanoids are synthesized from free fatty acid by a series of enzymatic reactions beginning with the 
formation of endoperoxides, in which the cyclooxygenase enzyme is important in the initial step of 
PG synthesis (507). COX is a membrane-bound multi-enzyme complex (222,232,233) contained in 
endoplasmic reticulum and nuclear membranes (232,244). The enzyme COX catalyzes oxygen 
insertion and rapid cyclization of AA into the hydroperoxy derivative prostaglandin PGG2 .• This 
transient hydroperoxy endoperoxide is transformed by the peroxidase component of COX into the 
endoperoxide PGH2 (235-238,503). The metabolism of AA by COX enzymes is found both in 
neoplastic and normal tissues (539). Vitamin E and other lipid antioxidants have been suggested to 
modulate the biosynthetic pathways in AA metabolism at a number of different points, including the 
COX enzyme (503,539). COX activity can be enhanced or inhibited by lipid antioxidants, dep~nding 
on their type and concentration (540). Furthermore, the PG-hydroperoxidase reaction associated with 
COX activity is believed to generate a variety of peroxy compounds and hydroxyl radicals when 
catalyzing the conversion of PGG2 to PGH2 (234,235,240,242,268) adding to the overall lipid 
peroxidation tone. It is reported by Panganamala et al (541) that vitamin E is not a good inhibitor in 
vitro of COX but has profound effects in vivo on PG metabolism. 
The present study was undertaken to determine the effect of combined vitamin E succinate and Asc 
supplementation on COX activity in LLCMK and BL6 cells. 
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4.5.2 MATERIALS AND METHODS 
MATERIALS 
Manganese protoporphyrin IX, Arachidonic acid (AA) and Prostaglandin B2 (PGB2) were purchased 
from Sigma Chemical Co., USA, while citric acid was obtained from H.W.O. Cl)emical Co., USA. 
Precoated silica gel 60F254 thin layer chromatography (TLC) plates were obtained from Merck, 
Darmstadt, Germany. Petroleum ether, ethyl ether and anhydrous sodium sulphate (N~S02) were 
purchased from Unilab, SAARCHEM, South Africa. 15-3H Arachidonic acid was purchased from 
Amersham, Int., England, while tris (Hydroxymethyl)-aminomethan was obtained from Boehringer 
Mannheim, Germany. 
METHODS 
4.5.2.1 Cell culture procedures 
The same procedures were used as those in 2.2.3.1 and 2.2.3.2, except that the resulting cdl pellets 
were resuspended in 1ml 0.2M Tris HCI buffer, pH 8.0. 
4.5.2.2 Homogenization of cells and separation of cellular components 
The same procedure was carried out as used iIi 3.2.1.2, except that the Dounce homogenizer was 
rinsed with 1ml of a 0.2M Tris HC! buffer, pH 8.0 and the final resulting pellet was resuspended in 
2m! 0.2M Tris HCI buffer. 
4.5.2.3 Determination of cyclooxygenase activity 
The method used for the determination of COX activity was a modified method of Yamamoto (542). 
The principle of this assay is based on the addition of radioactive substrate 3H AA to the enzyme 
preparation and the reaction product (PGG2) separated by TLC based upon their affinity for a non-
polar solvent. A reaction mixture containing 70pJ of 0.2M Tris HCI pH 8.0, lOpJ of 40/LM 
manganese protoporphyrin IX, 5nmol AA and 5/L13H AA (0.46pmol) was prepared for each sample. 
The reaction mixture was vortex mixed prior to the addition of lO/L! COX enzyme preparation to 
disperse the AA. The reaction mixture and enzyme preparation were mixed with shaking at 24°C for 
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2 minutes. The reaction was terminated by the addition of a 300jLI aliquot of a mixture containing 
ethyl ether:methanol:0.2M citric acid (30:4: l,v/v), precooled to -20°C. The tubes containing the 
terminated reaction mixture were immediately tran.sferred to an ice bath where 0.5g anhydrous 
sodium sulphate was added, and samples gently mixed. A 150jLI aliquot of the upper organic phase 
was removed using a graduated capillary tube and spotted on precoated silica gel 60F254 aluminium 
TLC plates. AA and PGB2 were spotted as markers (PGG2 is located between t~ese~markers (542) 
and is not commercially available). The plates were developed in TLC tanks containing ethyl 
ether:petroleum ether:acetic acid, (85:15:0.1, v/v/v) at 4°C. The plates were then air dried and AA 
and PGB2 markers visualised using iodine vapours, with the product PGG2 of COX activity located 
between these two markers. The silica gel regions corresponding to AA and PGG2 were scraped off 
into scintillation vials containing Wmls of emulsifier scintillator plus TM scintillation cocktail and 
counted in a Beckman scintillation counter (LS 2 800). The remaining silica gel for each sample run 
was also scraped off the plate and radioactivity determined as_above. Total counts per minute (cpm) 
was obtained by adding cpm AA + cpm PGG2 + cpm remainder of plate. Radioactivity in the AA 
and PGG2 portions were determined as a percentage of the total cpm. Percentage values were used 
to calculate the number of pmoles of radioactive PGG2 formed from radioactive AA by the COX 
activity. Final results were expressed as pmoles PGG2/W4 cells. 
4.5.3 RESULTS 
LLCMK and BL6 cells supplemented with combined vitamin E succinate and Asc resulted in 
increased COX activity in both cell lines (see Table 22). 
LLCMK cells supplemented with combined vitamin E succinate and Asc resulted in increased COX 
activity, with significant (p sO. 0 1) increases occurring at 10:50; 10:25 and 20:25jLg/ml respectively, 
compared with control cultures (OE). A similar trend was observed for that of the BL6 cells, in which 
significant (p s 0.001) increases in COX activity were observed at each combined vitamin 
concentration set relative to control cultures (OE). 
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TABLE 22: The effect of combined vitamin E succinate . and ascorbic acid supplementation on 
cyclooxygenase activity in the LLCMK and BL6 cells. Results are the mean of three cultures ± SEM. 
< 
[vitamin E succinate:ascorbate] Cyclooxygenase activity formed 
J(g/ml pmoles PGG2 1106 cells 
LLCMK CELLS BL6 CELLS 
OE 
-
5:25 
10:50 
10:25 
20:25 
a - p S; 0.01 relative to LLCMK control cultures (OE) 
b - pS;O.OOl relative to BL6 control cultures (OE) 
4.5.4 DISCUSSION 
0.018 
±0.001 
0.016 
±0.003 
0.032" 
0.006 
0.027" 
±0.002 
0.032" 
±0.004 
0.019 
±0.001 
0.117b 
±0.004 
0.143b 
0.003 
0.145b 
±0.008 
0.343b 
±0.009 
Recent investigations on the metabolism of AA by COX have revealed that intermediate peroxy 
compounds and hydroxyl radicals are produced in the PGH2- forming reactions (237,242,268,529). 
This suggests the higher the activity of COX, the higher the levels of lipid peroxidation within a 
system. Studies of the COX catalytic mechanism showed that a variety of lipid peroxides can trigger 
the acceleration of COX (242,259,529,543), including PGG2 - the reaction product of the COX 
enzyme (237). 
In addition to serving as an antioxidant in the protection of PUF As in cellular membranes, vitamin 
E is active in a number of aspects of eicosanoid metabolism (196). It has been suggested that vitamin 
E may be involved in the modulation of the activity of key regulatory enzymes in the eicosanoid 
pathway (196,503), such as the COX enzyme. The role of vitamin E in COX reactions has however 
been disputed for some time. 
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Data from these studies have shown that supplementation of combined vitamin E succinate and Asc 
to LLCMK and BL6 cells resulted in a significant increa~e in COX activity. Possible explanations for 
this increased COX activity in both cell lines may be· due to the effect of vitamin E in membrane 
stabilization (500), by virtue of specific physicochemical interactions between its phytyl side chain 
and the fatty acyl chains (125), and the subsequent altering of membrane enzymatic activities 
(501,502) such as COX. Furthermore the plane of orientation of the vitamin E molecule in the 
membrane enables the chromanol ring to participate in polar interactions at the membrane surface, 
resulting in Asc gaining access to the vitamin E radical formed at the membrane water interface 
regenerating vitamin E in turn prolonging its action (82,127,129,174). It is proposed that due to this 
synergistic action, increased COX activity was observed and with increasing concentration of vitamin 
E, increased COX activity is observed. 
Furthermore, the PG-hydroperoxidase reaction (the second step of PG biosynthesis), associated with 
COX activity, is believed to produce a variety of peroxy compounds and hydroxyl radicals when 
catalizing the conversion of PGG2 to PGH2 (237,268,529,543). Hence any compound capable of 
increasing the activity of the COX enzyme would increase PG-hydroperoxide activity and ind.~rectly 
increase the levels of free radicals within a system. Thus, we propose that supplementation of 
LLCMK and BL6 cells with increasing concentration of vitamin E resulted in the increased COX 
activity, in turn activating PG-hydroperoxidase activity. This protection of PG- hydroperoxidase by 
vitamin E is further enhanced by the regenerating capacity of vitamin C. The increased levels of 
oxygen-containing radicals may attack membrane PUF As and increase lipid peroxidation levels_ Thus 
our findings support the "scheme" proposed by Panganamala (503) of vitamin E acting as a highly 
lipid-soluble agent protecting COX from autooxidation without diminishing the concentrations of 
oxygen-centred radicals in the aqueous phase. Hence, in the BL6 cell system combined vitamin E and 
Asc supplementation enhances COX activity, in turn increasing the transient PGH2 levels from AA 
and increasing free radical and lipid peroxidation levels as found in Chapter 3 . 
In LLCMK and BL6 cells, compared with the basal COX levels in the control cultures (OE),a slightly 
lower activity was observed in the melanoma, BL6 cells. This supports the finding that in tumour 
cells, COX is decreased in activity compared with that of normal cells, but at present the reason for 
this reduction is not known (529). 
Since prostaglandin synthesis is regulated by the activation ofPLA2 and the subsequent release of AA, 
and since the net production is dependent on the COX activity, the effect of combined vitamin E 
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succinate and Asc supplementation on PG production was determined. 
4.6 PROSTAGLANDIN E2 LEVELS AND COMBINED VITAMIN E SUCCINATE AND 
ASCORBIC ACID SUPPLEMENTATION 
4.6.1 INTRODUCTION 
119 
PGs are cell-to-cell messengers produced by eukaryotic cells in response to extracellular stimuli (283). 
PGs are not stored within the cell, thus any stimulation of their release requires the prior mobilization 
of substrate precursors (222,225-227,283), followed by oxidation by the PES complex (224,237). 
PGs, especially the E series, have been shown to be elevated in a large number of tumours 
(9,22Q,228,300-304). Increased PGE2 leveis were found in tumours induced by the Maloney Sarcoma 
virus in mouse leg tissue, compared with normal leg tissue (226,305,320). Untransformed baby 
hamster kidney (BHK) and Balbc 3T3 fibroblasts in culture secrete small quantities of PGs into the 
medium, whereas transformation of these cells by polyoma virus results in a significant incre"ase in 
PGE2 levels released into the medium (554). Uncertainty remains as to whether the increase in the 
synthesis and release of PGs is the cause or the effect of increased proliferation rates, or whether it 
merely accompanies this phenomenon (300). Increased production and secretion of PGs by tumours 
has led to the proposal that tumour tissue could contain elevated amounts of PG synthetic enzymes 
and increased substrate availability due to altered enzyme activities within the PG biosynthetic 
pathway (306). Furthermore, PGs are suggested to interact with growth factors possibly contributing 
to the ability of the tumour cells to establish themselves at a metastatic site (300,303,306). 
EIAttar and Lin (148) were the first to examine the in vitro effects of vitamin C and E on PGE2 
levels. They found that a combination of vitamins E and C at 100p,M levels resulted in significant 
reduction of PGE2 levels in both the fibroblast and SCC-25 cell line. Since the rate of synthesis and 
the net production of PGs is controlled by PLA2 and COX (229,238), the present study was 
undertaken to investigate the effect of combined vitamin E succinate and Asc supplementation on 
PGE2 levels in the two cell types used. 
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4.6.2 MATERIALS AND METHODS 
MATERIALS 
Methyl formate was purchased from Fluka, Switzerland. SEP-PAK C18 cartridges were obtained from 
Waters Associated, Inc., Massachusettes, USA. The PGE2 [ 1251] assay kit with Amt:;.rlex-M™ magnetic 
separation was purchased from Amersham International, Amersham, UK. 
METHODS 
4.6.2.1 Cell culture procedures 
The methods recorded in 2.2.3.1 and 2.2.3.2 were repeated. _ 
4.6.2.2 Homogenization of cells and separation of cellular components 
The method described in 3.2.1.2 was repeated, except that 2ml milli Q water was used to'finse the 
homogenizer. Thus, the pellet (membrane fraction) was resuspended in 2ml PBS solution and 2ml 
milli Q water. 
4.6.2.3 Extraction and isolation of prostaglandins 
The PGs were extracted according to a modified method of Powell (545,546,cited in 547). The 4ml 
cellular fractions were added to 15ml cold ethanol (95%) and shaken for 10 minutes. The samples 
were diluted to 100m I with precooled water and vortex mixed for 1 minute. The pH of the suspension 
was adjusted to 3.0 using IN HCI. The samples were then passed through SEP-PAK C18 cartridges 
which had previously been wetted with 20ml of 80% aqueous ethanol followed by 20ml of water to 
remove excess ethanol. The cartridges were washed with lOml water and lOml petroleum ether, 
before eluting the PGs with 5ml of methyl formate. The eluent was dried under a stream of N2 at 
25°C. The SEP-PAK C18 cartridges were regenerated for re-use by washing with 20ml of 80% 
aqueous ethanol solution followed by 20ml of water. 
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4.6.2.4 Prostaglandin E2 [1251] assay 
This assay is based upon the competition betweell< unlabelled prostaglandin E2 (methyl oximate 
derivative) and a fixed quantity of 125I-labelled prostaglandin E2 (methyl oximate derivative) for a 
limited number of binding sites on a prostaglandin E2 specific antibody which is specific for the 
methyl oximate derivative (548). Prior to analyzing the extracted PG fractions using the assay system, 
the PGs were converted to their methyl oximate derivatives as follows: the dried PG fractions were 
reconstituted with 1OO/Ll of assay buffer, pH 7.0. A 1OO/Ll aliquot of methyl oximation reagent 
(supplied with the PGE2 assay kit) was added to the reconstituted sample and vortex mixed. The 
resulting solutions were incubated at 60°C for 1 hour to allow methyl oximation of the sample to 
occur. Samples were then diluted to a final volume of 500/Ll with PBS (PH 7.0) and assayed using 
the radioimmunoassay procedure as described in the assay protocol. A 1OO/Ll aliquot of sample was 
pipetted into appropriately labelled tubes. Tracer (100/Ll aliquots) was added to each tube followed 
by 1OO/Ll of antiserum. All the tubes were vortex mixed and incubated for 2 hours at 25°C in a water 
bath. After incubation, 250/Ll Amerlex-M second antibody reagent was added to each tube. The tubes 
were incubated for a further 15 minutes at room temperature before separating the antibody-::~ound 
fraction by centrifuging at 1500g for 10 minutes at 4°C. After centrifugation, the superhantant was 
poured off and discarded and the radioactivity present in each tube was determined by counting for 
1 minute in a Packard auto-gamma scintillation counter. The pgPGE2/ tube was read directly from 
the PGE2 standard curve as represented in Appendix 6. 
4.6.3 RESULTS 
The PGE2 concentration in the LLCMK control cultures (OE) and corresponding vitamin-
supplemented cultures was significantly (p::;;O.OOl) higher than the PGE2 concentration found in the 
BL6 control cultures and corresponding vitamin supplemented cultures (Table 23). 
In LLCMK cells, PGE2 concentrations increased slightly with combined vitamin supplementation, with 
a significant (P::;; 0.001) increase observed at 1O:50/Lg/ml relative to control cultures (OE). A similar 
trend was observed in the BL6 supplemented cells (Table 23) except that significant increases in PGE2 
concentrations relative to BL6 control cultures were observed at 1O:50/Lg/ml (p::;; 0.01) and 
20:25/Lg/ml (p::;; 0.001) combined vitamin E succinate and Asc supplementation. 
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TABLE 23: The effect of combined vitamin E succinate and ascorbic acid supplementation on 
prostaglandin E2 concentration in LLCMK and BL6 cells, respectively. Results are the mean of three 
cultures ± SEM. 
< • 
[vitamin E succinate:ascorbate] [pGEJ pg/104 cells 
J.(g/mI 
LLCMK CELLS BL6 CELLS 
OE 13.5S" r 1.65 
±1.78 ±0.07 
- 5:25 13.59" 2.33 
± 1.23 ±0.11 
10:50 38.44'b 4.74c 
±0.74 0.15 
10:25 15.89' 2.49 
±0.06 ±0.08 
'-
- 20:25 15.79' 12.26d 
±0.74 ±0.89 
a - p ~ 0.001 relative to BL6 control cultures (OE) and corresponding supplemented vitamin cultures 
b - p~O.OOl relative to LLCMK control cultures (OE) 
c - p~O.Ol relative to BL6 control cultures (OE) 
d - p~O.OOl relative to BL6 control cultures (OE) 
4.6.4 DISCUSSION 
Vitamin E is believed to play an important role in a number of aspects of eicosanoid metabolism 
(95,196,503). Depending on the system, vitamin E did, or did not, have an effect (503). In one study 
(503), it was found that microsomes isolated from vitamin E supplemented animals synthesized far 
greater amounts of PGs than microsomes isolated from vitamin E-deficient animals. On the other 
hand, studies by EIAttar and Lin (148) have shown that a combination of vitamin E and C resulted 
in significant reduction of PGE2 concentration in both the fibroblast and SCC-25 cell lines. In this 
study BL6 cells supplemented with 5:25J.tg/ml and 1O:25J.tg/ml combined vitamin E succinate and Asc 
resulted in a non significant increase in PGE2, while at 10:50 and 20:25J.tg/ml a significant increase 
in PGE2 levels occurred relative to control cultures (OE). This study therefore does not support the 
findings of EIAttar and Lin. However, EIAttar and Lin (148) propose that the effects they observed 
of combined vitamin E succinate and Asc on endogenous PGE2 were a reflection of the activities of 
both the PLA2 and COX enzymes. The synthesis of PGE2 is usually limited by the availability of free 
AA, which is liberated from membrane phospholipids by PLA2 (549). This suggests that the observed 
increase in PGEz levels in BL6 cells in this study, following combined vitamin E succinate and Asc 
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could be as a result of the increased PLA2 and COX activity as found in Section 4.2 and 4.5. 
Furthermore, another finding (Section 4.3) was th~t of marked increases in percentage AA 
composition in the membrane and stroma fraction -of the substrate AA in combined vitamin 
supplemented BL6 cells. 
In LLCMK cells, supplementation with varying levels of combined vitamin E succin<lte (5-20JLg/ml) 
and Asc (25-50g/ml) resulted in an increase in PGE2 levels compared with control cultures (OE), 
-
although this was only significant at the 1O:50JLg/mllevel. Studies on the effects of combined vitamin 
E succinate and Asc supplementation on COX activity in LLCMK cells (Section 4.5) have shown that 
supplementation increases COX activity but inhibits PLA2 activity. Furthermore, combined vitamin 
supplementation of LLCMK cells resulted in an increase in percentage AA composition in the 
membrane fraction only, suggesting the free AA levels in LLCMK cells may be low. This in turn 
suggests that the observed increase in PGE2 levels in LLCMK cells was a result of increased COX 
activity and not PLA2 • 
In this study, PGE2 concentrations in the LLCMK control cultures (OE) were significantly highe.r than 
the PGE2 levels in the BL6 control cultures. It has been suggested that the metastatic potentfai ofBL6 
cells is inversely related to the ability of these cells to synthesize PGE2 (226,300,308,316,318), and 
that the highly metastatic BL6FlO as used in this study synthesizes smaller amounts than the less 
metastatic BL6F1 cells (308). Furthermore, PGE2 levels have been suggested to be dependent on 
tissue specificity (300). The general conversion of AA to PGs varies with cell type and effector 
molecule, although each cell type appears programmed to produce certain types of PGs (283), hence 
it was of vital importance to determine the quantity and type of other PGs present in the cells used 
in this study. 
Since Fulton (300) states that in the B16 melanoma system, besides PGE2 , the most common 
arachidonate metabolites are PGD2 , PGF2a and PGI2 , the levels of these PGs in BL6 cells were 
determined as was the effect of combined vitamin E succinate and Asc supplementation on the levels 
of these particular PGs. No quantitation of the above-mentioned PGs was carried out in LLCMK 
cells, since combined vitamin E succinate and Asc supplementation was shown to have little effect 
on cell growth of this cell line and in view of the cost factor obtaining the assay kits, these assays 
were omitted. 
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4.7 COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID AND PGD2, PGF2a AND 
PGI2 LEVELS 
4.7.1 INTRODUCTION 
AA can interact with prostaglandin endoperoxidase synthase (PES), a membrane-b.ouna mUlti-enzyme 
complex (222,232). The ubiquitous PES catalyzes the first step in the formation ofPGs and TXs from 
AA. This enzyme has two activities, a COX which converts AA to PGG2 and a peroxidase which 
reduces PGG2 to form PGH2 (234-237,249). PGH2 is the precursor of all PGs (270) as PGH2 is at 
a pivotal stage in the divergent pathways leading to the synthesis of various types of PGs and TXs 
(237). Although the products are derived from a common intermediate, differences in the effects of 
inhibitors on each, demonstrate that separate receptors and enzymes are involved in the formation of 
each IJroduct from the PGH2 intermediate (271). PGH2 is- converted to a combination of the 
prostanoids by the numerous synthase enzymes which are dependant on the cell or tissue (238,239). 
4.7.2 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON PGD2 AND PGF2a LEVELS IN BL6 CELLS 
4.7.2.1 MATERIALS AND METHODS 
MATERIALS 
Refer to 3.6.1.1 
The prostaglandin D2 [3H] assay kit and prostaglandin F2a [3H] assay kits were purchased from 
Amersham Int., Amersham, UK. 
METHODS 
4.7.2.2 Cell culture procedures 
The methods given in 2.2.31 and 2.2.3.2 were repeated. 
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4.7.2.3 Homogenization of cells and separation of cellular components 
- The method described in- 3.1.2.2 was repeated-. 
4.7.2.4 Extraction and isolation of prostaglandins 
Extraction and isolation of PGDz and PGFZa was carried out using the method described in 4.6.2.3, 
except that dried PG extract was reconstituted in 500jll of assay buffer and duplicate aliquots (lOOjll) 
were used for the determination of PGDz and PGFZa ' 
4.7.2.5 Prostaglandin D fH] assay system 
The assay is based upon competition between unlabelled PGDz _and a fixed quantity of tritium-labelled 
PGDz for binding to a limited quantity of an antibody which has high specificity and affinity for 
PGDz (551). Preparation of samples for scintillation counting, using a Beckman L528 00 model 
scintillation counter, was as described in the assay kit. One hundred micro litre aliquots of s~ple 
were pipetted into appropriately labelled tubes. One hundred microlitres tracer was added, "followed 
by the addition of 100jll of antiserum and 100jll of assay buffer. All the tubes were vortex mixed and 
incubated overnight at 2-8°C. Following incubation all tubes were placed in an ice-water bath to 
equilibrate for 10 minutes. Thereafter, 500jll of charcoal suspension was added to each tube and 
vortex mixed whereafter the tubes were left to stand in an ice-water bath for 10 minutes agail1._ All 
tubes were centrifuged at 2 OOOg for 10 minutes at 4°C. The resulting supernantant material was 
immediately decanted into scintillation vials containing lOml of emulsifier scintillation plus TM 
scintillation coctail. The concentration of unlabelled PGDz (pg PGDzltube) in the sample was then 
calculated from a standard curve recorded in Appendix 7. 
4.7.2.6 Prostaglandin F2« [3H] assay system 
The assay is based upon competition between unlabelled PGFZa and a fixed quantity of 3H-PGFza for 
binding to a limited quantity of an antibody which has high specificity and affinity for PGFZa (552). 
Preparation of samples for scintillation counting was as described in the assay kit. A 100jll aliquots 
of sample were pipetted into appropriatetly labelled tubes. One hundred microlitres of tracer was 
added to each tube followed by the 100jll of antiserum and 100jll of assay buffer. All tubes were 
vortex mixed and incubated overnight at 2-8°C. Following incubation period all tubes were placed in 
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an ice-bath and allowed to equilibrate for 10 minutes. To each tube a 500JlI aliqout of charcoal 
suspension was added. The tubes were vortex mixed a!ld allowed to incubate in an ice-bath for 10 
minutes again. All tuoes'were centrifuged at 2 OOOg for 10 minutes at 4°C. Resulting supernatant 
solutions were decanted into scintillation vials containing lOml of emulsifier plus TM scintillation 
cocktail. The concentration of unlabelled PGF2a (pg PGF2)tube) in the sample was then calculated 
from a standard curve recorded in Appendix 8. 
4.7.3 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION ON PGIz LEVELS IN BL6 CELLS 
4.7.3.1 MATERIALS AND METHODS 
MATElUALS 
Sulphuric acid (H2S04) was purchased from Holpro Chemical Co., South Africa. 6-Keto-prostaglandin 
Flc< enzyme immunoassay (EIA) system was purchased from Amersham Int., Amersham, UK" 
METHODS 
4.7.3.2 Cell culture procedures 
Methods used in 2.2.3.1 and 2.2.3.2 were repeated. 
4.7.3.3 Homogenization of cells and separation of cellular components 
The method described in 3.1.2.2 was repeated. 
4.7.3.4 Extraction and isolation of PGIz 
Extraction of PGI2 was carried out using the method described in 4.6.2.3. 
4.7.3.5 6-Keto-prostaglandin FIIX enzyme immunoassay (EIA) system 
Prostacyclin, also known as PGI2 , is an unstable vinyl ether formed from the PG endoperoxide, 
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PGH2 , which undergoes spontaneous hydrolysis to 6-keto-prostaglandin F I",. Due to this spontaneous 
hydrolysis to PGI2 , the quantitation of 6-keto-prostagl~ndin F I", is accepted by many researchers as 
a measure of PGI2 formation (553). 
The assay is based on the competition between unlabelled 6-keto-prostaglandin F I ", and a fixed 
quantity of peroxidase labelled 6-keto-prostaglandin F I ", for a limited number of binding sites on a 6-
keto-prostaglandin F I ", specific antibody (553). Preparation of samples for PG~ determination was 
-
carried out as described in the assay kit, and the resultant solution read at 450nm in a EAR 400 plate 
reader. Fifty micro litre aliquots of samples were pipetted into appropriate wells in a microtitre plate. 
Fifty microlitres of antiserum was added to each well, followed by shaking for 30 minutes on a 
microtitre plate shaker at room temperature. Following incubation, 50p'! of 6-keto-prostaglandin F I ", 
peroxidase conjugate was added to each well, and the microtitre plate further incubated at room 
temperature by shaking for 1 hour on a microtitre plate shaker, Thereafter, wells were aspirated and 
washed four times with 400j-t1 wash buffer. To the washed wells was added 150j-t1 enzyme substrate 
followed by further incubation at room temperature by shaking for 15minutes. A 100j-t1 aliquot of 1M 
sulphuric acid was added into each well and the optical density determined in a plate reader at 450nm 
within 30 minutes. The concentration of unlabelled 6-keto-prostaglandin F I ", (pg PGFljwell) in a 
sample was determined from a standard curve recorded in Appendix 9. 
4.7.4 RESULTS 
Basal PGE2 levels in BL6 cells were significantly (p:S;O.OOI) higher than PGD2 , PGF2", and PG~ 
levels. From the Table below it can be seen that basal levels in decreasing order of magnitude are 
as follows: PGE2 ; PGD2 ; PGF2", and PGI2 • 
TABLE 24: Comparison of prostaglandin levels in control cultures of BL6 cells. Results are the mean 
of three cultures ± SEM. 
*Treatment Prostaglandin levels [pg/104 cells] 
PGD2 PGE2 
OE 0.1853' 1.6535 
±0.0307 ±0.0712 
* - control cultures (OE) containing 0.1 % final volume of ethanol 
a - p::;O.OOl relative to PG~ levels 
PGF2a 
0.0595' 
±0.0111 
PGI2 
0.0077' 
±0.0003 
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TABLE 25: The effect of combined vitamin E succinate and ascorbic acid supplementation on PGD2 , 
PGF2a and PGI2 levels in BL6 cells respectively. Results are the mean of three cultures ± SEM. 
[vitamin E succinate:ascorbate] Prostaglandin levels [pg/104 cells] 
Itg/ml 
PGD2 
OE 0.185 
±0.031 
5:25 0.387' 
- ±0.069 
10:50 0.220 
±0.034 
10:25 0.188 
±0.007 
20:25 0.255 
- ±0.005 
a - p::S;0.05 relative to PGD2 control cultures (OE) 
b - p::S;O.OI relative PGI2 control cultures (OE) 
c - p::s; 0.05 relative PGIz control cultures (OE) 
d - p::s; 0.001 relative PGIz control cultures (OE) 
PGF2a PGI2 
0.060 0.0077 
±0.01l ±O.OQ01 _ 
0.085 0.0078 
±0.017 ±O.OOOI 
0.093 0.0093b 
±0.006 ±0.0004 
0.059 0.0094c 
±0.003 ±0.0003 
0.074 0.0164d 
±0.nD4 ±0.0003 
The levels of PGD2 and PGF2a in BL6 cells (Table 24) were found to be greater with combined 
vitamin E succinate and Asc supplementation, although the only significant (p ~ 0.05) increase was 
in PGD2 at 5:25g/ml relative to control cultures (OE). In these cells combined vitamin E succinate and 
Asc resulted in an increase in the PGI2 levels, with significant increases recorded at 10:50 (p ~ 0.01); 
10:25 (p~0.05) and 20:25p,g/ml (p~0.001) relative to the control cultures (OE). 
4.7.5 DISCUSSION 
The quantity and type of PGs produced by the given cells is critical to the metabolic effect they exert 
(283). Results from a number of laboratories studying the mechanisms controlling the synthesis of 
these molecules have clearly shown that at least two critical determinants exist in PG synthesis. These 
are the activation ofPLA2 and the action PES (228,283). Studies described earlier on PLA2 and COX 
activity (Sections 4.2 and 4.5) showed significant increases in PLA2 and COX activity following 
combined vitamin E succinate and Asc supplementation. Since COX activity forms an integral part 
of the PES, which functions to catalyze the conversion of AA to PG precursor PGH2 (232-239), it 
would seem that any increase in PLA2 and COX activity would be expected to increase the overall 
levels of various PGs. 
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Results from this study have shown that combined vitamin E succinate and Asc supplementation of 
BL6 cells resulted in marked increases in PGEz, PGDz, :rGFz<x, and PGlz levels. PGEz concentrations, 
as described earlier, were significantly increased at .10:50 and 20:25j1g/ml combined 'vitamin E 
succinate and Asc levels respectively, while PGlz levels were significantly increased at 10:50; 10:25 
and 20:25j1g/ml relative to the respective control cultures (OE). The alteration in PG levels observed 
within these cells following combined vitamin supplementation may be due to. alterations in the 
individual PG synthetase enzymes. Toivanen (501) and Chan et al (554) have shown that vitamins E 
-
and C affect PGI synthesis in in vitro studies. Table 25 shows a comparison of PGDz, PGEz, PGFz<x 
and PGlz levels within the BL6 control cultures (OE). Fulton (300) states that in the B16 melanoma 
system PGEz, PGDz, PGFz<x and PGlz are the major arachidonate metabolites. It is evident from this 
table that BL6 cells convert AA to PGDz, PGEz, PGFza and PGlz however, the PGEz concentration 
was significantly higher than the PGDz levels. This observation is contradictory to what has been 
reported by other researchers (300), although PGFz<x and PGlz levels found in this study support their 
findings that PGlz levels in BL6 cells are markedly lower in BL6 cells than were the other PGs. Lipid 
hydroperoxides, which are formed as a result of free radical formation (54,206,211), and 
hydroperoxide intermediates in PG synthesis (268,237,529,543), inhibit PGI2 synthesis (501}. The 
low PGlz levels may therefore be the result of markedly high levels of lipid peroxidation'found in 
BL6 cells (Section 3.1). 
It has been reported that the synthesis of PGFz<x and PGEz are linked. Studies by Kowaza et al (555), 
on cultured neonatal mouse calvaria reported that PGFza stimulates AA release and PGE2 synthesis. 
This implies that any changes in PGFza levels will correlate with similar changes in PGE levels. BL6 
cells supplemented with combined vitamin E succinate and Asc did in fact show increases in PGFZa 
levels, with a similar trend being observed for PGE2 levels. 
PGE2 (285,320,416,447,453) and PGlz (286,287,422,447) are thought to exert their cellular effects 
via a cAMP-adenylate linked system. Therefore it was of interest in this study to determine the effect 
of combined vitamin E succinate and Asc supplementation on the levels of AC activity and cAMP 
levels in both LLCMK and BL6 cells. 
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4.8 COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID SUPPLEMENTATION 
ADENYLATE CYCLASE ACTIVITY AND CYCLIC ADENOSINE MONOPHOSPHATE 
FORMATION . , 
4.8.1 INTRODUCTION 
Alterations in the membrane intracellular signalling systems are frequently implicated in the 
development of neoplasia (346,510). One of the major intracellular signalling systems identified to 
date is the AC-cAMP linked system (510), which is membrane bound (198,331,383) and composed 
exclusively of intrinsic membrane-bound proteins (198,332,390). 
Like many other membrane-bound enzymes, AC activity is affected by changes in the composition 
of the phospholipid fatty acyl chains and polar head groups (121). This phenomenon is explained by 
the ability AC to exist in different conformations, and the fact that alterations in membrane lipid 
composition cause the enzyme to shift from one conformation to another (121). AC activity is also 
affected by changes of membrane lipid environment (405,408). Canuto et al (409) found that i9 AH-
130 Ascites Hepatoma cells there was an enhanced AC activity which was not only related to 
membrane fluidity but also to an increase in lipid peroxidation. This sensitivity to alterations in 
membrane fluidity is believed to be due to the changes in the conformational flexibility of intrinsic 
proteins (186,198) and also due to alterations in the efficacy of interaction of the various components 
of the AC system (186,198,390). 
Studies using transformed and normal cell lines in culture showed that transformed cells had a lower 
cAMP level than normal cells, and that the levels of cAMP were inversely related to cell growth 
(427,456-461). Intracellular cAMP levels are regulated by the AC and/or PDE (386,462) hence 
alterations in AC, and/or PDE through changes in the membrane fluidity could account for the 
decrease in cAMP levels observed in tumour cells (386,398,453,462). In addition to regulation by 
membrane fluidity the AC system appears to be affected by PGs (341,410,412-415) as well as 
intracellular Ca2+ levels (344,426). Since combined vitamin E succinate and Asc supplementation has 
been shown to influence the cellular concentrations ofPGs, particularly PGE2 (Section 4.6) and Ca2+ 
(Section 4.1) in LLCMK and BL6 cells, this study was undertaken to determine the effect of 
combined vitamin E succinate and Asc supplementation on AC activity and cAMP levels in these 
cells. 
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4.8.2 MATERIALS AND METHODS 
MATERIALS 
Adenosine 5'-triphosphate disodium salt (ATP), Adenosine 3'-5'-cyclic monophosphate sodium salt 
(cAMP) and 3-isobutyl-1-methylxanthine (IBMX) were purchased from Sigma Chemical Co., USA. 
r- I 
Triethanolamine and aluminium oxide 90 (Woeln N active-neutral) were obtained from Merck, 
Dar~stadt, Germany. (2,5'8-3H) Adenosine 5'-triphosphate ammonium salt and the PH] cAMP assay 
kit were purchased from Amersham, Int., PLC, USA. Creatine-kinase and creatine-phosphate-
Na.4H20 (creatine-phosphate) were obtained from Boehringer Mannheim, Germany. 
METHODS 
4.8.2.1 Cell culture procedures 
Methods described in 2.2.3.1 and 2.2.3.2 were repeated, except that the cell pellet was resuspended 
in 1ml ofO.1M Tris HCl buffer, pH 7.5 containing 4mM EDTA. ' 
4.8.2.2 Homogenization of cells and separation of cellular components 
The method described in 3.1.1.2 was used with the following changes. The Dounce homogenizer was 
rinsed with 1ml of Tris HCl buffer. After centrifugation the supernatant fractions were retained for 
cAMP determinations and membrane fractions were resuspended in 2ml Tris HCl buffer, pH 7.5. 
4.8.2.3 Protein Determination 
Protein determinations of the membrane fractions were carried out using the modified method of 
Lowry et al (cited in 514). The protein standard curve is recorded in Appendix 5. 
4.8.2.4 Adenylate cyclase activity assay 
AC activity of the membrane fraction of the cells was determined using the modified method of 
Schultz and lakobs (383) and Salomon (385). The assay involves measuring the rate of conversion 
of [a_32P]ATP to [32P] cAMP. To 20/11 1M Tris HCl buffer, 20/11 [a_32p] ATP and a 30/11 aliquot of 
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the standard component mixture was added. The standard component mixture contained 500JLI 1M 
triethanolamine buffer, 500JLI 100mM MgCl2 solution, 1ml lOmM 3-IBMX (PDE inhibitor), 100JLI 
cAMP solution, 100JLI ATP solution, 16.4mg creatiae;-phosphate, 4mg creatine kinase, lOmg BSA 
and 800JLI of milli Q water to give a final volume sufficient for 100 assays. After mixing thoroughly, 
the tubes were allowed to equilibrate thermally at 37°C for five minutes. A 30JLI aliquot of the 
membrane suspensions was added to the tubes, vortex mixed and incubated f9-r a_ period of one 
minute. The reactions were stopped at 15 second intervals by adding 400JLI 125mM ZnCl2 solution 
and 500JLI 125mM N~C03 solution, to determine the optimum reaction time. 
The samples were centrifuged for 5 minutes at 10 OOOg in a Eppendorf 5203 centrifuge. After 
centrifugation, 800JLI of the supernatant was transferred to alumina columns which had been prepared 
by pouring dry neutral alumina into plastic syringes to a height of 2cm. These columns were then 
washed. with lOml O.lM Tris HCI buffer before the samplt! was applied. After the sample had 
drained, 2ml of the Tris HCI buffer was applied, followed (after draining) by another 2ml of this 
buffer. The entire eluant was collected in scintillation vials . containing lOml emulsifier scintillator 
plus TM scintillation cocktail. The columns were regenerated by washing with 10ml of the the same 
Tris HCI buffer. . 
AC activity was calculated as catalytic activity relative to the mass of protein expressed as the 
formation of 1pmol cAMP per minute (lunit) per mg protein. 
4.8.2.5 Cyclic adenosine monophosphate extraction 
The respective stroma fractions of the LLCMK and BL6 cells were heated in a boiling water bath for 
5 minutes to coagulate protein. The protein was precipitated by centrifugation at 8 OOOg for 10 
minutes and the supernatant then assayed for the presence of cAMP. 
4.8.2.6 Cyclic adenosine monophosphate fH] assay 
A commercial radio-immunoassay kit was used to determine the cAMP levels in the stroma fraction 
of the LLCMK and BL6 cells, respectively. The assay is based on the competition between unlabelled 
cAMP and a fixed quantity of PH] cAMP for binding to a protein which has a specificity and affinity 
for cAMP (556). 
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The samples were heated in a boiling water bath for 5 minutes to coagulate protein. After 
centrifugation, at 3 OOOg, in a Eppendrof 5203 centrifug~, the cAMP in the supernantant was assayed 
- ~ 
using a cyclic AMP[3H] assay system. The tubes, as t:equired, were placed in racks in an ice bath 
which was kept at OOC. Fifty microlitres of the samples were added to appropriate assay tubes. 
Labelled cAMP (50111) was added to every assay tube followed by 100111 of the binding protein. All 
the tubes were vortex mixed for 5 seconds. The ice bath containing the tubes w~s placed in a cold 
room at 4°C and left for 2 hours. At least 15 minutes before the end of the incubation time, 20ml of 
ice cold distilled water was added to the charcoal reagent which was strirred continously during use. 
At the end of the 2 hour incubation period, 100111 of the charcoal suspension was added to each tube. 
The tubes were centriifuged at 3 OOOg for 4 minutes. A 200111 aliquot of the resultant supernantant 
was removed, without disturbing the sediment, and placed in scintillation vials containing 10ml 
emulsifier scintillator plus TM scintillation cocktail. The amount of labelled protein-cAMP complex 
formed is inversely related to the amount of unlabelled cAMP present in the assay sample. The cAMP 
standard curve is recorded in Appendix 10. 
4.8.3 RESULTS 
4.8.3.1 Adenylate cyclase activity 
AC activity (Table 26) in the LLCMK control cultures (OE) was significantly (p ~ 0.01) higher than 
the AC levels detected in the BL6 control cultures (OE). 
In the LLCMK cells (Table 26) supplemented with varying levels of combined vitamin E succinate 
and Asc respectively no increasing or decreasing trend in AC activity was found. However, at 
1O:50llg/ml combined vitamin E succinate and Asc supplementation a significant (p ~ 0.001) increase 
in AC was observed relative to control cultures (OE). On the other hand, in BL6 cells (Table 26), 
significantly (p ~ 0.01) higher levels of AC activity were detected following combined vitamin E 
succinate and Asc supplementation compared to control cultures (OE). 
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TABLE 26: The effect of combined vitamin E succinate. and ascorbic acid supplementation on 
adenylate cyclase activity in LLCMK and BL6 cells. Results are the mean ofthree cultures ± SEM. 
[vitamin E succinate:ascorbate] Ade~ylate cyclase activity (U/mg protein) 
I'g/ml 
LLCMK CELLS 
OE 
5:25 
-
10:50 
10:25 
20:25 
-
a - p:::;O.OI relative to BL6 control cultures (OE) 
b - p:::;O.OOI relative to LLCMK control cultures (OE) 
c - p:::;O.OI relative to BL6 control cultures (OE) 
d - p:::;O.01 relative to BL6 control cultures (OE) 
4.8.3.2 Cyclic adenosine monophosphate levels 
58.30' 
±2.15 
61.05 
±0.98 
79.16b 
±1.52 
58.21 
±0.58 
54.66 
-. 
±0.76 
BL6 CELLS 
51.80 
:1;:0.2.5 
61.02° 
± 1.15 
64.72° 
±0.56 
63.44° 
±0.83 
93.71d 
±3.05 
cAMP levels in the control cultures (OE) of LLCMK cells are significantly (p:::; 0.01) higher than the 
cAMP levels found in control cultures (OE) of BL6 cells (Table 27). 
At the varying levels of combined vitamin E succinate (5-20Ilg/ml) and Asc (25-50Ilg/ml), 
significantly (p:::; 0.001) higher levels of cAMP were also detected in LLCMK than the corresponding 
BL6 cells, however at 20:25Ilg/ml a significantly (p:::; 0.05) lower cAMP level was found relative to 
the corresponding BL6 cell group (Table 27). 
In the LLCMK cells significant increases in cAMP levels were detected at 5 :25 (p:::; 0.001); 10:50 
(p:::; 0.001); 10:25 (p:::; 0.05) and 20:25Ilg/ml (p:::; 0.001) respectively compared to control cultures 
(OE). BL6 cells supplemented with combined vitamin E succinate and Asc also resulted in significant 
increases in cAMP levels at 5:25; 10:50; 10:25 (p:::;0.05) and 20:25Ilg/ml (p:::;0.001) respectively 
when compared to control cultures (OE). 
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TABLE 27: The effect of combined vitamin E succinate and ascorbic acid supplementation on cyclic 
adenosine monophosphate levels in LLCMK and BL6 cells. Results are the mean of three cultures ± 
SEM. 
[vitamin E succinate:ascorbate] cAMP concentration 
p.g/mJ 
LLCMK CELLS 
OE 6.37" 
±0.19 
-
5:25 1O.931xl 
±0.48 
10:50 1O.861xl 
±0.21 
10:25 7.44be 
±0.13 
- 20:25 13.75cd 
±0.46 
a - p:O;;O.OI relative to BL6 control cultures (OE) 
b - p:o;; 0.001 relative to corresponding BL6 supplemented cells 
c - p:o;; 0.05 relative to corresponding BL6 supplemented cells 
d - p:o;; 0.001 relative LLCMK control cultures (OE) 
e - p :0;;0.05 relative LLCMK control cultures (OE) 
f - p:O;;O.05 relative to BL6 control cultures (OE) 
g - p:o;;O.OO1 relative to BL6 control cultures (OE) 
3.8.4 DISCUSSION 
--
pmoJ/mg protein 
BL6 CELLS 
4~32~ 
±0.23 
6.33f 
±0.13 
5.95f 
±0.12 
6.44f 
±0.16 
15.61g 
± 1.17 
The AC enzyme is a ubiquitous, multicomponent and membrane bound enzyme (198,331,383) which 
catalyzes the conversion of ATP to cAMP (331,384,385). cAMP acts as a second messenger for many 
systematic and local hormones and consequently controls many physiological processes at the cellular 
level (198,386). 
When comparing the basal levels of AC and cAMP in LLCMK and BL6 cells, LLCMK cells had a 
significantly higher AC activity and cAMP levels. These results support numerous other studies which 
report lower AC activity and cAMP levels in transformed cells compared to their normal counterparts 
(427,456-461). These results suggest that transformation of a normal cell to tumour cells produce 
changes in the plasma membrane which alter AC activity, resulting in decreased activity. 
Supplementation of BL6 cells with vitamin E succinate (5-20p,g/ml) and Asc (25-50p,g/ml) resulted 
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in a significant increase in AC activity at each combined vitamin concentration combination. Changes 
in membrane fluidity is characteristic of tumour cells (123), hence the ability of vitamin E to alter 
memorane fluidity through its physicochemicarinteractions (95,125,127,498) could account for the 
observed increase in AC activity in BL6 cells. Furthermore Asc would increase the action of the 
vitamin E due to the regeneration capacity of vitamin C. In addition, various PGs are known to 
influence AC activity (410,411). Hence the marked increases PGE2 levels found following ~ - ~ 
supplementation of combined vitamin E succinate and Asc (Section 4.6) could also be a factor causing 
-
an increase in AC acitivty in BL6 cells. 
The increase in cAMP levels in BL6 cells as a result of vitamin supplementation were positively 
correlated with increases in AC activity found in these cells (Table 26). In LLCMK cells, significant 
increases in cAMP levels were also detected at each combined vitamin concentration set compared 
to control cultures (OE) which also correlated with AC activity at 5:25 and 1O:50jLg/ml respectively, 
however at 10:25 and 20:25jLg/ml no such correlation existed. 
The effect of combined vitamin E succinate and Asc supplementation on the relationship between the 
second messengers and AA metabolites described in this chapter and the possible influence this may 
have on cell growth and metabolism will now be discussed. 
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CHAPTER 5 
- ~ 
COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID SUPPLEMENTATION IN 
RELATION TO OXIDATION STATE, SECOND MESSENGERS AND CELL GROWTH 
Cell metabolism is a collective term for the processes by which a cell regul;ltes_ its myriad of 
chemical reaction sequences, and in doing so, controls its internal environment (176). The cells 
motif for metabolism is to extract energy and reducing power from the cell environment and to 
synthesize the building blocks for macromolecules (392). The pathway outlined in Figure 9 
(repeated on page 139) is just one of the numerous pathways in this highly integrated network. It 
is however, a pathway that is vital to metabolism as it produces secondary messengers which 
control various metabolic processes as well as the cell cycle. 
The micronutrients, which include the vitamins, minerals and some trace elements are dietary 
components essential to normal metabolic function (25). A number of studies clearly indicate a 
relationship between diet and cancer incidence in human populations. Furthermore, differen.~es in 
cancer rates have been associated with these particular differences in diet (7,25,80,227( One of 
the most widely explored areas of cancer research is that of anticarcinogenesis, a concept first put 
forward by Crabtree (cited in 80). Evidence suggests that natural foods contain factors that protect 
against cancer. Two such micronutrients obtained from the diet are the antioxidants E and C 
which have received much attention in preventing, enhancing and inhibiting various forros. of 
cancer. Vitamin E supplementation has been shown to have an inhibitory effect on numerous cell 
lines (49,91,92,94,96,97,148,477) while vitamin C has been reported to have both an inhibitory 
and a stimulatory effect on the growth of various tumour cell lines (48,64,67,76,478-480). 
Vitamin E and Asc have been proposed to act synergistically, where vitamin C represents a pool 
of antioxidant potential regenerating oxidized vitamin E (103,135,167,168,174) in turn prolonging 
the action of vitamin E. Since studies by Prasad and Rama (92), Kline et al (97) and Prasad and 
Edwards-Prasad (94) showed significant inhibition of cell growth in various cell lines following 
vitamin E succinate supplementation one would expect a more pronounced inhibitory growth effect 
following combined vitamin E succinate and Asc due to the sparing effect of vitamin E. Hence of 
principal concern in this study has been the effect of combined vitamin E succinate and Asc 
supplementation on the metabolism of the non-malignant LLCMK and malignant BL6 cells. The 
particular pathway under scrutiny in these cells is outlined in Figure 9. This study does consider AA 
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AA supplementation, but the emphasis is on combined vitamin E succinate and Asc supplementation. 
Chapter 2 investigated the effect of nutrient supplementation on both LLCMK and BL6 cell growth, 
while Chapter 3 determined the effect of nutrient supplementation on free radical formation and lipid 
peroxidation levels within these cells. In Chapter 4 the effect of combined nutrient supplementation 
on certain AA metabolites within these cells was determined. This chapter will relate LLCMK and 
BL6 cell growth to the free radical formation, lipid peroxidation levels, and se{;ood messengers 
assoc~ated with the above pathway, as well as to factors influencing this pathway. 
It is important to note that as discussed in Chapter 2, there was considerable variation in the effect 
of combined vitamin E succinate and Asc supplementation on cell growth between experiments. 
Consequently, relationships between cell growth and free radical formation, lipid peroxidation, and 
AA metabolites will be discussed on the basis of the results of each of the individual studies which 
made up this investigation. An attempt will then be made to draw together these individual cell 
growth, free radical formation, lipid peroxidation and AA metabolites relationships with respect to 
the pathway under consideration. It must be noted that since supplementation of combined vitamin 
E succinate and Asc to LLCMK cells resulted in variable and less significant effects on cell growth 
and second messenger metabolism with no real correlation between the two, attentiol1 will 'be placed 
on the BL6 cells. 
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Figure 9: Schematic representation of the AA cascade pathway investigated in this study. 
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Lipid peroxidation is initiated by free radical attack on membrane PUF As which produces large 
amounts of toxic radical products that have been impHcated in carcinogenesis (219). Studies have 
revealed that the inhibitory effect on cell proliferatioli Is related to lipid peroxidation (543;557-559). 
PUFAs generate lipid peroxides in tissue culture and may represent only one of several pathways in 
which fatty acid metabolism can alter cell proliferation (557). Thus of concern here is the relationship 
between cell growth, free radical formation, lipid peroxidation levels and combined vitamin E 
succinate and Asc supplementation . 
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Figure 21: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and free radical formation. 
Combined vitamin E succinate and Asc supplementation of LLCMK cells did not significantly affect 
cell growth or free radical formation. Supplementation of the combined vitamins to the BL6 cells, 
however, resulted in a significant decrease in cell growth, together with a marked increase in free 
radical formation (Figure 21). A similar inverse relationship would be expected of cell growth and 
lipid peroxidation levels in BL6 cells as lipid peroxidation is mediated by free radicals. This was in 
fact found in BL6 cells (Figure 22). 
Supplementation of combined vitamin E succinate and Asc to LLCMK cells did not result in an 
inverse relationship between cell growth and lipid peroxidation levels, although a significant increase 
in lipid peroxidation levels following combined vitamin E succinate and Asc was observed at 5:25 
and 20:25fLg/ml respectively and this correlated with a slight decrease in cell growth. Goldring et al 
(214) suggest that the levels of lipid peroxidation are inversely related to the rate of cellular growth 
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irrespective of whether they are malignant or not. Furthermore, these peroxidation products, or 
breakdown products therefrom may influence the way in ~hich proliferative signals cross membranes. 
This however, was not the case with LLCMK cells in this study, while BL6 cells on the other hand 
exhibited an inverse relationship. These results were further substantiated by studies of Ottino and 
Duncan (560). This suggests that free radical formation and lipid peroxidation levels are negative 
regulators of BL6 cell growth and furthermore that combined vitamin E succinate-and Asc enhance 
free radical formation and lipid peroxidation levels. 
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Figure 22: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and lipid peroxidation levels. 
Lipid peroxidation is the process of oxidative turnover of PUF As in which both enzymic and non-
enzymic (529,543) lipid peroxidation are initiated by free radicals. Recent investigations on the 
metabolism of AA by COX and LOX have revealed that intermediate peroxy compounds and 
hydroxyl radicals are produced in these reactions (237,242,268,529). Since COX activity is known 
to produce peroxy compounds and hydroxyl radicals adding to the overall lipid peroxidation state, 
a study was undertaken to determine a relationship between cell growth, and the enzyme activities 
following combined vitamin E succinate and Asc supplementation. In this experiment, LLCMK cell 
growth was significantly deceased when supplemented with combined vitamin E succinate and Asc. 
This decrease in cell growth was inversely related to a significant increase in COX activity with the 
exception at 5:25jLg/ml where COX activity decreased slightly. Combined vitamin E succinate and 
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Asc supplementation of BL6 cells also resulted in a significant decrease in cell growth, together with 
a significant increase in COX activity (Figure 23). This suggests an inverse relationship between BL6 
cell growth and COX activity, and furthermore supplementation of combined vitamin E succinate and 
Asc markedly increases the activity of the COX enzyme. 
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Figure 23: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and cyclooxygenase activity. 
In another experiment supplementation of combined vitamin E succinate and Asc of the LLCMK cells 
did not significantly effect cell growth or 5-LOX activity, although at 5:25/lgiml and 1O:50/lgiml 
respectively, an inverse relationship between cell growth and 5-LOX activity could be seen. In BL6 
cells supplementation of combined vitamin E succinate and Asc resulted in an overall significant 
decrease in cell growth (Figure 24). This significant decrease in growth was accompanied by an 
overall significant increase in 5-LOX activity. Since investigations on the metabolism of AA by LOX 
and COX have revealed that intermediate peroxy compounds and hydroxyl radicals are produced in 
these reactions (237,242,268) and since the activities of both LOX and COX were increased in this 
study, this would account for the increases in free radicals and lipid peroxidation levels observed in 
this study as a result of vitamin supplementation. 
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Another factor which needed to be taken into consideration in this study was the effect of combined 
vitamin E succinate and Asc on intracellular Ca+ levels, since it has been suggested that Ca2+ controls 
cell proliferation (329,335,356) and it is known that Caz+ affects PLAz, LOX and AC activity. In 
LLCMK cells, combined vitamin E succinate and Asc supplementation did not result in any trend 
between cell growth and Caz+ levels while in BL6 cells (Figure 25) cell growth decreased significantly 
with the exception at 5:25JLg/ml where a slight increase in cell growth was observed. Caz+ levels 
increased significantly following combined vitamin E succinate and Asc supplementation, although 
at 5:25JLg/ml a decrease in Caz+ was detected. Thus, combined vitamin E succinate and Asc 
supplementation results in an inverse relationship between BL6 cell growth and cellular Ca2+levels. 
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As already mentioned Ca2+ exerts an important regulatory role in modulating the activity oCLOX 
enzyme (533,535). It may also affect cell metabolism indirectly via the activation ofPLAz and release 
of AA (347,348,350,352). Hence an additional factor which needed to be investigated was the effect 
of combined vitamin E succinate and Asc supplementation on PLA2 activity. With the exceptions of 
the 5:25/Lg/ml and 10: 25/Lg/ml combined vitamin E succinate and Asc supplemented LLCMK 
cultures, no relationship between cell growth and PLA2 activity was observed. However, with respect 
to BL6 cells (Figure 26), a significant decrease in cell growth together with a significant increase in 
PLA2 activity following combined vitamin E succinate and Asc supplementation was observed. This 
suggests that combined vitamin E succinate and Asc stimulates the PLA2 enzyme. The activation of 
PLA2 and subsequent release of AA from phospholipid stores is an important rate limiting substrate 
of COX activity and eicosanoid metabolism (229,238,347-350). Therefore as a result of the increase 
in PLAz activity an increase in free EF A levels particularly AA and subsequent stimulation of 
eicosanoid metabolism could be expected. 
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Figure 26: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and PLA2 activity. 
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In order to establish whether any changes in AA composition of the cells under investigation was the 
result of increased PLA2 activity or a possible increase of AA uptake, investigations of the effect of 
combined vitamin supplementation on uptake of AA was undertaken. Supplementation of combined 
vitamin E succinate and Asc together with 3H· AA in LLCMK cells resulted in a significant increase 
in both cell growth and 3H AA uptake. Inhibition of BL6 cell growth at all combined vitamin 
concentration groups was found. 3H AA uptake was inversely correlated to BL6 cell growth (Figure 
27). Further investigation on the effect of combined vitamin E succinate and Asc supplementation 
together with AA on AA composition and cell growth of these two cell lines also resulted in an 
overall significant decrease in BL6 cell growth and an accompanying increase in total percentage AA 
composition (Figure 28). Total percentage AA composition was inversely related to BL6 cell growth. 
A similar trend was observed in the LLCMK cells. 
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combined vitamin E succinate and ascorbic acid supplementation. 
1Jl 125 25 
0 
.b 
c 
0 
u 
v 100 20 
2 
nJ 
ill 
L 
+' 75 15 <r: c <r: 
::J 
"- "" 0 
'" ~ 50 10 +-' 0 f--
C 
co 
+-' 
n 
s:: 
~ 
25 5 
s:: 
+-' 
3: 
;: 0 0 
(') OE 525 10 50 1025 2025 
[vitamin E succinate ascorbic aCld]lJg/ml 
• BL6 cell growth % AA 
Figure 28: BL6 cell growth and total percentage arachidonic acid 
composition with combined vitamin E succinate and ascorbic acid 
supplementation. 
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This suggests that the effects of combined vitamin E succinate and Asc supplementation on AA uptake 
into the BL6 cells could be partly responsible for the inyerse relationship between PL~ activity and 
cell growth. Furthermore, the magnitude of AA uptake was far greater in the membrane fraction 
while AA levels were far more noticeable in the stroma fraction following vitamin supplementation 
hence the increased AA levels observed in this study are likely to be a combined effect of AA uptake 
and increased PLA2 activity. 
Summarizing the results discussed so far, it appears that supplementation of combined vitamin E 
succinate and Asc in BL6 cells results in a significant decrease in cell growth compared to control 
cultures and furthermore that these decreases are inversely correlated to the levels of free radicals, 
lipid peroxidation and Ca2+ as well as the activities of COX, 5-LOX and PLA2 together with total 
percentage and cell stroma AA composition. 
Since PG synthesis is regulated by the activation of PLA2 and subsequent release of AA, and 
furthermore the net production is dependent on the COX activity (229,238), it was necessary to 
determine the effects of combined vitamin E succinate and Asc supplementation on PG synthesis. 
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Figure 29: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and prostaglandin E2 levels. 
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Upon combined vitamin E succinate and Asc supplementation, the PGE2 levels found in LLCMK cells 
were positively correlated with cell growth, with the _ exception at 20:25JLg/ml where an inverse 
relation was shown. However, upon combined vitamin E succinate and Asc supplementati"on of BL6 
cells, the PGE2 levels were found to be inversely related to BL6 cell growth (Figure 29) with an 
exception at 1O:25JLg/ml. The precise role of PGE2 in tumourgenicity and metastasis is still unclear 
(300), although some researchers suggest that in BL6 cells (226,288,300), £.G~ is negatively 
correlated with metastatic potential. The quantity and type of PG produced within a cell is essential 
-
to the metabolic effect it has (280) and in view of melanoma cells being unique in that they synthesize 
more than one prostaglandin (300), it was of importance for the study to determine whether combined 
vitamin E succinate and Asc supplementation affected the levels of other PGs within the BL6 cells. 
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Figure 30: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and prostaglandin D2 levels. 
Combined vitamin E succinate and Asc supplementation of BL6 cells resulted in an overall increasing 
trend in PGD2 (Figure 30) and PGF2a (Figure 31) levels. With regards to PGD2 levels, this increase 
was inversely related to BL6 cell growth as were PGF2a levels with the exception at 1O:25JLg/ml 
where the PGF2a level decreased and there was a decrease in cell growth. 
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Figure 32: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and prostaglandin 12 levels. 
149 
5. Second Messengers and Cell Growth 150 
In the experiment examining the effect of combined vitamin E succinate and Asc supplementation on 
PGIz levels, a significant increase in this PG was found when compared to control cultures. Hence 
an inverse relationship also existed between BL6 cell growth and PGIz levels, with the exception at 
5:25p,g/ml where cell growth increased with increased PGIz levels (Figure 32). These results suggest 
that the effects of combined vitamin E succinate and Asc supplementation on BL6 cell growth is 
mediated in part by increasing the levels of PGEz, PGDz, PGFZa and PGlz. PGs are known to exert ~- -
many of their effects through changes in the levels of cAMP (415,416,431,447) with the PGs of the 
D, E and I series capable of increasing cAMP formation in numerous systems (561) and cAMP in 
turn influencing the cell cycle (328). 
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Figure 33: The effect of combined vitamin E succinate and ascorbic 
acid supplementation on BL6 cell growth and adenylate cyclase 
activity. 
Combined vitamin E succinate and Asc supplementation of the LLCMK cells, significantly inhibited 
cell growth, while having no affect on AC activity. Combined vitamin E succinate and Asc 
supplementation, however resulted in a significant decrease in BL6 cell growth, together with a 
significant increase in AC activity (Figure 33). A similar inverse relationship was also observed when 
comparing cAMP levels and cell growth in BL6 cells (Figure 34). Hence, as also suggested by 
another study done on BL6 cells (394,446) it would seem that as more ATP is converted to cAMP, 
cAMP may in turn negatively regulate cell growth. Thus results from these studies suggest that 
combined vitamin E succinate and Asc supplementation induce AC activity and hence cAMP levels 
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which may act as a negative regulator of BL6 cell growth. _ 
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In conclusion, no definite relationship was determined between LLCMK cell growth and the second 
messengers shown in Figure 9, as a result of combined vitamin E succinate and Asc supplementation. 
At certain combined vitamin concentrations an inverse relationship between LLCMK cell groW!~ and 
second messengers existed, but the magnitude of this relationship varied significantly between 
individual experiments. However, the combined vitamin E succinate and Asc supplementation to BL6 
cells exhibited a definite inverse relationship between cell growth and the secondary messengers 
shown in Figure 9. A primary effect of combined vitamin supplementation in the BL6 cells, appeared 
to be on the uptake of AA from the medium and increased activity of the key regulatory enzyme, 
PLA2 • Thus, the percentage AA composition of the BL6 cells is affected and this in turn appears to 
influence the cellular levels of the AA metabolites in the eicosanoid pathway. 
Combined vitamin E succinate and Asc supplementation of the BL6 cells in this study also resulted 
in marked increases in both free radical and lipid peroxidation levels while it has been proposed that 
vitamin C acts synergistically with vitamin E, regenerating oxidizing vitamin E in turn lowering the 
free radical and lipid peroxidation levels within the cell, results from this study, however, clearly 
indicate a prooxidant rather than an antioxidant effect. This increase in free radical and lipid 
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peroxidation levels within the cell appears to be due to the increased activities of both LOX and COX 
since intermediate oxygen containing radicals are produced in the conversion of AA to the various 
products by LOX and COX (237,242,268,529f 
In an attempt to confirm that the inhibition of BL6 cell growth following combined vitamin E 
succinate and Asc supplementation was mediated via the proposed cascade effe$t apd whether an 
association between free radical formation, lipid peroxidation levels and COX activity exists as 
proposed, a potent PLA2 inhibitor, dexamethasone, was used. Secondary messenger levels and enzyme 
activities were then assayed following combined vitamin E succinate and Asc supplementation, in the 
presence of dexamethasone. 
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CHAPTER 6 
COMBINED NUTRIENT AND DEXAMETHASONE SUPPLEMENTATION OF BL6 CELLS 
6.1 INTRODUCTION 
In the_ last two decades a significant link between cancer development, cancer progression, 
invasiveness and prostaglandins has been reported. Although, some of these reports are conflicting 
the exact role of PGs in cancer development and progression is not yet clarified (562). PGs act 
mainly by their specific receptors and by interfering with DNA, RNA, protein synthesis, cell 
membranes and cell communication (562). PGs which are synthesized from AA by cellular 
enzymes, are important bioactive substances and modulate diverse cellular functions in ubiquitous 
cells. As the concentration of free AA is low (339,366), it is well recognized that AA release is a 
rate limiting step of PG synthesis (555) and the inhibition of AA release could suppress the 
formation of these mediators. Therefore an inhibition of PLA2 could result in the suppression of . 
important lipid mediators which offers an attractive therapeutic approach to the design of npvel 
agents for the treatment of various diseased states (563). The glucocorticoid steroids are extremely 
effective inhibitors of the synthesis of AA metabolites via the inhibition of PLA2 • Dexamethasone 
(Figure 35), a potent PLA2 inhibitor, is the most widely used of the glucocorticoid steroids (564). 
The mechanism of dexamethasone inhibition is still uncertain. Initially dexamethasone was thought 
to exert its action by inducing the formation of PLA2 inhibitory proteins known as lipoco[1:ins 
(565,566), however numerous other mechanisms have been proposed. 
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Figure 35: Structure of Dexamethasone (I). 
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Since the aim of this study was to determine whether the inhibition of BL6 cell growth that was 
observed is due to the AA flux in these cells and subse.quent effects on the PGE2-AC-cAMP linked 
pathway outlined in Figure 9 (page 139) nutrient supplemented BL6 cells were subjected to 
dexamethasone treatment. 
6.2 THE EFFECT OF COMBINED VITAMIN E SUCCINATE, ASCORBIC ACID AND 
DEXAMETHASONE SUPPLEMENTATION ON CELL GROWTH 
6.2.1 INTRODUCTION 
As discussed earlier in Section 4.6, PGs have been reported by some to promote cell proliferation and 
by others to inhibit. Studies have shown that the addition of PGs to cultured cells resulted in a dose 
dependent inhibition of cell proliferation (9). Cell inhibition was most frequently noted with PGs of 
the E series and was positively correlated with changes in cAMP, hence the PGE effect was thought 
to be mediated through the activation of AC. PG synthesis fs regulated in turn by the activation of 
PLA2 and subsequent release of AA, and furthermore, the net PG production is determined by COX 
activity (229,238). Dexamethasone is a potent PLA2 inhibitor, preventing the release of AAfrom the 
sn-2 position of the phospholipid stores (357,563,564). In an attempt to determine whether the 
activation of PLA2 , resulting in the cascade effect was responsible for the inhibition of BL6 cell 
growth, dexamethasone together was combined vitamin E succinate and Asc was supplemented to BL6 
cells. 
6.2.2 MATERIALS AND METHODS 
MATERIALS 
Materials used were the same as in 2.2. Dexamethasone (65mg/g) was purchased from Sigma 
Chemical Co., USA. 
METHODS 
6.2.2.1 Preparation of vitamin E succinate, ascorbic acid and dexamethasone stock solutions 
Stock solutions of vitamin E succinate (20mg), Asc (5mg) and dexamethasone (lOmM) were freshly 
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prepared in absolute ethanol and milli Q water respectively and diluted 1: 1000 in media containing 
10% (v/v) FCS to give a final concentration of20JLg/m1.vitamin E succinate, 50JLg/ml Asc and lOJLM 
dexamethasone respectively, in 0.1 % final concentration of ethanol. 
The concentration of dexamethasone required to inhibit PLA2 activity at all concentrations tested was 
determined by preliminary range finding experiments, and was shown to be most-effective at lOJLM 
dexa~ethasone. At this concentration total inhibition of PLA2 activity was found. 
6.2.2.2 Cell culture procedures 
For experiments Section 6.3*, 3 x 105 BL6 cells were seeded into 5 sets of 5 25cm2 flasks. To four 
sets of these flasks, lOml of MEM basal medium containing 10% FCS; lOJLM dexamethasone and 
varying levels of combined vitamin E succinate (5-20JLg/ml) and Asc (25-50JLg/ml) was added. The 
sixth set of flasks received lOml 10% (v/v) FCS media containing 0.1 % final volume of ethanol and 
lOpM dexamethasone, and were referred to as control cultures (OE). In experiments 6.4*, 6.5* and 
6.6*, BL6 cells were seeded into 5 sets of 3 75cm2 flasks. To 4 of the 5 sets of flasks was added 30ml 
medium containing 10% (v/v) FCS containing lOJLM dexamethasone and varying levels o(combined 
vitamin E succinate (5-20JLg/ml) and Asc (25-50JLg/ml). The fifth set of flasks received 30ml of media 
containing 0.1 % (v/v) ethanol and lOJLM dexamethasone and were referred to as the controls (OE). 
The flasks were incubated at 37°C for the duration of the experiment with one media change during 
this period. Experimental cells were harvested as described in 2.2.3.2. 
* Numbers refer to analytical experiments performed on these cultured cells further on in this chapter. 
6.2.2.3 Statistical analysis 
The results obtained were analysed using a one-way analysis of variance (ANOV A) followed by the 
Student-Newman Keuls Multiple Range Test. Data in all subsequent sections of this chapter were 
analysed by this method. 
6.2.3 RESULTS 
The BL6 cell growth in the relevant experiments, in which varying levels of combined vitamin E 
succinate (5-20JLg/ml) and Asc (25-50JLg/ml) were supplemented, together with dexamethasone is 
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represented in Table 28. Relevant to this discussion, is the mean of growth inhibition of the 
percentage of untreated controls of all the experiments. Growth inhibition as a percentage of untreated 
cells for each individual experiment will be discussed relative to particular cell metabolites in 
subsequent sections. 
The overall mean growth values, recorded in Table 28, indicated that combined ¥-itarnin E succinate 
and Asc, together with dexamethasone supplementation resulted in a slight stimulatory effect (non-
significant), on BL6 cell growth. 
TABLE 28: The effect of combined vitamin E succinate and ascorbic acid supplementation, together 
with dexamethasone on BL6 cell growth. Results are the mean of five' or three cultures ± SEM. 
-
Growth inhibition [% of untreated controls] 
[vitamin E succinate:ascorbate] 
Jlg/ml Sect. Sect. 
6.3 6.3 
OE 100 100 
±0.54 ±0.57 
5:25 101.83 113.09 
±5.36 ±5.36 
10:50 108.34 101.55 
±2.95 ±5.38 
10:25 99.83 120.16 
±2.47 ±2.5 
20:25 100.28 111.56 
±2.27 1.78 
a - p::;; 0.001 relative to the respective control cultures OE 
b - p::;; 0.01 relative to the respective control cultures (OE) 
c - p::;; 0.05 relative to the respective control cultures (OE) 
Exp 
6-.4 
100 
±1.31 
104.83 
±5.54 
96.05 
±2.74 
103.07 
±4.49 
98.15 
±5.62 
Exp Exp Mean 
6.5 6.6 
100 100 100 
± 1.18 ±1.57 ±0.21-' 
'.' 
97.52 141.89a 114.25 
±4.25 ±7.80 ±6.36 
120.16c 83.33 103.25 
±2.06 ±0.90 ±5.19 
106.81 96.75 103.81- -
±4.36 ±2.03 ±3.65 
98.42 105.41 103.21 
±8.01 ±5.41 ±2.13 
In some cases, BL6 cell growth in individual experiments was significantly increased following 
combined vitamin E succinate and Asc supplementation with dexamethasone relative to respective 
control cultures (OE). 
6.2.4 DISCUSSION 
Recently it has been found that dexamethasone may have direct apoptotic or antiproliferative effects 
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on myeloma cell (567), while Reyes-Moreno et al (568) reported that dexamethasone arrested cell 
progression at the G l/Go phase of the cell cycle in mous~ mammary tumours. Results from this study 
do not support the above finding since combined vitamin E succinate and Asc supplementation ofBL6 
cells together with the pharmacological dose of dexamethasone resulted in a general increase in cell 
growth. However, glucocorticoids have shown both inhibitory and stimulatory growth effects in vivo 
and in vitro depending on the normal and transformed cell lines investigated and little is known about 
the mechanism of this cellular response (568). In fact in this study the overall mean of growth ofBL6 
cells with combined vitamin E succinate and Asc supplementation as well as with dexamethasone 
resulted in a substantial increase in BL6 cell growth when compared to combined vitamin 
supplementation alone (Table 2a). Since it is known that the concentration of free AA in cells is low 
and it is well recognized that AA release is a rate limiting step of PG synthesis (229,238,555) this 
suggests that the increase in cell growth observed in dexamethasone treated BL6 cells may be the 
result _of decreased PLA2 activity which would lead to the decrease in AA liberation and hence PG 
production. As already mentioned PG synthesis is inversely related to cell growth, thus a decrease 
in PG synthesis would ultimately lead to the observed increase in BL6 cell growth. 
Certain enzymes and their relevant metabolites which are associated with this cascade effect were 
selected for further investigation of the effects of combined nutrient and dexamethasone 
supplementation in BL6 cells. 
6.3 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID-
SUPPLEMENTATION TOGETHER WITH DEXAMETHASONE ON FREE RADICAL 
AND LIPID PEROXIDATION FORMATION 
6.3.1 INTRODUCTION 
As indicated previously the mechanism(s) by which vitamin E succinate inhibits tumour cell 
proliferation is unclear although, it has been suggested that the anticarcinogenic effect of vitamin E 
and C may be in their ability to scavenge free radicals and prevent lipid peroxidation 
(22,24,36,54,57,63,71,122,128,477). However earlier studies (Section 3.2) have shown significant 
increases in both free radical formation and lipid peroxidation levels following combined vitamin E 
succinate and Asc supplementation. Furthermore, Cilliard et al (569,570) have suggested that high 
concentrations of the vitamins E and C may reverse the antioxidant effect of these vitamins to a 
prooxidant one. 
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Lipid peroxidation is the process of oxidative turnover of PUF As and both enzymic and non-enzymic 
(529)_lipid peroxidation is initiated by free radicals. ·Since lipid peroxidation of PUFA can be 
. . 
initiated enzymatically through the catalytic action of cox enzyme (123,258,529), it was suggested 
earlier that the observed increase in free radical and lipid peroxidation levels in BL6 cells is a result 
of the increased COX activity obtained (Section 4.5) within these cells. COX activity is in turn partly 
regulated by the availability of its substrate, free AA. 
In an attempt to demonstrate this relationship, BL6 cells were supplemented with the PLA2 inhibitor, 
dexamethasone. 
6.3.2 MATERIALS AND METHODS 
MATERIALS 
Materials used were the same as in 3.2. 1 and 6.2.2. 
METHODS 
6.3.2.1 Cell culture procedures 
The same procedures were used as those outlined in 2.2.3.2 and 6.2.2.2. 
6.3.2.2 Free radical formation 
The same procedure was used as that in 3.1.2.2. 
6.3.2.3 Lipid peroxidation determination 
The same procedure was used as described in 3.1.2.3. 
6.3.3 RESULTS 
Treatment of BL6 cells (Table 29) with lOILM dexamethasone and varying levels of combined vitamin 
E succinate (5-20ILg/ml) and Asc (25-50ILg/ml) resulted in a decrease of free radical levels when 
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compared with control cultures (OE), although no significance was recorded. 
TABLE 29: The effect of dexamethasone treatment<on free radical and lipid peroxidation levels in 
BL6 cells supplemented with varying levels of combined vitamin E succinate and ascorbic acid. 
Results are the mean of five cultures ± SEM. 
Free radical Lipid peroxidatioJl_ 
-
[vitamin E succinate:ascorbate] formation nmoles MDA/I04 cells 
jtg/ml nmoles Diformazanl 
104 Cells 
OE 0.026 0.032 
±O.OOI ±O.OOI 
5:25 0.022 0.026 
±0.004 ±0.001 
10:50 0.023 0.012' 
±0.003 -. ±0.002 
10:25 0.020 0.012' 
±0.003 ±0.004 
20:25 0.019 0.001' 
±0.004 ±0.002 
a - p::::;O.OOl relative to control cultures (OE) 
Lipid peroxidation in BL6 cells following dexamethasone treatment was generally decreased. This 
- -
decrease in lipid peroxidation levels was significant (p ~ 0.001) at 10:50; 10:25 and 20:25JLg/ml 
following IOJLM dexamethasone and combined vitamin supplementation when compared with control 
cultures (OE). 
6.3.4 DISCUSSION 
The activity of the COX enzyme has been shown to be dependent on the presence of lipid 
hydroperoxides, and these hydroperoxides are continually required during the catalytic mechanism 
(237,242,258,259,264). Furthermore, it was found that various lipid hydroperoxides could stimulate 
COX activity, and the levels of PGG2, the reaction product of the enzyme (237,242,259). 
The lipid hydroperoxides can decompose into TBA reactive materials such as MDA (269,570). This 
suggests that an increase in COX activity will result ultimately in the increase in MDA levels through 
the production of lipid peroxides. The conversion of PGG2 to PGH2 by PG hydroperoxidase is also 
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known to produce oxygen containing free radicals, suggesting that any compound capable of 
increasing the COX activity will also lead to increased hydroperoxidase activity of the PES and 
indirectly increase the levels of free radicals within tbese cells. 
In this study, supplementation of BL6 cells (Table 29) with dexamethasone resulted in a decrease in 
both lipid peroxidation and free radical levels when compared with respective cOfltroi cultures (OE). 
Whe~ comparing free radical and lipid peroxidation levels in combined vitamin E succinate and Asc 
supplemented cells not treated with dexamethasone (Table 13) with the dexamethasone treated cells, 
a substantial decrease was also found in the dexamethasone treated cells. These results suggest that 
the earlier findings of an increase in free radical and lipid peroxidation levels in BL6 cells 
supplemented with combined vitamin E succinate and Asc were possibly due to a stimulation of COX 
activity, since dexamethasone treatment would limit this activity as a result of an inhibition of release 
of its substrate AA, by PLA2 
To substantiate this, the effect of dexamethasone supplementation on COX activity was determined. 
6.4 EFFECT OF DEXAMETHASONE AND COMBINED NUTRIENT SUPPLEMENTATION 
ON CYCLOOXYGENASE ACTIVITY 
6.4.1 INTRODUCTION 
The initial step of PG biosynthesis is an oxygenative cyclization to produce PGG2 , which contains 
both an endoperoxide and a hydroperoxidase moiety. The enzyme responsible for this reaction is 
referred to as a fatty acid COX, the same enzyme also catalyzes the second step of PG biosynthesis 
to PGH2 from PGG2 (237). Because AA is the precursor for the biosynthesis of PGs, inhibition of 
AA release could suppress the formation of these mediators. Therefore an inhibition of PLA2 could 
result in the suppression of the lipid mediators. 
6.4.2 MATERIALS AND METHODS 
MATERIALS 
Materials used were the same as in 4.1.2 and 6.2.1. 
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METHODS 
--
6.4.2.1 Cell culture procedures 
The same procedures were used as in 2.2.3.2 and 6.2.2.2. 
6.4.2.2 Homogenization of cells and separation of cellular components 
The same procedures were carried out as in 3.2.1.2 and 4.1.2.2. 
6.4.2.3 Determination of cyclooxygenase activity 
The procedure used for determination of COX activity outlined in 4.1.2.3 was repeated. 
6.4.3 RESULTS 
.. ' 
TABLE 30: The effect of dexamethasone treatment on cyclooxygenase activity in ELf) cells 
supplemented with varying levels of combined vitamin E succinate and ascorbic acid. Results are the 
mean of three cultures ± SEM. 
[vitamin E succinate:ascorbate] Cyclooxygenase activity 
jtg/ml pmoles PGG2 (xlO)/106 Cells 
OE 0.0510 
±0.003 
5:25 0.0540 
±0.002 
10:50 0.0012" 
±O.OOOI 
10:25 0.0009" 
±O.OOOI 
20:25 0.0009a 
±O.OOOI 
a - p:::; 0.001 relative to control cultures (OE) 
Treatment of BL6 cells (Table 30) with 10JLM dexamethasone and varying levels of combined vitamin 
E succinate and Asc resulted in a significant (p =:;; 0.001) decrease in COX activity, with the exception 
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of 5:25/lg/ml where a slight increase in COX activity was found when compared to control cultures 
(OE). 
6.4.4 DISCUSSION 
While glucocorticoids inhibit PG synthesis from AA at the level of PLA2 , they have" also known to 
inhibit PG synthesis at the COX enzyme level (562). In these studies, supplementation of BL6 cells 
(Table 30) with the glucocorticoid dexamethasone resulted in an overall significant decrease in COX 
activity when compared to control cultures (OE). Furthermore, when comparing COX activity in BL6 
cells following combined vitamin E succinate and Asc supplementation alone (Table 22) to 
dexamethasone treated cells a marked decrease in COX activity was observed in dexamethasone 
treated cells. Although the mechanism in which dexamethasone inhibits the stimulatory effect of 
combined vitamin E succinate and Asc on COX activity in BL6-cells is still unclear, this data suggests 
that the observed decrease in COX activity in dexamethasone treated cells is due at least partly to the 
inhibition of PLA2 activity and subsequent AA release. As the concentration of free AA is low, it is 
well recognized that AA release is a rate limiting step in PG synthesis (229,239,555). A.direct 
inhibition of the COX enzyme itself is also possible. The observed decrease in free radical and lipid 
peroxidation levels in dexamethasone treated cells therefore appears to be due to the decreased COX 
activity in BL6 cells. 
6.5 EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION TOGETHER WITH DEXAMETHASONE ON PGE2 LEVELS 
6.5.1 INTRODUCTION 
Eicosanoids are not stored but are synthesized on demand, therefore inhibitors of the various 
metabolizing enzymes have instantaneous effects on eicosanoid levels (571). Each PG has its own 
range of biological activities, hence the determination of the role of PGs in tumour growth is a 
perplexing task. Although there has been a great deal of interest in the involvement of AA metabolites 
in cancer, there is uncetaintity about which metabolites are the most important and how they 
contribute to specific steps in cell transformation, tumour growth and metastasis (571). The quantity 
and type of PG produced within a cell is essential to the metabolic effect (284) and the fact that PGE2 
is negatively correlated with metastatic potential in BL6 cells, it was necessary in this study to 
determine what effect dexamethasone treatment had on PGE2 levels in combined vitamin E succinate 
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and Asc supplemented BL6 cells. 
6.5.2 MATERIALS AND METHODS 
Materials used were the same as in 4.6.2 and 6.2.1. 
METHODS 
6.5.2.1 Cell culture procedures 
The methods used in 2.2.3.2 and 6.2.2.2 were repeated. 
6.5.2.2 Homogenization of cells and separation of cellular components 
The methods described in 3.2.1.2 and 4.6.2.2 were repeated. 
6.5.2.3 Extraction and isolation of prostaglandins 
The same procedure was used as that described in 4.6.2.3. 
6.5.2.4 Prostaglandin E2 assay system 
163 
The same assay system was used as that described in 4.6.2.4. The PGE2 standard curve is represented 
in Appendix 6. 
6.5.3 RESULTS 
Treatment of BL6 cells with lOJLM dexamethasone (Table 31) and varying levels of combined vitamin 
E succinate and Asc resulted in no increasing or decreasing trend of PGE2 levels in BL6 cells when 
compared with control cultures (OE). 
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TABLE 31: The effect of dexamethasone treatment on PGE2 levels in BL6 cells supplemented with 
varying levels of combined vitamin E succinate and a.scorbic acid. Results are the mean of three 
cultures ± SEM. 
[vitamin E succinate:ascorbate] pg PGE2 / 104 Cells 
Itg/mt 
OE 1.675 
~ . 
±0.088 
5:25 2.311 
±0.451 
10:50 2.732 
±0.481 
10:25 1.681 
±0.320 
20:25 '. 1.471 
±0.142 
6.5.4 DISCUSSION 
Studies by Kowaza et al (555) demonstrated that supplementation of dexamethasone to osteoblast-like 
cells resulted in the inhibition of PGE2 release. In the present study supplementation of lOJ-tM 
dexamethasone to combined vitamin E succinate and Asc supplemented BL6 cells (Table 31) resulted 
.. -
in no increasing or decreasing trend in PGE2 levels. However, when comparing PGE2 levels following 
combined vitamin E succinate and Asc supplementation alone (Table 23) with dexamethasone treated 
cells (Table 31) a marked decrease in PGE2 levels was observed. EIAttar and Lin (148) have 
suggested that endogenous PGE2 levels are a reflection of the activities of the enzymes PLA2 and 
COX. The synthesis of PGE2 is usually limited by the availability of free AA which is liberated from 
membrane phospholipids by PLA2 on agonist stimulation (549). This suggests that the observed 
decrease in PGE2 levels in BL6 cells may be due to the decreased PLA2 and COX activity following 
dexamethasone supplementation. 
PGE2 (285,320,416,447,453) is known to exert its effects via a cAMP-AC linked system. PGE2 is 
reported to have stimulatory (415) and inhibitory effects on AC activity, while cAMP levels within 
the cells are positively correlated to AC activity (462). Consequently, AC activity and cAMP levels 
were determined following dexamethasone supplementation. 
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6.6 THE EFFECT OF COMBINED VITAMIN E SUCCINATE AND ASCORBIC ACID 
SUPPLEMENTATION TOGETHER WITH DEXAMETHASONE ON ADENYLATE 
CYCLASE ACTIVITY AND CYCLIC ADENOSINE MONOPHOSPHA TE LEVELS 
6.6.1 INTRODUCTION 
Alter!ltions in the membrane intracellular signalling systems are frequently implicated in the 
development of neoplasia (345,510). The major intracellular signalling system identified to date is the 
AC-cAMP linked system (510). AC, the catalytic protein converts ATP to cAMP (331,383,384,385). 
The activity of the AC enzyme may be influenced by a number of factors within a cell (405,424,465). 
Numerous studies have shown that PGs function to stimulate AC activity (286,405,416,453,465), and 
furthermore that numerous biological functions appear to be mediated through cAMP levels 
(315,416,427,447,453,465). cAMP when added to various cells in culture was found to affect the 
growth of these cells in either a positive or negative manner depending on the cell type (328,429). 
In vitro studies have shown higher levels of cAMP in normal cell lines when compared to transformed 
cell lines, and furthermore an inverse relationship existed between cAMP levels and cell growth 
(328,427,429,442,445,459,462). 
6.6.2 MATERIALS AND METHODS 
MATERIALS 
Materials used are the same as in 4.8.2 and 6.2.1. 
METHODS 
6.6.2.1 Cell culture procedures 
The methods described in 2.2.3.2 and 6.2.2.2 were repeated. 
6.6.2.2 Homogenization of cells and separation of cellular components 
The methods described in 3.1.1.2 and 4.8.2.2 were used. 
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6.6.2.3 Protein determination 
Protein was determined as outlined in Section 4.3.2.< 
6.6.2.4 Adenylate cyclase activity assay 
The method used for AC determination was the same as described in 4.8.2.4. 
6.6.2.5 Cyclic adenosine monophosphate extraction 
The same procedure was used as that in 4.8.2.5. 
6.6.2.6· Cyclic adenosine monophosphate [3H] assay 
The same procedure was used as that described in 4.8.2.6. 
6.6.3 RESULTS 
TABLE 32: The effect of dexamethasone treatment on adenylate cyclase activity and cyclic adenosine 
monophosphate levels in BL6 cells supplemented with varying levels of combined vitamin E succinate 
and ascorbic acid. Results are the mean of three cultures ± SEM. 
[vitamin E succinate:ascorbate] Adenylate cyclase activity 
J!g/ml U/mg protein 
OE 25.991 
± 1.202 
5:25 20.093b 
0.921 
10:50 17.923b 
0.483 
10:25 14.954" 
2.201 
20:25 13.712" 
2.451 
a - p::; 0.001 relative to respective control cultures (OE) 
b - p::; 0.01 relative to respective control cultures (OE) 
cAMP levels 
pmol/mg protein 
0.200 
±0.007 
0.060" 
0.001 
0.036" 
±0.003 
0.045" 
0.009 
0.0285" 
±0.006 
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Treatment of BL6 cells with lOJlM dexamethasone and varying levels of combined vitamin E 
succinate and Asc resulted in a significant (p ::;; 0.001) decrease in both AC activity and cAMP levels, 
when compared with respective control cultures (OEj .. 
6.6.4 DISCUSSION 
The i~tracellular levels of cAMP are regulated in part by AC activity (434,435) hence any change in 
AC activity would be expected to bring about similar changes in cAMP levels. In these studies, 
significant decreases in both AC activity and cAMP levels (Table 31) in BL6 cells were observed 
following dexamethasone treatment. Furthermore, when comparing AC activity and cAMP levels in 
cells supplemented with combined vitamin E succinate and Asc alone (Table 26) with dexamethasone 
treated cells, substantial decreases in both AC activity and cAMP . levels were found in the 
dexamethasone treated cells. PGs function to stimulate AC activity and, since a decrease in PGE2 
levels were observed following dexamethasone treatment in BL6 cells (Section 6.5) it is likely that 
the decrease in AC activity and subsequent cAMP levels were as a result of the decreased PGE1 
levels. 
Data from these studies suggest that the inhibitory effects of vitamin supplementation on BL6 cell 
growth are a result of a stimulatory effect of combined vitamin E succinate and Asc on PLA2 activity, 
resulting in a cascade effect throughout the eicosanoid pathway. The following discussion will 
summarize the effect in individual experiments of combined vitamin E succinate and- Asc 
supplementation together with dexamethasone. 
6.7 GENERAL DISCUSSION ON THE RELATIONSHIP BETWEEN ARACHIDONIC ACID 
METABOLITES AND CELL GROWTH 
Results from Chapter 4 on the effect of combined vitamin E succinate and Asc supplementation on 
AA metabolites and second messengers in BL6 cells showed that combined vitamin supplementation 
significantly increased the activity of COX activity, PGE2 , AC activity and cAMP levels within the 
cells. Relating these enzyme activities and second messengers to BL6 cell growth in Chapter 5, it was 
evident that an inverse relationship exists between the levels of COX activity, AC activity, PGE2 and 
cAMP and cell growth. In this Chapter the effects of dexamethasone supplementation on the 
relationship between COX activity, PGE2 levels, AC activity and cAMP levels as well as the effect 
these have on BL6 cell growth were examined. 
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A comparison of the relationship between COX activity and BL6 cell growth following vitamin 
supplementation and dexamethasone treatment revealed that COX activity decreased significantly while 
BL6 cell growth showed no increasing or decreasing frend (Figure 36). Looking at the relationship 
between PGE2 levels and BL6 cell growth following dexamethasone supplementation it can be seen 
that cell growth and PGE2 levels were affected in a similar way (Figure 37). As PGE2 stimulates AC 
activity (320,282), the relationship between AC and growth in BL6 cells sUpplemented with 
dexatp.ethasone should be similar to that of PGE2 levels and BL6 cell growth. In this study 
supplementation of BL6 cells with combined vitamins and dexamethasone resulted in no significant 
change in BL6 cell growth, while AC activity was significantly decreased compared to control 
cultures (OE) (Figure 38). A similar effect to that observed for AC activity and BL6 cell growth was 
found when comparing cell growth and cAMP levels (Figure 39). 
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Figure 36: The effect of combined vitamin E succinate and ascorbic 
acid supplementation together with dexamethasone on BL6 cell growth 
and cyclooxygenase activity. 
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In summary, as described in earlier sections combined vitamin E succinate and Asc supplementation 
of BL6 cells resulted in significant increases in the levels of COX activity, PGE2 levels, AC activity 
and cAMP levels, and furthermore these increases were found to be inversely related to BL6 cell 
growth. Treatment of nutrient supplemented BL6 cells with the PLA2 inhibitor, dexamethasone had 
no effect on cell growth or PGE2 levels while COX and AC activity as well as cAMP levels 
decreased. This provides further evidence that the inhibitory effects of combined vitamin E succinate 
and Asc supplementation on BL6 cell growth observed in earlier studies (Chapter 5) were probably 
a result of the ability of combined vitamin E succinate and Asc to increase PLA2 activity, resulting 
in a cascade effect which brings about an increase in endogenous levels of PGE2 and this in turn 
affects cell proliferation by an interaction with an AC-cAMP linked system. 
171 
CHAPTER 7 
GENERAL DISCUSSION 
Fundamental differences regarding cellular function and composition are reported between non-
malignant and malignant cells (see Chapter 1). The normal and tumour cells refer~d to in these 
repor!s usually originate from the same tissue types. In contrast, in this study non-malignant and 
malignant cells were derived from monkey kidney cells and murine melanoma cells respectively. 
Despite originating from different tissue types, the non-malignant and malignant cells in this study 
did display considerable differences with respect to certain enzyme activities and secondary 
metabolite levels determined for these two cell types. Cell growth is one of the major 
physiological features distinguishing tumour cells from normal cells. This is due to the fact that 
tumour -cells usually have less control of proliferation rates (19). In this case both maintenance and 
control cultures of the BL6 melanoma cells consistently showed higher rates of proliferation than 
non malignant LLCMK control and maintenance cultures. 
The treatment of metastatic cancer with chemotherapeutic drugs has always presented 'problems 
owing to the non specificity of the drugs used. Researchers are therefore continuing to search for 
agents which are selectively toxic to tumour cells. One of the foremost approaches is that of 
chemoprevention. Attention has been focused on nutritional compounds which are generally non-
toxic to normal cells, even in high doses, but may interfere with the proliferation of malig.nant 
cells. The potential of these natural substances as a preventative measures against neoplasia 
development is of paramount importance as numerous sources clearly indicate that natural foods 
contain factors that protect against cancer. Thus a relationship between diet and cancer incidence 
is clearly indicated in human populations (7,80). Epidemiological studies have shown that diets 
rich in one or more antioxidant nutrients may reduce the risk of cancers of the lung, uterine, 
cervix, mouth and gastrointestinal tract (7). The beneficial effects of Asc in the prevention (31) 
and management (31,52) of neoplasms has been extensively reported, while vitamin Ehas been 
shown to induce differentiation and growth inhibition in certain animal and human tumour cells in 
culture (49,96). Furthermore, emphasis has been placed on supplementation with more than one 
nutrient to tumours in the hope of enhancing the effects of the individual vitamins. 
Oxygen, a necessary element for the life of aerobic cells, is also the source of active states of 
oxygen, including radicals, which can disrupt cell structure and alter cell function (3,199,572). 
7. General Discussion 172 
Numerous studies over the years have led researchers to suggest that free radicals and products of free 
radical reactions may be involved in the aetiology of canGer (572). Substantial evidence has implicated 
free radicals in both tumour initiation and promotion (3,4,8-11,55,133,211,214). These findings have 
led to widespread interest in compounds capable of reacting with chain propagating radical species 
resulting in the formation of species no longer capable of hydrogen abstraction. Termination of chain 
propagation involves a variety of compounds in which attention has been focused in particular on 
vitamjn E - a major lipid-soluble antioxidant present in all membranes (103,110,121) - and Asc, a 
major water-soluble antioxidant present in the cytosol (33,40,49,52,54,56). Both vitamins function 
to scavenge free radicals and prevent lipid peroxidation, in vivo and in vitro (45,46,50,112,143) and 
vitamin E is said to be the first line of defence against free radicals. Furthermore, in vivo and in vitro 
experiments (29,156-168,174) demonstrate that vitamin C can act synergistically with vitamin E, 
bringing about a sparing effect of vitamin E. This sparing effect results in the slow depletion of 
vitamin- E. Since tumour incidence is linked with nutrition (7) -and an inverse relationship is believed 
to exist between serum vitamin E (123,139,146,151), serum Asc (43,67) and cancer incidence, this 
study was directed towards determining the effect of combined vitamin E succinate and Asc 
supplementation on the growth of malignant (BL6) melanoma cells and non malignant monkey~idney 
(LLCMK) cells. Furthermore, certain metabolic responses to combined vitamin E 'and Asc 
supplementation were studied. Attention should be drawn to the fact that although the vitamins E and 
C may act individually within the cells bringing about the observed effects, it was the synergistic 
action of the vitamins which formed the main concern of this study. Growth studies involving vitamin 
E succinate and ascorbic acid on various cell lines have been examined, however the individual effects 
of vitamin E succinate and ascorbic acid on the enzymes in the arachidonic acid pathway have yet to 
be explored. 
With reference to overall mean growth, supplementation of combined vitamin E succinate and Asc 
resulted in a significant decrease in BL6 cell growth, while LLCMK cells showed no increase or 
decrease in cell growth. This selective cytotoxicity of combined vitamin E succinate and Asc towards 
malignant BL6 cells may be indicative of their value in the treatment of malignant Cells and 
furthermore suggests that the contribution of vitamin E succinate to Asc is important for maximum 
inhibition ofBL6 cells. Vitamin E succinate (49,92,97) and Asc (43,49,59,61,471,472) on their own 
have been shown to inhibit growth of other cell lines, but the effect of combined vitamin E succinate 
and Asc has not previously been reported. The actual mechanism by which combined vitamin E 
succinate and Asc inhibits BL6 cell growth is not yet known. This study considered the possibility 
that the inhibitory effects of combined vitamin E succinate and Asc on BL6 cell growth was mediated 
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via the synergistic antioxidant properties associated with the vitamin E component molecule and Asc. 
Supplementation of BL6 cells with combined vitamin E succinate and Asc however, resulted in a 
marked increase in free ·radicals as well as in lipid' peroxidation levels. Studies by Ciliiard et al 
(569,570) have shown that the antioxidant effect of vitamin E and C can be reversed to a prooxidant 
effect, particularly when the vitamin concentrations are increased. The increases in both free radical 
and lipid peroxidation levels were inversely related to BL6 cell growth. These findings support 
Gold~ing et al (214), who reported that tumour cell growth is inversely related to lipid peroxidation 
levels, and that any agent capable of increasing lipid peroxidation levels within a cell could inhibit 
tumour cell growth (573). 
Although the vitamin E molecule is a naturally-occurring antioxidant, vitamin E succinate is a non-
physiological antioxidant which requires esterase activity in order to liberate the free alcohol, vitamin 
E, with antioxidant properties (93,97,490,491). Liberation of the free vitamin E from vitamin E 
succinate must occur in order for Asc to act synergistically with vitamin E bringing about the sparing 
effect. Since no species-specific hydrolysis of vitamin E succinate has been demonstrated (490), an 
attempt was made to demonstrate vitamin E succinate cleavage in BL6 cells. Supplementation of BL6 
- ",-' 
cells with combined vitamin E succinate and Asc resulted in no increasing or decreasing trend of 
vitamin E succinate levels in the cells while, vitamin E levels on the other hand increased markedly 
with increasing concentration of vitamin E succinate, although, no significance was recorded. These 
results suggest that vitamin E succinate is cleaved in these cells and that vitamin E and Asc may 
indeed act synergistically, resulting in the sparing effect of vitamin E. The inability of combined 
vitamin E succinate and Asc to reduce free radical formation and lipid peroxidation levels within BL6 
cells may therefore not be due to their ineffectiveness as antioxidants but rather the presence of other 
contributing factors which influence the oxidation state within the BL6 cells. 
Vitamin E has numerous other roles, within cells, besides its primary role as an antioxidant. Vitamin 
E is suggested to alter membrane stability or function by interacting with the unsaturated EF A portion 
of phospholipids (125,127), stabilizing the membrane which may be enhanced by the presence of Asc 
due to its sparing effect of vitamin E. In an attempt to substantiate this proposal, BL6 cells were 
supplemented with 3H vitamin E succinate and 14C ascorbic acid, and the relative uptake and cellular 
distribution of the vitamins determined. In this study, supplementation of 3H vitamin E succinate and 
14C ascorbic acid resulted in a significant increase in both 3H vitamin E succinate and 14C ascorbic 
acid uptake in BL6 cells. With respect to distribution of vitamin E succinate, significant increases in 
vitamin E succinate levels were detected, in both membrane and stroma fractions. Asc, on the other 
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hand, was significantly higher in the stroma fraction relative to corresponding membrane fractions. 
It would therefore appear that combined vitamin E succinate and Asc effects on BL6 cell growth are 
not mediated via their synergistic antioxidant role<but may rather have a modulatory' effect on 
membrane functions. Studies have shown that vitamin E supplementation stabilizes membranes and 
alters membrane-bound enzymes (125,127). Vitamin E has been suggested to playa role in a number 
of aspects of eicosanoid metabolism (196,218,503), altering the activity of key r.egulatory enzymes 
such ~s COX and PLA2 (196,503) and LOX (543). Hence, this study considered the possibility that 
the inhibitory effects of combined vitamin E succinate and Asc supplementation on tumour cell growth 
were mediated to a certain extent through an effect on AA composition in BL6 cells, resultant second 
messenger levels in the eicosanoid pathway and the final cAMP concentration (a known regulator of 
cell proliferation). It was also important to establish whether any such effects on these metabolites 
were the result of a direct or indirect influence of combined vitamin E succinate and Asc 
supplementation. 
Metabolism of AA by LOX has revealed that intermediate peroxy compounds and hydoxyl radicals 
are produced in these reactions (529), and these radicals in turn are known to stimulate" COX 
(237,259). Regarding COX and 5-LOX enzymes, supplementation of combined vitamin E'succinate 
and Asc to BL6 cells resulted in a significant increase in both COX and 5-LOX activity at all 
combined vitamin concentrations. Furthermore, COX activity was found to be approximately 2-fold 
higher than that of 5-LOX activity. Hemler et al (259) found that the lipid hydroperoxides formed 
by LOX were the most potent activators of COX, which could have accounted for the higher- COX 
activity. This result is also indicative of the fact that the combined vitamin E succinate and Asc 
inhibitory effects on BL6 cell growth are more likely to be due to changes in COX activity rather than 
to 5-LOX, and that the products of COX could play an important regulatory role in tumour cell 
growth. 
Although vitamin E is believed to stabilize membranes and alter the activities of membrane-bound 
enzymes (96,125,127) with Asc enhancing this function of vitamin E, the observed effects of 
combined vitamin E succinate and Asc supplementation on BL6 cells may be more complex than 
simply membrane stabilization. Many of the key enzymes involved in AA esterification and release 
are dependent on Ca2+, since it has a role in COX and LOX activity (339), and hence AA 
metabolites. The availability of Ca2 + within a cell is believed to be a key regulator of cell proliferation 
(329,335,356). Although it has been reported that BL6 melanoma cells have low Ca2+ content (535), 
these studies showed that an overall increase in Ca2 + levels was detected following combined vitamin 
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E succinate and Asc supplementation with a corresponding decrease in BL6 cell growth. 
Consequently, another factor accounting for elevated activities of COX and LOX as a result of 
vitamin supplementation may be an increased availal:fility of Ca2+ . 
The role of Ca2+ in modulating the activity of the PLA2 enzymes should also be considered. In 
particular, cPLA2 , the enzyme present in the cytosol, trans locates to membralles ~n response to 
chan&.es in intracellular Ca2+ levels (348,353,358,359). PLA2 functions to release AA - an important 
rate limiting substrate of 5-LOX, COX and eicosanoid metabolism (237,238,347-350,354,366). Due 
to PLA2's possible role in modulating 5-LOX and COX activity, and the resulting inverse relationship 
between the activity of these enzymes and BL6 cell growth as previosly discussed, the effect of 
combined vitamin E succinate and Asc supplementation on PLA2 activity was determined. PLA2 
activity was significantly increased at all combined vitamin concentrations following supplementation. 
Comparing Ca2+ levels and PLA2 activity it was clear that a positive correlation existed between the 
Ca2 + and PLA2 activity, indicating that PLA2 activity in BL6 cells may also be Ca2 + -dependent. 
Tumour cells have been reported to have altered EF A composition in their membranes, which!p turn 
modulates the activity of membrane-associated enzymes, such as PLA2 and AC (190): Since it would 
seem that the PLA2 activity is regulated in part by the EF A composition of the phospholipid bilayer 
in which it resides (515), and since we have already established a positive correlation between Ca2 + 
levels and PLA2 activity, it was important to determine AA content within BL6 cells. Due to a 
significant increase in PLA2 activity in vitamin supplemented cells an increase in free_ EFA 
composition - particularly AA - could beexpected, and was found to be the case. It was established 
that an inverse relationship existed between BL6 cell growth and percentage AA composition upon 
combined vitamin E succinate and Asc supplementation. This effect was the result of an increased 
uptake of AA by the BL6 cells from the medium and an increased release of AA from membrane 
phospholipids by PLA2 (317). 
Since AA was elevated in vitamin-supplemented cells, and AA is the substrate for COX - which is 
also elevated as a result of vitamin supplementation - it was important to investigate the effect of 
vitamin E succinate and Asc on the products of COX, the prostaglandins. PG-producing cells 
predominantly synthesize one type of PG due to the existence of a single PGH2 metabolizing enzyme 
(229). Several studies have indicated that BL6 cells are unusual in that PGD2 is the major metabolite, 
with lesser amounts of PGF2o<' PGE2 and PGI2 (300,309). However, when comparing the levels of 
PGs in BL6 cultures in this study, it was evident that in this case BL6 cells convert AA to PGE2 , 
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PGD2, PGF2a and PGI2 in descending order of magnitude, with PGI2 levels in BL6 cells being found 
to be markedly lower than PGE2, PGD2 and PGF2a levels. Supplementation of combined vitamin E 
succinate and Asc resulted in a significant increase in'PGE2 and PGI2 levels. PGD2 and PGF2a levels 
were markedly increased, although no significance was recorded. It has been suggested that AA 
metabolism can be diverted towards PGE2 synthesis when elevated levels of lipid hydroperoxides 
occur. Furthermore, EIAttar and Lin (148) suggest that the observed stimulatory Of-inhibitory effects 
of combined vitamin E succinate and Asc on endogenous PGE2 levels was a reflection of the increased 
or decreased activities of both the PLA2 and COX enzymes respectively. Combined vitamin E 
succinate and Asc supplementation in the present study in fact resulted in a significant increase in both 
PLA2 and COX activities in BL6 cells. Furthermore the resultant increase in PGE2 levels was 
inversely related to BL6 cell growth, as was total percentage AA composition. Hence the amount of 
PGE2 synthesized appeared to be dependent on the level of its precursor and its synthesizing enzyme, 
COX {317). Therefore, it is reasonable to assume that the growth inhibitory effects of combined 
vitamin E succinate and Asc supplementation was due, at least in part, to the increase in PGE2 
synthesis resulting from the cascade effect throughout the eicosanoid pathway. 
PGE2 in turn stimulates AC activity in a variety of cells, including tumour cells, although tumours 
can vary in the degree of cAMP response (282). cAMP acts as a second messenger for PGE2-
mediated modulation of biological activity within the cell (337). Combined vitamin E succinate and 
Asc supplementation of the BL6 cells significantly increased AC activity and cAMP levels. It is 
therefore reasonable to conclude that the increased AC activity and cAMP levels found are likely to 
be a result of increased PGE2 synthesis. Other studies have shown that supplementation of E-series 
PGs to various malignant and non-malignant cell lines inhibits the growth of these cells, and 
furthermore that this inhibition of cell growth is positively correlated with changes in cAMP levels 
(415,420). 
With respect to the non-malignant LLCMK cells in general, vitamin supplementation, exhibited no 
significant trends or relationship between cell growth and cell oxidation states or various metabolites 
and second messengers in the AA pathway. Furthermore, with regard to those experiments showing 
an inverse relationship between LLCMK growth and the levels of second messengers and activity of 
various enzymes in this pathway, no definite conclusion could be made since the magnitude of this 
relationship varied considerably from one experiment to the other. The malignant cell line (BL6 
melanoma) on the other hand, as outlined, exhibited consistent trends and relationships following 
combined vitamin supplementation, hence this discussion has focused on the BL6 cells. 
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Results from these studies therefore suggest that the inhibitory effect of combined vitamin E succinate 
and Asc on BL6 cell growth did not involve their synergistic antioxidant properties. The most 
important regulator of cell proliferation is most likely to be the final metabolite, cAMP~ which is 
significantly increased in BL6 cells with decreased cell growth and is known to be directly involved 
in the cell cycle and an important regulator of cell growth with intracellular cAMP levels rising with 
the entrance of cells into the quiescent state (447). However, in a sense this is an-indirect effect of 
combined vitamin E succinate and Asc supplementation, as it initially directly affects AA levels in 
BL6 cells, resulting in the cascade effect through the eicosanoid pathway. This effect in turn is 
expressed through PGE2 and subsequent AC activity. 
In an attempt to provide further evidence that combined vitamin E succinate and Asc mediated its 
growth inhibitory effects on BL6 cell growth through the initial activation of PLA2 and subsequent 
cascade- effect and that a direct link exists between free radical, lipid peroxidation levels and COX 
activity, BL6 cells were supplemented with PLA2 inhibitor, dexamethasone. Supplementation ofBL6 
cells with 1Ol-tM dexamethasone and combined vitamin E succinate and Asc resulted in an increas.e 
in growth when compared to control cultures although, no significance was recorded. Analysis of 
COX activity following dexamethasone and combined vitamin E succinate and Asc supple'mentation 
in BL6 cells showed a significant decrease in COX activity compared to control cultures, while 
supplementation with dexamethasone and combined vitamin E succinate and Asc resulted in no 
significant increases or decreases in PGE2 levels, while AC activity and cAMP levels were 
significantly decreased. These results provide further evidence that vitamin E succinate and- Asc 
growth-inhibitory effects on BL6 cell growth were a result of the combined vitamins' ability to 
increase endogenous PGE2 , which in turn affects cell proliferation through interacting with the AC-
cAMP linked system. With respect to free radical and lipid peroxidation in BL6 cells, dexamethasone 
supplementation resulted in a non significant decrease in free radical formation, while lipid 
peroxidation levels were significantly decreased. Therefore it is reasonable to conclude that the 
observed increase in free radical and lipid peroxidation levels was due the indirect effect of combined 
vitamin E succinate and Asc to increase COX activity within BL6 cells as a result of increased release 
of the enzyme substrate, AA. 
It can be concluded that in BL6 murine melanoma cells, combined vitamin E succinate and Asc 
supplementation in pharmacological concentrations mediates an alteration in AA metabolism. This 
results in a cascade effect throughout the eicosanoid pathway, which stimulates AC activity thus 
increasing cAMP production. The significant increase in cAMP levels is believed to be responsible 
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for the inhibitory effect of combined vitamin E succinate and Asc supplementation on BL6 cell 
growth. However, cAMP may not be the sole factor involved in the process, since other second 
messengers such as Ca2 +, AA, PGE2 etc may playa <more direct role. 
It is clear from the studies that vitamin E succinate and Asc may have an important role in controlling 
cell proliferation of malignant cells, while having little effect on non malignaat- cells. However, 
cautiqn should be exercised in extrapolating these results to all other cells since a certain amount of 
cell specificity in terms of these effects is likely to occur. The extension of these findings to 
chemoprevention of cancer will also require further investigation. 
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